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Abstract
The association between elevated uric acid (UA) concentrations and cardiovascular
disease is well established in epidemiology, but the possibility that UA plays a specific
role in the pathophysiology of cardiovascular disease remains a matter of debate.
Although there are putative mechanisms by which UA could injure the cardiovascular
system, it also has a number of properties that might be considered as protective. Most
notably, its role as a radical-scavenging antioxidant might be expected to mitigate the
effects of increased oxidative stress, which is characteristic of most risk factors for
cardiovascular disease and is an important precipitant of endothelial dysfunction. The aim
of the studies described in this thesis was to examine the effects of UA on endothelial
function and investigate whether UA has the potential to reverse endothelial dysfunction
induced by low-density lipoprotein (LDL).
Mesenteric arteries were isolated from Wistar-Kyoto rats and the responses to a
vasoconstrictor (PE, phenylephrine) and endothelium-dependent (ACh, acetylcholine)
and -independent (SNP, sodium nitroprusside) vasodilators examined using perfusion
myography. This model was considered advantageous because it enabled the
measurement of pharmacological responses in the presence of different luminal solutions
in an experimental environment that most closely mimics the conditions found in vivo.
Luminal perfusion with L-NAME and/or indomethacin demonstrated that nitric oxide
synthase (NOS) -derived nitric oxide (NO) was the major vasodilator released by the
endothelium in response to ACh in this experimental model.
Exposure of the vascular lumen to increasing concentrations ofUA (200, 400, 600pM) or
vehicle solution had no effect upon the responses to PE, ACh or SNP. This implied that,
in this model, acute exposure to elevated UA does not impair endothelial function. In
contrast, when the lumen was perfused with increasing concentrations of LDL (250, 500
and lOOOpg/ml), maximal vasodilatation towards resting diameter in response to ACh
was reduced to 42.6, 33.6 and 21.7% respectively. The failure of the NOS inhibitor L-
NAME to further impair vasodilatation implied that major effect of LDL was to abolish
endothelium-dependent NO-mediated vasodilatation. Supplementing the perfusing LDL
v
solution with ImM L-arginine restored endothelium-dependent responses, implying that
the LDL-induced endothelial dysfunction was in part explained by a disruption of L-
arginine metabolism. Supplementation with the extracellular Oi " scavenger, superoxide
dismutase (SOD), did not prevent the deleterious action of LDL.
Supplementation of 250pg/ml LDL with increasing concentrations of UA (200, 400,
600pM) partially reversed the inhibition of maximal vasodilatation towards resting
diameter in response to ACh to 62.2, 69.5 and 74.4% respectively. No such improvement
could be achieved in the presence of L-NAME. The beneficial effect of 400pM UA upon
LDL-induced endothelial dysfunction contrasted with the lack of effect of two other
water-soluble antioxidants, ascorbic acid (AA) and glutathione (GSH), at the same
concentration.
The experiments then focused on investigating the potential mechanism by which UA
prevented LDL-induced endothelial dysfunction. Isolated rings of thoracic aorta from
Wistar-Kyoto rats were mounted in a wire myograph and exposed to ACh in the presence
of varying concentrations of UA and 250pg/ml LDL. The superfusate was then
transferred to endothelium-denuded rings and caused significant vasodilation in
previously unresponsive ring segments. The extent of the vasodilatation in response to
the transferred solution was dependent on the concentration of UA and ox-Hb sensitive.
The decay in vasodilator response if the exposure of the denuded ring was delayed had a
half-life of 29 minutes. These results implied that the stimulation of an endothelium-
intact vessel by ACh in the presence of both UA and LDL results in the formation of an
endothelium-independent vasodilator that releases NO and may be a derivative ofUA.
In summary, the results of these experiments suggest that acute exposure to UA in
physiological concentrations does not impair either endothelium-dependent or -
independent vascular responses. Conversely, UA reverses the impairment of ACh-
induced vasodilatation caused by LDL and does so more effectively than other high
concentration hydrophilic antioxidants. Furthermore, UA appears to enable the formation
of an NO-releasing compound when it is present with LDL and endothelial cells
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stimulated by ACh. The presence and nature of a possible NO-donor compound formed
in these circumstances requires further investigation. Taken together, this work implies
that UA exposure is not directly injurious to vascular function and may protect against
the effects of LDL on the vascular endothelium. This might offer a physiological role for
a compound which is found in much higher concentration in the extracellular fluids of
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1.1 The Vascular System
The vascular system is the set of structures in the body that are concerned with
circulating the blood. The blood vessels are a major part of this system and form the
route by which blood is carried away from the heart to the tissues of the body and then
back to the heart. The structure and size of these vessels vary greatly and comprise a
complex network of circulation and regulation. The arteries are the vessels which carry
blood away from the heart to supply O2 and nutrients to the various tissues in the body.
The large arteries, such as the aorta and carotid or iliac artery, are known as the elastic
arteries and transfer blood from the heart to the muscular or medium-sized arteries.
These arteries then distribute the blood around the body by branching into smaller
arteries, know as the arterioles. These arterioles connect with a network ofmicroscopic
vessels called capillaries, which are distributed near to all the body cells. The thin wall
of these vessels facilitates the cellular exchange of O2, nutrients and waste tissue with
the blood.
The vascular wall of the arteries may be divided into three layers: the adventitia, the
tunica media and the intima, as shown in Figure 1.1 (Rhodin, 1980). The adventitia
consists mainly of connective tissue fibres. These attach the vessel to the surrounding
tissue and also form a sheath over the external elastic lamina which covers the tunica
media. The tunica media is formed by a layer of circumferential vascular smooth
muscle cells (VSMC), responsible for vascular contraction and relaxation, and variable
amounts of connective tissue. The intima is the inner layer of the blood vessel and
consists of an elastic basement membrane, the internal elastic lamina, and a monolayer
of endothelial cells (EC), which form the vascular endothelium.
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1.2 The Endothelium
The endothelium lines the inner layer of the vascular wall and acts as a protective
barrier to prevent extensive blood clotting and thrombus formation. EC release
chemical inhibitors of platelet activation, cell proliferation and migration, to prevent
unwanted thrombus formation. The endothelium also plays a crucial role in the
regulation of vascular tone and homeostasis via the release of endothelial-derived
vasoactive substances to the VSMC (Rubanyi, 1993). It releases a range of substances
which induce vasodilatation, such as nitric oxide (NO) (Moncada et al, 1986; Furchgott
et al, 1987; Palmer et al, 1987), prostacyclin (Moncada et al, 1976) and endothelium-
derived hyperpolarising factor (EDHF) (Mombouli et al, 1992), and potent
vasoconstrictors, such as endothelin-1 (ET-1), thromboxane A2 and prostaglandin H2
(Luscher & Tanner, 1993).
Neurotransmitters, hormones and platelet-derived substances may stimulate EC to
influence vascular tone. Blood flow through the vascular lumen also exerts a "tonic"
influence upon the endothelium. The nature of the substances released by the
endothelium is dependent upon the shear stress exerted by the flowing blood upon the
EC. For example, high shear stress induces the release of endothelium-derived relaxing
factors (EDRF), such as NO and prostacyclin, to the underlying smooth muscle.
Conversely, if shear stress is low, endothelium-derived contracting factors (EDCF),
such as ET-1 and thromboxane A2, are released to narrow the vessel diameter and
ensure that good perfusion pressure is maintained. Consequently, damage to these cells
results in the loss of both the control of vascular tone and the antithrombotic capacity
provided by the endothelium. Pathophysiological conditions that damage the arterial
wall and inhibit the endothelial control of vascular function may promote the onset of
cardiovascular disease and the clinical complications associated with this disease state
(Rubanyi, 1993; Shimokawa & Takeshita, 1995).
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1.3 Nitric Oxide
1.3.1 Identification of NO as EDRF
The release of EDRF from EC was established when it was demonstrated that
endothelial removal inhibited responses to ACh in rabbit aortic rings or strips, and
stimulation of endothelium-intact aortic strips could induce vasodilatation in adjacent
denuded strips (Furchgott & Zawadski, 1980). Other studies also reported that
endothelium-intact tissue could be used as a donor to dilate endothelium-denuded
VSMC (Griffith et al, 1984; Cocks et al, 1985; Gryglewski et al, 1986). Two
independent research groups suggested that EDRF was the free radical, NO (Ignarro et
al, 1986; Furchgott et al, 1987; Ignarro et al, 1988). Pharmacological comparison of
EDRF and NO demonstrated that both could mediate vasodilatation via the generation
of cGMP in VSMC, and was inhibited by Hb or O2 ~ (Palmer et al, 1987). Furthermore,
infusion of L-NMMA, a nitric oxide synthase (NOS) inhibitor, into hand veins
mimicked the effects of endothelial denudation and could be reversed by 1-arginine
supplementation, suggesting that EDRF was NO (Moncada et al, 1986). Several
differences have also been reported (Cocks et al, 1985; Long et al, 1987; Moncada et
al, 1991), but it is currently believed that the EDRF released from the endothelium to
produce vasodilatation is NO.
1.3.2 Synthesis of NO
The vascular endothelium has receptors for a variety of circulatory and local hormones,
such as ACh, bradykinin, substance P, noradrenaline, and adrenaline, which activate
receptor-mediated mechanisms to stimulate the generation and release of NO from the
EC. The endothelium also has ion channels that respond to increases in blood pressure,
stretch or shear stress to enhance NO production (Calver et al, 1993). Following
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agonist binding or ion channel opening, an elevation in the intracellular Ca
concentration occurs to activate NOS. This enzyme catalyses the oxidation of the
guanidine nitrogen of 1-arginine (Palmer el al, 1988; Sessa el al, 1994), for which it has
a low substrate requirement (/fm=l-10pM) (Vallance, 1998; Bult el al, 1999; Hobbs et
al, 1999), to produce NO and 1-citrulline with a 1:1 stoichiometry (Stuehr & Griffith,
1992). The reaction pathway for this is shown in Figure 1.2 (Stuehr & Griffith, 1992).
The reaction is Ca2+-dependent and requires O2, NADPH as a reducing cofactor, and
other cofactors such as tetrahydrobiopterin (BH4), flavin mononucleotide (FMN), flavin
adenine dinucleotide (FAD), and haem (Sessa et al, 1994; Marietta, 1994). The
terminal guanidine nitrogen of 1-arginine undergoes a five-electron oxidation, followed
by cleavage to form NO and 1-citrulline. Ca2+/calmodullin binds to NOS and the
enzyme receives electrons from NADPH at the reductase domain. These are then
transported by the flavin moiety to the oxidase domain where they reduce O2 to provide
a source for oxidising arginine.
1.3.3 NO Synthase
NOS exists in three isoforms in the human body - neuronal (nNOS), inducible (iNOS)
and endothelial (eNOS). The genes which code for these are located on chromosomes
7, 12 and 14 respectively (Moncada & Higgs, 1995). nNOS produces NO which acts as
a neurotransmitter in non-adrenergic non-cholinergic (NANC) nerves (Toda &
Okamura, 1990; Rajfer et al, 1992). iNOS is Ca2+-independent isoform of this enzyme,
and is active in VSMC and macrophages exposed to inflammatory cytokines, as part of
the immunological response (Moncada, 1992; Kanno et al, 1994). eNOS-derived NO
plays a crucial role in the regulation of blood pressure, vascular tone and platelet
aggregation in the cardiovascular system (Radomski et al, 1990; Radomski el al, 1993;
Moncada et al, 1991). eNOS and nNOS are expressed constitutively in cells and may
be grouped together as constitutive NOS (cNOS). The enzymatic activity of these










































Figure 1.2. The synthesis of NO and l-citrulline from l-arginine by eNOS, and
subsequent recycling of l-citrulline to l-arginine.
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concentrations greater than 400nM (Ashley et al, 1984). In the absence of intracellular
Ca2+, NOS is localised within the caveolae and inhibited by caveolin. Increasing
intracellular Ca2+ removes this inhibition (Michel et al, 1997). Under conditions in
which there is a deficiency in co-factors such as BH4 or substrate such as 1-arginine, an
imbalance in NOS activity may occur resulting in O2" generation.
L-arginine analogues such as asymmetrical NG,NG-dimethyl-L-arginine (ADMA), NG-
monomethyl-L-arginine (L-NMMA), and NG-nitro-L-arginine methyl ester (L-NAME)
act as competitive reversible inhibitors of NOS to prevent NO generation (Rees et al,
1988). This can cause vasoconstriction of arteries and arterioles, and increases resting
blood pressure (Rees et al, 1989; Vallance et al, 1989; Stamler et al, 1994). ADMA
levels are increased in certain disease states, such as hypercholesterolaemia (Yu et al,
1994; Bode-Boger et al, 1996) and atherosclerosis (Bode-Boger et al, 1996), and may
contribute to the pathophysiology of these conditions. NO may also inhibit NOS by
binding to the haem iron in the enzyme to exert a negative feedback mechanism (Buga
et al, 1993; Abu-Soud et al, 1995).
1.3.4 The properties of endothelial NO
NO has a diverse range of biological effects that may prevent the pathogenesis of
cardiovascular disease, as demonstrated in Figure 1.3. (Beckman et al, 1990; Cooke et
al, 1992; Rubbo et al, 1994; Rubbo et al, 1996; Hogg & Kalyanaraman et al, 1999;
Patel et al, 2000). Basal NO prevents excessive vasoconstriction to regulate vascular
tone (Vallance et al, 1989) and blood pressure (Haynes et al, 1993). It inhibits platelet
aggregation and platelet adhesion to the endothelium (Radomski et al, 1987; Radomski
& Moncada, 1993; Cooke & Tsao, 1994), as well as the activation and adhesion of
leukocytes to the endothelium (Lefer, 1997). NO inhibits the activation of the redox-




Figure 1.3. The major sites where endothelium-derived NO acts to prevent vascular
injury and cardiovascular disease.
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cytokines (Peng et al, 1995), which in turn prevents the transcription of chemokines,
such as monocyte chemoattractant protein-1 (MCP-1) and cellular adhesion molecules
(Peng et al, 1995; Zeiher et al, 1995). NO also inhibits the mitogenesis and
proliferation of VSMC (Garg & Hassid, 1989). NO relaxes contractile elements in EC
to maintain tight junctions between the EC and preserve endothelial impermeability
(Kanwar & Kubes, 1995; MacAllister, 1998). Platelets may also synthesise NO via
NOS (Radomski et al, 1990a; Radomski et al, 1990b) and may store NO in vesicles as
S-nitrosothiols (Hirayama et al, 1999). This is released when the platelets are activated,
as a form of negative feedback to prevent platelet aggregation.
NO may also act as an antioxidant in human physiology to scavenge free radicals,
protect against increased oxidative stress, and prevent vascular injury. It scavenges
lipid peroxyl radicals (LOO) in a termination reaction (Padmaja & Huie, 1993;
O'Donnell et al, 1997), to inhibit lipid peroxidation (Rubbo et al, 1994; O'Donnell et
al, 1997; Hogg & Kalyanaraman, 1999). Termination reactions are the likely point for
the suppression of lipid peroxidation by NO in the extracellular environment. NO
reacts with LOO in a two-step reaction, firstly it scavenges LOO to form a non-radical
species that has similar characteristics to peroxynitrite (ONOO) (Padmaja & Huie,
1993). This unstable intennediate then reacts with a further NO molecule to form a
stable nitrate (Patel et al, 2000). NO scavenges LOO' approximately 10,000 times
faster than a-tocopherol, the major hydrophobic antioxidant found in lipid phases
(Liebler, 1993; O'Donnell et al, 1997). As a result, a lower concentration of NO
(30nM) is required to scavenge LOO', compared to a -tocopherol (20pM) (O'Donnell
et al, 1997). Furthermore, the availability of NO is not limited by transport of a
hydrophobic moiety and is freely diffusible between the aqueous and lipid phases,
unlike a-tocopherol (Liu et al, 1998). NO rapidly scavenges 02" (Huie & Padmaja,
1993), which prevents 02 "-dependent cytotoxicity but produces ONOO", a potent pro-
oxidant and cytotoxic species (Radi, 1998).
10
1.3.5 Vasoactive properties of NO
Endothelial NO also decreases intracellular Ca2+ within the VSMC to reduce
contractility and induce vasodilatation. Once synthesised, NO diffuses from the EC to
the underlying VSMC, where it stimulates soluble guanyl cyclase (sGC). NO has a high
affinity for sGC and low concentrations ofNO (10-lOOnM) activate sGC in a rapid rate
reaction (107-108 M~V) (Kharitonov et al, 1997; Stone & Marietta, 1996). sGC is a
heterodimeric protein consisting of an a and P subunit, which may be divided into three
sections, cGMP-binding domain, the haem-binding domain, and the dimerisation
domain. sGC has some basal activity but is increased up to 500-fold by the interaction
of the ferrous iron (Fe2+) of the haem moiety with NO (Stone et al, 1996). This binding
ofNO to the haem moiety draws the Fe2+ from the plane of the porphyrin ring, breaking
the his 105 bond to produce a conformational change in the catalytic domain and
stimulating the production of cGMP from GTP (Gerzer, 1981; Rapoport & Murad,
1983).
cGMP then activates protein kinase G (PKG) to oppose agonist-mediated increases in
intracellular Ca2+ concentrations. Contractile agonists activate phospholipase C (PLC)
94-
to generate inositol 1,4,5,-triphosphate (IP3). This releases Ca from the sacroplasmic
reticulum, which then binds to calmodulin to activate myosin light chain kinase
(MLCK) and induce smooth muscle contraction. Flowever, PKG inhibits this by
phosphorylating PLC and IP3, or by phosphorylating and down regulating the activity
9+
of the IP3 receptor to prevent the increase in cystolic Ca . PKG also promotes the
cellular efflux of Ca2+ and uptake of cystolic Ca2+ into intracellular stores (Furkawa et
al, 1988). PKG also decreases the sensitivity of the muscular contractile apparatus to
cystolic Ca2+ (Carvajal et al, 2000).
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1.4 Other vasoactive factors released by the endothelium
1.4.1 Prostacyclin
The EC also release prostacyclin (Moncada et al, 1976), a potent vasodilator and
platelet anti-aggregator. Increases in endothelial intracellular Ca2+ also activate
phospholipase A (PLA). This liberates arachidonic acid from membrane
phospholipids, which may then metabolised by cyclo-oxygenase (COX) to eicosanoids,
one of which is prostacyclin. Prostacyclin produces vasodilatation by activating
adenylate cyclase (AC) and increasing the production of cyclic 3',5'-adenosine
monophosphate (cAMP) within the VSMC. This acts via protein kinase A (PKA) to
inhibit MLCK and vasoconstriction. Prostacyclin also increases cAMP within platelets
to inhibit stimulation and aggregation. The anti-platelet properties of prostacyclin have
a greater physiological role than its contribution to endothelium-dependent
vasodilatation (Radomski et al, 1987; Luscher & Barton, 1997).
1.4.2 Endothelium-derived hyperpolarising factor
EDHF is a putative vasodilator released by the endothelium and has been identified in
various vascular preparations (Garland & McPherson, 1992; Plane & Garland, 1992;
Rand & Garland, 1992; Garland et al, 1995). The role of EDHF in agonist-stimulated
endothelium-dependent vasodilatation varies between large and small blood vessels, in
which NO and EDHF predominate respectively. The release of EDHF by EC is
controlled by the intracellular Ca2+ concentration and is inhibited by calmodulin
antagonists. EDHF is thought to exert is effect upon vascular smooth muscle by
opening K+-ion channels (Edwards et al, 1998).
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Several possible suggestions have been proposed for the identity of EDHF. K+, in low
concentrations (<14 mM), induces hyperpolarisation and vasodilatation via the
activation of NA+/K+-ATPase (Edwards et al, 1998; Edwards et al, 1999). However,
other studies have concluded that K+ is not EDHF (Doughty et al, 2000; Drummond et
al, 2000; Lacy et al, 2000). Epoxyeicosatrienoic acids are metabolites of arachidonic
acid, produced by EC through the cytochrome P450 mono-oxygenase pathway, and
may function as EDHF (Rosolowsky & Campbell, 1993; Campbell et al, 1996;
Rosolowsky & Campbell, 1996; Fisslthaler et al, 1999; Halcox et al, 2001). These
acids can open Ca2+-activated K+ channels to cause vasodilatation. Substance P could
also be an EDHF, as it promotes the endothelium-dependent hyperpolarisation of the
VSMC in studies in guinea pig submucosal arterioles (Coleman et al, 2001). Hydrogen
Peroxide (H2O2) also increases K+ channel activity and hyperpolarises VSMC (Barlow
et al, 2000) to induce vasodilatation (Beny & von der Weid, 1991; Matoba et al, 2000).
Estrogen may also contribute to EDHF-mediated vasodilatation, as Wu et al (Wu et al,
2001) and Golding et al (Golding et al, 2001) demonstrated the varying contribution of
EDHF to vasodilatation in females and males. An alternative explanation for the
identification ofEDHF, is the direct intercellular communication via gap junctions, as it
has been demonstrated that these are involved in EDHF-mediated vasodilatation
(Edwards et al, 1999; Harris et al, 2000; Goto et al, 2002; Chaytor et al, 2003;
Karagiannis et al, 2004). The formation and release of cAMP from the EC may also
contribute to the gap junction-dependent vasodilatation attributed to EDHF (Griffith &
Taylor, 1999).
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1.4.3 Endothelium-Derived Constracting Factors
The endothelium may also mediate vasoconstriction by releasing endothelium-derived
constriction factors, such as ET-1, thromboxane A2, prostaglandin H2, and components
of the renin-angiotensin system, such as angiotensin II (Ang-II) (Luscher & Barton,
1997). Ang-II activates angiotensin receptors on the endothelium to stimulate the
release of ET-1, which may cause marked and sustained contractions (Yanagisawa et
al, 1988; Ohnaka et al, 1993). Agonists such as arachidonic acid, serotonin, histamine
and ACh may evoke the COX-mediated release of thromboxane A2 and prostaglandin
H2 (Kato et al, 1990; Luscher & Barton, 1997), which activate thromboxane receptors
in VSMC and platelets to counteract the effects ofNO and prostacyclin.
1.5 Endothelial Dysfunction
The vascular endothelium has a fundamental role in the regulation of cardiovascular
function. Consequently, damage to the EC and the resultant endothelial dysfunction,
have been implicated in the pathophysiology of numerous cardiovascular diseases, and
is regarded as an initial key event in the aetiology of these disease states (Rubanyi,
1993; Shimokawa & Takeshita, 1995; Luscher & Barton, 1997).). Endothelial
dysfunction can be characterised as the loss of endothelium-dependent vasodilatation,
the reduced release of relaxing factors or the enhanced release of vasoconstrictors from
the endothelium (Yanagisawa et al, 1988; Vallance & Collier; 1994). However, the
term 'endothelial dysfunction' commonly refers to an impairment of the NO-system
alone, due to the major consequences this may have. The impairment of the NO-system
may arise due to the inhibition of NO synthesis, reduced NO-availability, or as a result
of the diminished effects of NO. NO contributes to the maintenance of basal vascular
tone (Vallance et al, 1989) and blood pressure (Haynes et al, 1993). Therefore, a
reduced efficacy of endogenous NO would cause impaired vasodilatation and increased
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peripheral vascular resistance, resulting in the development of hypertension (Peart,
1980; Vallance & Collier; 1994; Ferro & Webb, 1997).
Impairment of the vascular NO system is present in hypertension (Panza et al, 1990),
heart failure (Katz et al, 1993), hypercholesterolemia (Creager et al, 1992), diabetes
mellitus (Calver et al, 1992), cigarette smokers (Zeiher et al, 1995), and
homocysteinamia (Mayer et al, 1996). All of these conditions are associated with the
increased risk of vascular and cardiovascular disease. However, the role of endothelial
dysfunction in these conditions may vary, as it may be a cause or an effect of the
associated condition. For example, endothelial dysfunction may be a contributing
factor to the development of hypertension (Panza et al, 1990), thus having a causative
role in the development of this condition. However, in hypercholesterolaemia, the
lipids present may directly damage the endothelium (Creager et al, 1992; Dart & Chin-
Dusting, 1999), therefore endothelial dysfunction may occur as a result of the disease
state.
1.6 Hypercholesterolaemia
Hypercholesterolaemia is a disease condition in which there is an excess concentration
of fat, or lipids, in the blood. This condition is a risk factor for cardiovascular disease,
as the association between elevated cholesterol in the blood and this pathophysiological
condition is well established (Goldstein & Brown, 1977; Steinberg, 1983; Martin et al,
1986). Hypercholesterolaemia can occur as a consequence of a genetic malfunction in
the physiological handling of cholesterol or due to the saturation of the liver via the
high dietary intake of cholesterol and lipids, resulting in increased accumulation in
plasma. This condition precipitates the development of cardiovascular disease via
increased expression of endothelial surface adhesion molecules (Hwang et al, 1997;
Abe et al, 1998), the recruitment and adhesion ofmonocytes and leukocytes (Tsao et al,
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1994; Gauthier et al, 1995; Scalia et al, 1998), impaired fibrinolysis and excessive
thrombosis (Puccetti et al, 2001; Puccetti et al, 2002), or impaired vascular function
(Verbeuren et al, 1986; Zeiher et al, 1993; Anderson et al, 1995)
1.6.1 Hypercholesterolaemia and endothelial dysfunction
In vitro and in vivo data from both hypercholesterolaemic animal (Verbeuren et al,
1986; Anderson et al, 1995) and human studies (Zeiher et al, 1991) have demonstrated
the impairment of endothelial function in hypercholesterolaemia. Human studies have
shown that endothelial dysfunction is widespread in hypercholesterolaemia, and is not
restricted to the coronary circulation (Chowienczyk et al, 1992). Impaired
endothelium-dependent vasodilatation to ACh has been demonstrated in coronary blood
vessels (Quyymi et al, 1995; Treasure et al, 1995; Mullen et al, 1997) and the
peripheral small arteries (Vallance & Moncada, 1994; Goode et al, 1997) of
hypercholesterolaemic human patients. This endothelial dysfunction may precede
clinical evidence of vascular disease in both coronary (Drexler et al, 1991) and
resistance vessels (Chowienczyk et al, 1992) in hypercholesterolaemic patients.
Endothelial dysfunction has also been demonstrated in children with familial
hypercholesterolaemia prior to the development of clinically evident vascular disease
(Clarkson et al, 1997). Lipid lowering in hypercholesterolaemia improves coronary
endothelial function (Leung et al, 1993; Chin & Dart, 1994; O'Driscoll et al, 1997;
Tamai et al, 1997; Guven et al, 2006). This endothelial dysfunction is unlikely to result
form an inability of VSMC to respond to NO, as vasodilatation to exogenous NO-
donors such as glyceryl trinitrate (GTN) or sodium-nitroprusside (SNP) is generally not
impaired in hypercholesterolaemia (Flavahan, 1992; Labinjoh & Webb, 1997;
Wilkinson & Cockroft, 1998; Dart & Chin-Dusting, 1999). Therefore, the endothelial
dysfunction that occurs in this pathophysiological state may reflect a reduction in NO-
availability.
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This reduced NO availability could occur due to decreased substrate availability,
reduced NOS expression, reductions in the presence of NOS co-factors, or increased
inactivation of NO by Oy". In hypercholesterolaemic patients, 1-arginine restores
endothelium-dependent vasodilatation to ACh (Creager et al, 1990; Creager et al, 1992;
Chowienczyk et al, 1992), suggesting the reduced NO availability may be a result of
impaired 1-arginine metabolism. In hypercholesterolaemic rabbit aortic vessels, there is
an increase rather than a reduction in NO generation (Minor et al, 1990). However, O2 ~
production is three times higher in these vessels than normal vessels, and is correlated
with a significant impairment in endothelium-dependent relaxation to ACh (Minor et
al, 1990). Ohara et al. also reported that hypercholesterolaemic vessels generated
increased concentrations of endothelial Oy~, which was related to the loss of endothelial
function (Ohara et al, 1993). Furthermore, Ohara et al. demonstrated that the dietary
correction of hypercholesterolemia in the rabbits prevented endothelial O2 ~ generation
(Ohara et al, 1995). Similarly, the treatment of hypercholesterolaemic rabbits with
SOD, which dimutates 02~, partially restores impaired endothelium-dependent
vasodilatation (Mugge et al, 1991). Therefore, hypercholesterolaemia-induced
endothelial dysfunction could be attributed to lipoprotein-induced increases in oxidative
stress within the EC (Tanner et al, 1991).
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1.7 Lipoproteins
1.7.1 Lipids and lipoproteins
Lipids are insoluble in plasma so are bound to a suitable transport vehicle. These lipid
transport systems are known as 'lipoproteins' and are essential to life. The important
components of this system are; chylomicrons, high-density lipoproteins (HDL), low-
density lipoproteins (LDL) and very-low density lipoproteins (VLDL)
LDL is the major carrier of cholesterol in plasma and the main source of lipids found
to accumulate in the blood. LDL consists of a cholesterol ester core surrounded by
phospholipids and lipophilic antioxidants, such as a-tocopherol and P-carotene. LDL
circulates in the blood and is recognised by LDL receptors on the peripheral cells that
require cholesterol for cellular metabolism. Each LDL particle contains one apo-Bioo
protein that serves as a ligand for this LDL receptor. This facilitates the binding and
internalisation of LDL by receptor-mediated endocytosis. The amount of LDL present
in plasma is proportional to the amount of cholesterol in the plasma. Consequently,
LDL may be the primary mediator of the deleterious actions of hypercholesterolaemia
on endothelial and vascular function.
The endothelium is continuously exposed two forms of LDL, native (n-) and oxidised
(ox-), and both may have direct effects on vascular function (Jacobs et al, 1990;
Fontana et al, 1999). They may impair endothelium-dependent vasodilatation by
inactivating or having a deleterious effect upon NO (Galle et al, 1991; Vergnani et al,
2000). In atherosclerotic patients, impaired vascular function and endothelial injury
have been demonstrated at the site of the arterial plaque, formed by the accumulation of
LDL within the vascular wall (Ludmer et al, 1986; Gordon et al, 1989; Helaly, 1990).
As previously mentioned, there is extensive evidence to suggest that elevated plasma
LDL concentrations are associated with impaired NO-mediated endothelium-dependent
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vasodilatation and that reducing these can restore vasodilatation (Leung et al, 1993;
Chin & Dart, 1994; O'Driscoll et al, 1997; Tamai et al, 1997; Matsuoka, 2001; Guven
et al, 2006).
1.7.2 LDL and endothelial dysfunction
The oxidative modification of LDL causes profound changes in the physiochemical
properties of the LDL particle and alters both the lipid and protein components (Cox &
Cohen, 1996). It has been suggested that ox-LDL may be the most important single
factor in producing endothelial dysfunction (Chin et al, 1992; Cox & Cohen, 1996;
Steinberg, 1997; Rosendorff, 2002). Ox-LDL is a key component of endothelial injury
(Ross, 1993; Dart & Chin-Dusting), and is known to impair endothelium-dependent
vasodilatation by reducing NO availability (Galle et al, 1991; Plane et al, 1993; Myers
et al, 1994; Galle et al, 1995; Lewis et al, 1997; Hein & Kuo, 1998; Fontana et al,
1999; Chan et al, 2003). This inhibition of vasodilatation by ox-LDL is irreversible
(Jacobs et al, 1990; Kugiyama et al, 1990; Yokoyama et al, 1990; Simon et al, 1990).
Ox-LDL may also impair vasodilatation to endothelium-independent vasodilators, such
as SNP or GTN (Jacobs et al, 1990; Tanner et al, 1991), as it can impair cGMP-
mediated vasodilatation (Ezaki et al, 1994; Pohl et al, 1995). Lysophosphatidylcholine
or lysolecithin, produced upon the oxidative modification of LDL, may be responsible
for the diminished vascular response to endothelial NO (Cox & Cohen, 1996).
Lysolecithin derived from ox-LDL inhibits endothelium-dependent vasodilatation in
rabbit aorta (Kugiyama et al, 1990; Yokoyama et al, 1990), whereas the remaining lipid
fractions had no effect (Yokoyama et al, 1990).
Ox-LDL is also directly injurious to the endothelium and enhances EC permeability to
macromolecules, acts as a chemotactic agent for monocytes, stimulates expression of
adhesion molecules on the endothelium, and may cause EC apoptosis (Hessler et al,
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1979; Frostegard et al, 1991; Frostegard et al, 1992; Labinjoh & Webb, 1997).
Furthermore, ox-LDL can induce the generation and release of ET-1 from EC to
promote vasoconstriction and prevent vasodilatation (Boulanger et al, 1992).
The role of n-LDL in lipoprotein-induced endothelial dysfunction remains one of great
debate. Several in vitro studies using various isolated tissue preparation have reported
that n-LDL can inhibit endothelium-dependent vasodilatation (Andrews et al, 1987;
Jacobs et al, 1990; Tomita et al, 1990; Galle et al, 1991; Fontana et al, 1999).
However, unlike the deleterious effects of ox-LDL, this occurs due to a rapid and
reversible mechanism (Jacobs et al, 1990; Tomita et al, 1990; Galle et al, 1991). In
contrast, several in vitro studies have failed to demonstrate any effect of n-LDL on or
NO-availability or endothelium-dependent vasodilatation (Kugiyama et al, 1990;
Simon et al, 1990; Yokoyama et al, 1990; Galle et al, 1994; Galle et al, 1995; Chan et
al, 2003).
1.7.3 The mechanism of LDL-induced endothelial dysfunction
The deleterious effects of n- and ox-LDL on endothelial function may be mediated via
impaired NO synthesis or reduced NO availability, as a consequence of increased
oxidative stress within the vascular wall (Harrison, 1997). Both n-LDL and ox-LDL
enhance eNOS activity (Galle et al, 1990; Schaefer et al, 1993; Fries et al, 1995; Allen
et al, 1998), demonstrating that reduced NO availability is not a result of impaired
enzymatic activity. The inhibitory action of human LDL may be prevented by
supplementation with antioxidants, such as ascorbic acid (AA) and probucol (Plane et
al, 1993; Brown & Goodman, 1998; Fontana et al, 1999; Chan et al, 2003),
demonstrating that the inhibition of vasodilatation may be caused by increased
oxidative stress. This may occur due to eNOS-mediated generation of O2" (Galle et al,
1991; Ohara et al, 1993; Vergnani et al, 2000; Fleming et al, 2005). The generation of
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this radical species increases intracellular oxidative stress and reduces NO availability,
as O2 " radicals readily inactivate NO (Gryglewski et al, 1986; Rubanyi & Vanhoutte,
1986).
Prolonged endothelial exposure to n- or ox-LDL causes the enhanced generation of O2 "
(Ohara et al, 1993; Pritchard et al, 1995; Vergnani et al, 2000; Fleming et al, 2005).
This may be prevented by NOS inhibition (Huk et al, 1997). The incubation of isolated
carotid arteries with ox-LDL or n-LDL stimulates an 8- and 4-fold increase in the
generation of O2" by eNOS, respectively (Stepp et al, 2002). This may be caused a
lipoprotein-induced decrease in 1-arginine availability (Huk et al, 1997; Vergnani et al,
2000), as the in vitro supplementation of cultured EC with high concentrations of 1-
arginine restores NO-availability (Pritchard et al, 1995; Huk et al, 1997; Vergnani et al,
2000). This is in accord with studies that demonstrated that administration of 1-arginine
restored vasodilatation in hypercholesterolaemia (Cooke et al, 1991; Drexler et al,
1991; Chowienczyk et al, 1994; Clarkson et al, 1996; Wolf et al, 1997; Yin et al,
2005). Therefore, LDL may cause endothelial dysfunction by uncoupling the 1-
arginine/NO-pathway, resulting in the eNOS-mediated generation of O2" and reduced
NO-availability. Consequently, enhanced oxidative stress has a prominent role in the
development of LDL-induced vascular dysfunction and its clinical manifestations.
1.8 Atherosclerosis
Hypercholesterolaemia is an established risk factor for atherogenesis (Goldstein &
Brown, 1977; Steinberg, 1983; Martin et al, 1986), as this is the major clinical
manifestation of elevated plasma LDL concentrations (Cox & Cohen, 1996; Dart &
Dusting, 1999). Atherosclerosis occurs due to the narrowing of the arteries by the
deposition of lipids in the subendothelial layer. This can result in acute cardiovascular
events such as myocardial infarction, stroke, peripheral vascular disease, renal failure
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and other clinical syndromes, depending on the anatomical location of the
atherosclerotic lesions.
Endothelial dysfunction is well established in atherosclerosis and is regarded as a major
precursor of the disease (Harrison et al, 1987). LDL-induced endothelial dysfunction
could have a prominent role in atherogenesis by increasing oxidative stress within the
vascular wall, thus preventing the anti-atherogenic actions of NO and promoting the
oxidative modification of LDL (Cox & Cohen, 1996; Dart & Dusting, 1999). The
potential role of LDL in endothelial dysfunction and atherogenesis is demonstrated in
Figure 1.4. The EC bind n-LDL (Baker et al, 1984) and generate free radicals that
oxidise the attached LDL to form ox-LDL (Steinbrecher, 1987). Oxidative
modification of LDL causes the destruction of the 'classic' LDL receptor-binding
ligand to prevent n-LDL clearance and metabolism (Steinbrecher et al, 1988). Ox-LDL
also promotes monocyte recruitment, monocyte adhesion to the vascular wall, and
enhanced VSMC proliferation (Quinn et al, 1987; Quinn et al, 1988; Ross, 1993). The
monocytes permeate the vascular wall were they differentiate into macrophages and
accumulate ox-LDL (Steinbrecher et al, 1984) via their 'scavenger' receptors (Goldstein
et al, 1979; Steinberg et al, 1989; Witzum & Steinberg, 1991). These cells become
lipid-laden and form foam cells (Steinberg et al, 1989; Steinbrecher et al, 1990;
Esterbauer et al, 1992), which grows into an advanced atherosclerotic lesion and
develop into a fibrous plaque that impedes arterial blood flow (Ross, 1993). This is
prone to rupture and may result in arterial occlusion (Berliner et al, 1995).
1.9 Oxidative Stress
Oxidative stress is an important aetiological factor in many pathophysiological states
and may be a major cause of endothelial dysfunction in cardiovascular disease
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Oxidative stress is a situation in which cells are exposed to excessive levels of reactive
oxygen species (ROS) due to an imbalance between pro-oxidant and antioxidant forces.
A free radical is a highly reactive pro-oxidant species that contains one or more
unpaired electron, and is capable of independent existence (Halliwell & Gutteridge,
1988). These radicals attack other molecules to produce an electron pair and a stable
species. Consequently, the target molecule is oxidised and contains an unpaired
electron, becoming a free radical which may further propagate a free radical chain
reaction (Halliwell & Gutteridge, 1988). Oxygen radicals and other ROS initiate the
chain reaction of lipid peroxidation that induces the oxidative modification of LDL and
produces additional reactive intermediates, such as hydroperoxides, aldehydes and
epoxides.
These in turn cause further damage to cells and tissues by affecting nucleic acids, DNA,
RNA, cellular proteins and membrane constituents (Kukreja & Hess, 1992). Oxidative
stress within the vascular wall may be caused by the release of ROS from the cells
present. Several pathways and enzymes have been implicated in the generation of these
free radicals, such as NADH/NADPH oxidase, XO, lipoxygenases, myeloperoxidase
and NOS (Keaney & Vita, 1995; Harrison, 1997; Cai & Harrison, 2000; Zalba et al,
2000). The key role of excess ROS generation in the development of LDL-induced
endothelial dysfunction has been demonstrated by the ability of antioxidants to restore
endothelium-dependent vasodilatation in patients with risk factors for cardiovascular
disease, such as hypercholesterolaemia (Anderson et al, 1995; Ting et al, 1996a; Ting
et al, 1996b; Levine et al, 1996; Engler et al, 2003).
1.9.1 Superoxide
Superoxide (O2 ") is the major free radical in biological systems and has a half-life of
less than milliseconds (Fridovich, 1978). It is a potent free radical that may cause
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oxidative damage within biological systems, as shown in Figure 1.5. The charged
nature of O2 ~ prevents dissolution in the hydrophobic bilayer of cellular membranes
and could prevent its diffusion into cells. However, whilst in vitro studies have
suggested that O2 " cannot penetrate lipid bilayers (Dix & Aikens, 1993; Frimmer et al,
1996), the free radical may permeate biological membranes (Mao & Poznansky, 1992)
via anion channels (Fridovich, 1978; Lynch & Fridovich, 1978; Gus'kova et al, 1984).
Under physiological conditions, O2" is produced by all tissues via mitochondrial
oxidative metabolism during aerobic respiration. O2 " reacts readily with NO to
maintain low physiological concentrations of O2 ~ within the EC (Gryglewski et al,
1986; Rubanyi & Vanhoutte, 1986). Various enzymatic processes generate O2 ~ via the
oxidation of NADH or NADPH by NAD(P)H oxidase (Loschen et al, 1974), which is
constitutively active in smooth muscle cells. EC also contain several oxidase enzymes
which are capable generating O2 " (Rubanyi & Vanhoutte, 1986; Katusic & Vanhoutte,
1989), such as NAD(P)H oxidase, XO (Engerson et al, 1987; Ohara et al, 1993), COX
(Muggq et al, 1991), and cytochrome P450 (Sligar et al, 1974). In pathophysiological
conditions, the generation of this potent free radical is may be increased. The
deleterious action of LDL upon vascular function is attributed to the increased eNOS-
mediated generation of O2" (Ohara et al, 1993). Furthermore, O2" can cause
vasoconstriction either by a direct action on smooth muscle cells or by an indirect
action via the inactivation of basal endothelium-derived NO (Rubanyi & Vanhoutte,
1986; Gryglewski et al, 1986; Auch-Schwelk et al, 1989; Katusic & Vanhoutte, 1989).
Endothelial removal decreases O2" production in hypercholesterolaemic vessels, but
increases production in normal vessels (Ohara et al, 1993). This suggests that, while
the endothelium may be a source of O2 it protects against the harmful effects of this
radical via the production of basal NO to scavenge O2 ~. This also suggests that under
physiological conditions, NO production is greater than basal O2" production.
Importantly, NO production is similar in normal and hypercholesterolaemic vessels


















Figure 1.5. The major reactions of 02". 02" reacts rapidly with NO to form the
highly reactive and cytotoxic radical ONOO". Dismutation with SOD converts 02"
to H202, which is then decomposed by catalase or GPX. An overview of the
deleterious effects of the formation of these potentially-damaging radical species is
also shown.
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relationship with EC and NO, suggest it has a vital role in the aetiology of endothelial
dysfunction and the disease states associated with this condition.
1.9.2 The interaction of 02" and NO
In various pathophysiological conditions, 02" may form more reactive and damaging
agents (Freeman & Crapo, 1982). The role of NO is different in the presence of 02"
compared with the absence (Rubbo et al, 1994). 02" can directly decrease NO
availability and impair NO-mediated dilatation (Beckham & Koppenol, 1996).
However, more significantly, when produced in close proximity, NO and 02" react
rapidly to form the potent cytotoxic oxidant, peroxynitrite (ONOO") (Pryor &
Squadrito, 1995; Beckman & Koppenol, 1996; Ma et al, 2000; Radi et al, 2001).
NO +02" < ► ONOO"
ONOO" is formed in situ when a vascular imbalance in the production of NO and 02'"
occurs. These react rapidly to produce ONOO" at an almost diffusion-limited rate of 6.7
x lC^M-1 s"1 (Huie & Padmaja, 1993). This reaction is limited by the radical precursor
produced at lower rates, but occurs optimally when 02" and NO are present in an
equimolar basis (Miles et al, 1996). ONOO" may be formed in either the aqueous or
the hydrophobic phase of the cell. NO is more soluble in the hydrophobic phase (Khan
& Wilson, 1995), and the reaction between NO and 02" occurs approximately 300
times more rapidly within membranes than in the surrounding aqueous medium (Liu et
al, 1998). NO has a biological half-life of seconds and freely diffuses across
membranes (Denicola et al, 1996), however 02" lasts less than milliseconds and may
only permeate membranes via anion channels (Fridovich, 1978). Therefore, ONOO"
formation will predominantly occur nearer to the site of 02" generation.
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1.9.3 Peroxynitrite
ONOO" is a highly reactive cytotoxic compound that may yield ROS and reactive
nitrogen species (RNS) (Beckman et al, 1990; Koppenol et al, 1992; Koppenol, 1998;
Radi et al, 2001). It is relatively stable anion, due to the delocalisation of the negative
charge over the entire molecule. However, upon protonation to peroxynitrous acid
(ONOOH) (pKa 6.8) it decays to nitrate. Under biological conditions, the ratio of
ONOO" to ONOOH is dependent upon the pH. Under physiological conditions (pH
7.4), 80% of ONOO" is present in the anionic form and decomposes after only a few
seconds (Beckman et al, 1990; Koppenol et al, 1992; Pryor & Squadrito, 1995). This
generates further free radicals, such as OH' or NO2' (White et al, 1994; Beckman &
Koppenol, 1996; Squadrito & Pryor, 1998; Patel et al, 2000; Ma et al, 2000), which
cause further radical reactions.
ONOO" is able to freely permeate membranes via anion channels (ONOO") and passive
diffusion (ONOOH) (Maria et al, 1997; Denicola et al, 1998). It has an estimated half-
life of less than 100ms (Radi et al, 1998; Romero et al, 1999), which is sufficient for
ONOO" to potentially travel 5-20pm across extracellular and/or intracellular
compartments. As a result, ONOO" has ready access to hydrophobic compartments
within cells, and to hydrophobic structures such as atherosclerotic plaques, were it may
induce membrane lipid and lipoprotein oxidation reactions (Radi, 1998).
ONOO" may react with a variety of biomolecules such as lipids, proteins, carbohydrates
and DNA (Moreno & Pryor, 1992; Rubbo et al, 1994; Pryor & Squadrito, 1995; Salgo
et al, 1995; Evans et al, 1996), and is implicated in the aetiology of numerous disease
processes, such as cardiovascular disease, atherosclerosis and severe inflammatory
conditions (Radi et al, 2001). The potential pathophysiological effects include
inactivation of mitochondrial manganese-SOD (Ischiropoulos et al, 1992) and
glutamine synthase (Berlett et al, 1998), oxidative modification of LDL (Steinberg et
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al, 1989), lipid peroxidation (Radi et al, 1991), alteration of the lipid aggregatory
properties of surfactant protein A (Berlett et al, 1998), inactivation of sodium transport,
inactivation of al-antiproteinase (Moreno & Pryor, 1992), modification of tyrosine
phosphorylation (Gow et al, 1996; Kong et al, 1996). It may also cause one- or two-
electron oxidations of sulphydryls, resulting in the formation of thiyl radicals, radical
chain reactions and the depletion of thiols (Quijano et al, 1997). ONOO" also attacks
and decreases plasma antioxidant levels, thus reducing the natural physiological
defence mechanism and allowing oxidative damage to tissues and organs (van der Vliet
et al, 1994; Pryor & Squadrito, 1995).
ONOO" reacts readily with phenolic compounds, such as tyrosine, to form nitrated and
dimerised products, such 3-nitrotyrosine (Ischiropoulos, 1998) and dityrosine (van der
Vliet et al, 1994). Protein tyrosine residues are key-targets for ONOO'-mediated
nitrations and modify protein and enzyme function (Ischiropoulos, 1998). The presence
of 3-nitrotyrosine in proteins may represent modifications induced by the biological
formation of ONOO" (Ischiropoulos, 1998). Endogenous ONOO" formation causes the
nitration of certain cellular proteins in vivo, such as Mn-SOD (Hooper et al, 1997) and
prostacyclin synthase (Haddad et al, 1996; MacMillan-Crow et al, 1998). ONOO" may
also reduce NO-availability, by irreversibly inhibiting NOS via the oxidation of the
haem thiolate bond in the catalytic site of the enzyme (Pasquet et al, 1996).
ONOO" may have contrasting effects upon the vascular system depending on the
concentrations present. When present in low concentrations, ONOO" may form a
vasoactive compound that can restore and maintain NO-mediated vascular function
(Liu et al, 1994; Moro et al, 1995; van der Vliet et al, 1998). However, in greater
concentrations (>30pM) the deleterious properties of ONOO" on the vascular system
are predominant (Ma et al, 1997; Ma et al, 2000; Radi et al, 2001).
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1.10 Antioxidants
The generation of harmful free radicals, such as O2 ~ and ONOO", can have disastrous
effects upon human physiology. Consequently, an extensive antioxidant defence
system is present within the human body. Three requirements must be fulfilled before a
substance can be regarded as a physiological antioxidant. The potential antioxidant
must interact with and scavenge biologically relevant oxidants and free radicals. This
interaction must lead to the chemical modification of the antioxidant which generates a
product that is physiologically less harmful than the initial oxidant or radical. Finally,
the antioxidant should be present in adequate physiological concentrations to ensure a
sufficient reaction.
The antioxidant defence system within the human body may be separated into three
main classes:
■ Antioxidant enzymes. This includes enzymes such as superoxide dismutase
(SOD), glutathione peroxidase (GPX) and catalase which prevent the deleterious effects
of ROS (Carlsson et al, 1995; Straitlin et al, 1995). These enzymes are mainly part of
the intracellular antioxidant defence system.
■ Preventative antioxidants. These are proteins, such as albumin, transferrin and
caeruloplasmin, which bind transition metal ions to prevent the oxidation of LDL
(Heinecke et al, 1984; Steinbrecher et al, 1984).
■ Chain-breaking antioxidants. These are low molecular weight compounds that
scavenge free radicals to prevent damage to important target molecules. They can be
divided into lipid-soluble antioxidants, such as tocopherols, ubiquinol-10, and
carotenoids, and water-soluble antioxidants, such as uric acid (UA), ascorbic acid (AA)
and glutathione (GSH). Lipid-soluble antioxidants exist within cellular membranes and
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lipoproteins, and have a major role in preventing the oxidative modification of LDL.
LDL oxidation in vitro is preceded by the depletion of lipid-soluble antioxidants
(Schlotte et al, 1998). Water-soluble, or hydrophilic, antioxidants prevent the lipid
peroxidation induced by transition metal ions, peroxyl radicals and a number of
different cell types (Frei et al, 1989). In addition to their radical scavenging ability,
hydrophilic antioxidants such as AA and UA can sequester transition metal ions or
modify the metal-binding sites of LDL to prevent metal-ion dependent oxidation
(Retskyeta/, 1993).
The various classes act synergistically to provide an efficient antioxidant defense
system. For example, hydrophilic antioxidants may act as sacrificial antioxidants to
prevent the consumption of those with in the lipid phase. Interaction also allows the
regeneration of other antioxidants, for example, AA may regenerate the a-tocopherol
radical, and UA may protect and stabilise AA (Abuja, 1999).
1.11 Uric Acid
UA is a weakly acidic (pKa=5.8), non-enzymatic compound distributed throughout the
extracellular fluid in the body as urate, a monoanion salt. This is removed from plasma
by glomerular filtration. 10% is filtered and secreted, but the remaining 90% is
reabsorbed from the proximal renal tubule and returned to the blood. The concentration
of UA in plasma varies widely between individuals and is determined by the rate of
purine metabolism and renal clearance (Steele, 1971; Tykarski et al, 1991). However
the typical reference range for physiological plasma concentration is 100-400pmol/l
(Alderman et al, 1999; Fang & Alderman, 2000).
UA is derived exclusively from the breakdown of adenine and guanine-based
compounds. These purine compounds are essential to all animal cells and subject to
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continuous metabolic turnover. Through a series of enzymatic steps they are degraded
to hypoxanthine (HX) then xanthine. UA is then formed by the further oxidation of
xanthine (Figure 1.6) (Becker, 1993; Waring et al, 2000). This is exclusively catalysed
by XDH (xanthine dehydrogenase), using NAD+ as an electron acceptor, or by xanthine
oxidase (XO), which transfers the reducing equivalents direct to O2 to form ROS, such
as O2 " and H2O2 (Parks & Granger, 1986; Rubanyi & Vanhoutte, 1986; Ohara et al,
1993). During normal metabolism UA is produced by XDH (Parks & Granger, 1986).
However, under ischaemic conditions or oxidative stress, endothelial XDH is converted
to XO (Rubanyi & Vanhoutte, 1986). XO activity is inhibited by NO and ONOO"
(Ichimori et al, 1999; Lee et al, 2000). Therefore, UA production may be increased
under conditions in which NO availability is reduced by the formation of ONOO". The
major site ofUA production in the cardiovascular system is the EC, as XO is primarily
located within these cells (Jarasach et al, 1981; Nees et al, 1985; Jarasach et al, 1986).
These cells release UA into the vascular lumen and abluminal compartment (Becker,
1993; Leyva et al, 1998).
1.11.1 UA solubility
UA is generally thought to be biologically unreactive in humans. However, it is poorly
soluble and enhanced production and retention may be clinically manifest as crystal
formation. This predisposes to the development of pathophysiological conditions such
as gout or nephrolithiasis. UA accumulates in physiological fluids and tissues by
several pathways, such as passive transudation from plasma, active transport as occurs
in renal tubular cells, local generation by XO, and intracellular production from purine
precursors. Although sparingly soluble in aqueous media, UA is insoluble in
hydrophobic media, such as biological membranes and lipid phases. Therefore, UA is
restricted to aqueous environments (Emerson, 1996). It is generally accepted that
plasma UA saturation occurs at approximately 415pmol/l and that the concentration of
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Figure 1.6. The formation of UA from Xanthine by XO. The reduced enzyme is
subsequently re-oxidised by O2 to yield H2O2.
33
UA in male blood approaches maximum solubility. As a result, humans with elevated
concentrations are susceptible to crystal deposition and the resultant pathophysiological
conditions (Emerson, 1996).
1.11.2 Comparative physiology
As previously mentioned UA is produced in human physiology as the end product of
purine metabolism and undergoes renal excretion. UA is also the end-product of purine
degradation and excreted in the urine of higher primates. The excess amino acid-
nitrogen of terrestrial reptiles, birds and insects are also catabolised to UA. However,
in other animals UA is further processed to more soluble products before excretion, as
shown in Figure. 1.7. (Becker, 1993; Waring et al, 2000). Mammals, other than
humans and higher primates, oxidise UA to their excretory product, allantoin, and fish
and amphibians degrade this further prior to excretion. This occurs as these species
express urate oxidase, the enzyme responsible for the oxidative degradation of UA.
Consequently, the plasma levels of UA found in these species are less than 10% of
those found in man. The concentration in human blood, 400pmol/l, is close to the
maximum solubility. However, most mammals, such as rats or prosimians have
markedly lower levels, less than 40pmol/l (Roch-Rammel & Peters, 1978).
In humans, the gene that codes for urate oxidase is located on chromosome 1.
However, as the result of two non-sense mutations this is not expressed (Wu et al,
1992). This evolutionary process could suggest that elevated serum UA concentrations
have an important role in human physiology (Ames et al, 1981). The increase in
human UA levels that has occurred during the course of approximately 60 million years
of evolution has been accompanied by a significant increase in life-span. It is possible
that UA may be responsible for this. An interspecies comparison in mammals gives a
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Figure 1.7. UA is produced in human physiology as the end product of purine
metabolism and undergoes renal excretion. Other species that express uric oxidase
further oxidise UA to produce more soluble excretory products.
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of example, monkeys have higher plasma UA concentrations than prosimians, but less
than longer-lived apes (Roch-Rammel & Peters, 1978). Oxidants and free radicals have
a prominent role in the development of cellular aging and terminal diseases, such as
cancer and cardiovascular disease, thus, the positive association could be attributed to
the antioxidant ability ofUA (Ames et al, 1981).
1.11.3 Is UA treated as a 'waste product' in human physiology?
In human physiology, UA may regarded as a waste product of purine metabolism.
Purines such as adenine, guanine, HX, adenosine and inosine are readily removed from
the blood and recycled into cellular purine pools. However, no such process occurs to
recycle and reincorporate UA or xanthine (Manfredi & Holmes, 1985). Therefore,
purines that are degraded to UA must be replaced by synthesis or by scavenging
precursors, which results in the considerable loss of energy. However, despite the
requirement to replenish the purine balance and the considerable loss of energy that
occurs, dietary-ingested purines are not reabsorbed within the gastrointestinal tract but
are converted exclusively to UA by mucosal XDH. This has been demonstrated as only
UA appears in systemic circulation following purine consumption (Becker, 1993).
Furthermore, as previously mentioned, 90% of filtered UA is reabsorbed from the
proximal renal tubule. This physiological treatment of UA suggests that the human
body does not treat it as a 'waste product' and may imply that it has a very important
physiological role.
1.12 The association ofUA with cardiovascular disease
Hyperuricaemia is usually defined as a serum UA concentration greater than 415pM in
males and 357pM in females (Alderman et al, 1999; Fang & Alderman, 2000). These
concentrations of UA are present in cardiovascular disease (Torun et al, 1998; Johnson
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et al, 1999). Various epidemiological and clinical studies have linked these elevated
UA concentrations to an increased risk of cardiovascular disease and it has been
suggested that UA has a prominent role in the pathogenesis of this state (Fessel, 1980;
Brand et al, 1985; Bonora et al, 1996; Persky et al, 1997; Bengtsson et al, 1998; Lehto
et al, 1998; Ward, 1998; Liese et al 1999; Fang & Alderman, 2000; Johnson et al,
2003).
In contrast, several studies have suggested that the association between UA and
cardiovascular disease is due to a non-causal relationship with pathophysiological
conditions, in which cardiovascular risk is mediated by other risk factors. For example,
under conditions of ischaemia and tissue hypoxia, vascular adenosine synthesis and
release are upregulated to relax VSMC (Fredholm & Sollevi, 1986; Raatikainen et al,
1994). This adenosine may be rapidly degraded to UA by the EC (Kroll et al, 1992), as
XO activity is increased under ischaemic conditions (Clark et al, 1990; Idstrom et al,
1990). Increased UA concentrations are also associated with insulin resistance
syndromes, which result in the inhibition of insulin-mediated glucose metabolism and
cause a significant increase in cardiovascular risk (Cleland et al, 1998). In this disease
state, the effect of insulin upon glucose metabolism is impaired but the sensitivity of the
renal tubule to insulin is not (Muscelli et al, 1996). Consequently, this condition could
cause the accumulation ofUA (Muscelli et al, 1996). Therefore, the link between UA
and cardiovascular disease may arise from a non-causal relationship with conditions
such as ischaemia, diabetes mellitus (Perry et al, 1995) and hypertension (Selby et al,
1990).
Despite the established clinical association between elevated concentrations ofUA and
cardiovascular disease, no causative mechanism has been proposed. Several,
epidemiological studies have negated a predictive link between plasma UA levels and
cardiovascular disease, suggesting that the relationship does not exist after accounting
for co-existing risk factors (Reunanen et al, 1982; Iribarren et al, 1996; Wannamethee
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et al, 1997; Culleton et al, 1999; Alderman, 2001; Alderman, 2002). Studies have
associated elevated serum UA to hypertension, hypercholesterolaemia, reduced HDL
cholesterol, hyperinsulinaemia, reduced physical activity, increased body mass index,
and increased alcohol intake - all of which have a causal role in the development of
cardiovascular disease (Patten et al, 1980; Tykarski, 1990; Agamagh et al, 1991; Lee et
al, 1995; Alderman et al, 1999). Therefore, whilst elevated serum UA concentrations
are associated with increased cardiovascular risk, it remains unclear whether UA is an
independent risk factor or merely a predictor of cardiovascular disease and mortality,
and whether it has a causative or protective role in cardiovascular disease.
1.13 The causative role of UA in cardiovascular disease
1.13.1 Evidence for the involvement of UA in the development of
cardiovascular disease
UA has the potential to exert an antioxidant action and scavenges harmful radicals in
the body. However, in conjunction with genetic or environmental factors, UA may be
associated with vascular disease. Therapeutic interventions that lower serum UA
concentrations have been reported to reduce the development of degenerative vascular
disease in man (Emerson, 1979). UA has been found to enhance platelet and leukocyte
adhesion to the vascular wall (Newland, 1975; Emerson, 1979; Boogaerts et al, 1983),
and cause increased platelet lysis (Ginsberg et al, 1977), thus enhancing thrombus
formation. UA can stimulate endothelial granulocyte adherence (Boogaerts et al, 1983)
and the release of peroxide and Of from these cells (Boogaerts et al, 1983; Falasca et
al 1993). UA may also enhance VSMC proliferation to contribute to arterial injury
(Rao et al, 1991) and is strongly associated with the chronic inflammation that occurs
in cardiovascular disease (Leyva et al, 1998). It may also traverse dysfunctional EC
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and accumulate as crystals within atherosclerotic plaques (Kroll et al, 1992; Patetsios et
al, 1996; Kanellis et al, 2003). Plaque samples have been found to contain increased
concentrations of UA compared to control arteries (Suarna et al, 1995). Crystals
consistent with urate have also been identified in diseased blood vessels (Lehto et al,
1998) and cardiac valves (Johnson et al, 1999). UA crystals are proinflammatory and
stimulate neutrophils to release ROS, stimulate macrophages, and activate platelets and
coagulation (Johnson et al, 1999). Therefore, UA could potentially have a role in the
development of cardiovascular disease via its interaction with the cells present in the
blood. This may indirectly enhance the pathophysiology of cardiovascular disease by
increasing oxidative stress and exerting a further deleterious effect upon vascular
function.
1.13.2 The pro-oxidant action of UA
The vital task of preventing the oxidative modification of LDL oxidation has been
attributed to the major low molecular weight antioxidants within plasma, such as UA.
However, under certain in vitro conditions UA may potentiate this (Sanguinetti et al,
2004). Many aqueous antioxidants have been found to promote metal-catalysed
oxidation of LDL when the major endogenous antioxidant, a-tocopherol, is consumed
(Abuja, 1999). UA shares this ability and can exert a pro-oxidant action when added
after the partial depletion of a-tocopherol (Abuja, 1999; Bagnati et al, 1999). The pro-
oxidant potential of UA is high compared to other conditional pro-oxidants, as it only
requires the partial depletion of a-tocopherol, where as others only become pro-oxidant
after most or all has been consumed (Abuja, 1999; Bagnati et al, 1999). Clinical data
has also suggested that elevated UA production causes increased free radical formation
(Anker et al, 1997; Leyva et al, 1997) and oxidative stress (Yasquez-Vivar et al, 1996).
The oxidation of UA can also result in the generation of free radical metabolites
(Maples & Mason, 1988). Furthermore, UA may react with the generated ONOO" to
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produce a potentially damaging aminocarbonyl radical with the ability to cause further
oxidative damage (Vasquez-Vivar et al, 1996; Santos et al, 1999). This is supported by
in vitro experiments that demonstrated UA could potentiate ONOCT-induced oxidation
of LDL (Bowry & Stacker, 1993; Thomas et al, 1998). Therefore, UA has the potential
to enhance the development of cardiovascular disease by potentiating the oxidative
damage caused by transition metal ions (Smith et al, 1992; Garner et al, 1997) and
ONOO" (Beckman & Koppenol, 1996).
1.13.3 UA and endothelial dysfunction
Evidence regarding the causal role of UA in endothelial dysfunction remains
inconsistent (Alderman, 2002). Vascular EC are strong candidates for involvement in
the pathological role of UA in vascular disease, as a result of their various functions
and localisation. Chronic exposure of the endothelium to blood containing
hyperuricaemic concentrations of UA, may trigger initial damage within the intimal
layer of the vessel wall, and therefore, may represent a vital factor among the metabolic
abnormalities responsible for pathologic damage and the of development vascular
disease (Rathmann et al, 1993; Persky et al, 1997). In vitro and in vivo findings
suggest that UA may contribute to endothelial dysfunction by inducing antiproliferative
effects on endothelium and impairing NO production (Kanellis & Kang, 2005).
Hyperuricaemic rats have impaired NO generation and decreased NO availability
which can be reversed by lowering UA levels or by supplementation with 1-arginine
(Khosla et al, 2005). This suggests that UA can inhibit NOS and NO production to
directly induce endothelial dysfunction (Khosla et al, 2005), and may provide a
pathogenic mechanism by which UA can induce hypertension and cardiovascular
disease.
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In hyperuricaemic patients, endothelium-dependent vasodilatation is impaired when
compared to control patients with normal UA levels but an elevated risk of
cardiovascular disease (Mercuro et al, 2004). This is improved following a three-
month therapeutic reduction of UA concentrations with allopurinol, which inhibits XO
(Mercuro et al, 2004). Chronic heart failure is associated with reduced endothelial
function, impaired peripheral blood flow, and is accompanied by hyperuricaemia.
Treatment with allopurinol may improve endothelial function in this disease state
(Farquharson et al, 1999; Farquharson et al, 2002). Flowever, this may occur by
preventing XO-mediated O2 ~ generation (Doehner et al, 2002). UA could also induce
vascular dysfunction via an indirect deleterious action of UA upon the endothelium.
For example, UA stimulates leukocyte adherence to the vascular endothelium
(Boogaerts et al, 1983; Falasca et al, 1993), which may result in the inhibition of
endothelial function. UA may also contribute to vascular injury by accumulating in the
vascular wall to cause further damage (Kroll et al, 1992; Patetsios et al, 1996; Kanellis
et al, 2003), and enhance the development of cardiovascular disease. However, a
recent clinical study examined the direct effect of local or systemic administration of
UA on vascular function in healthy adults (Waring et al, 2004). This study reported
that UA administration caused a twofold increase in serum concentrations but did not
acutely alter haemodynamic variables, basal forearm blood flow, or NO-dependent
endothelial function (Waring et al, 2004).
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1.14 The beneficial role of UA in cardiovascular disease
1.14.1 The antioxidant properties of UA
Although the role of elevated UA in endothelial dysfunction is uncertain, the well-
established relationship between UA, cardiovascular disease and the associated risk
factors may be misleading. Despite this association, UA is regarded as a major
hydrophilic antioxidant in human physiology (Proctor, 1970; Ames et al, 1981; Becker,
1993; Nyyssonen et al, 1997; Glantzounis et al, 2005). Endogenous antioxidants
constitute the first line of defence against oxidative stress and the damage caused by
this. Therefore, hyperuricaemia may be a compensatory mechanism to counteract
oxidative damage related to cardiovascular disease in humans.
Clinical studies have reported increased UA levels account for the compensatory
increase in total oxidant-trapping capacity in patients with carotid atherosclerosis,
(Nieto et al, 2000). This implies that UA may indeed have a cardioprotective role by
increasing protection against mediated by oxidative stress. In ischaemic skeletal
muscle HX and xanthine progressively accumulate to levels 15 times greater than
normal (Idstrom et al, 1990). These are not converted to UA until reperfusion occurs.
This occurs to combat the increased generation of ROS following reperfusion (Idstrom
et al, 1990). Studies in perfused rat hindlimbs have proposed a similar mechanism in
smooth muscle (Clark et al, 1990). Ischaemia and reperfusion also results in the local
generation of large amounts of UA by both VSMC XO and EC XO (Parks & Granger,
1986; Castelli et al, 1995). This causes substantial increases in UA formation and the
potential antioxidant capacity within the vessel wall (Rao et al, 1991). UA may prevent
the impairment of endothelium-dependent vasodilatation caused by O2 ~ in the coronary
system (Becker et al, 1991).
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UA has the ability to exert a chain-breaking antioxidant action and is found in higher
concentrations in the body than other potential non-enzymatic antioxidant compounds,
such as AA (20-60pM), a-tocopherol (20-40pM) and GSH (1-lOp.M). UA contributes
approximately 60% of the peroxyl-radical scavenging potential of the human serum
(Wayner et al, 1987; Frei et al, 1988; Maxwell et al, 1997), and interacts with ONOO"
to produce a stable, partially characterized, nitrate derivative and prevent any further
damage to the vascular system (Skinner et al, 1998). UA is a major inhibitor of ozone-
induced oxidation in plasma (Cross et al, 1992), scavenges singlet oxygen (Ames et al,
1981), and provides at least 15-20% of OH' radical scavenging activity (Thomas, 1992).
At physiological concentrations, UA may prevent haem- and peroxide-catalysed
peroxidation of erythrocyte membranes (Ames et al, 1981; Smith & Lawing, 1983). UA
also chelates transition metal ions to prevent metal catalysed oxidation reactions
(Davieseta/, 1986).
UA also attenuates the oxidative modification of plasma lipids, lipoproteins and
unsaturated fatty acids (Esterbauer et al, 1989; Bagnati el, 1999; Kopprasch et al,
2000). UA can prevent the in vitro oxidative modification of n-LDL by preventing the
consumption of endogenous LDL antioxidants. 100pM UA reduces the rate of a-
tocopherol degradation by 50% and prevents PUFA oxidation (Schlotte et al, 1998).
This indicates that UA is able to spare the oxidation of endogenous LDL antioxidants.
UA can also act as a protective or sacrificial antioxidant for other hydrophilic
antioxidants, such as AA (Sevanian et al, 1993; Lam et al, 1984). Therefore, UA has
the potential to protect against the oxidative damage caused by oxidative stress and
exert a cardioprotective effect in the pathophysiology of cardiovascular disease.
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1.14.2 Mechanism of antioxidant action of UA
1.14.2.1 Metal Chelator
Transition metals are involved in the redox reactions that occur within the cells of the
vascular wall (Garner et al, 1997), such as the metal-induced oxidative modification of
LDL, and catalyse the generation of ROS (Aust et al, 1985). A potential role for UA in
cardiovascular disease may be to protect against this by sequestering and inactivating
transition metals, such as Fe2+ and Cu2+, thus preventing reactions involving these
redox-active metals. UA has metal-binding abilities and is able to form stable co¬
ordination complexes with transition metal ions, making them less redox active with
regard to the initiation of oxidative reactions (Davies et al, 1986; Sevanian et al, 1991).
On an equimolar basis, UA is approximately 10 times more effective than AA in
preventing the Cu2+-catalysed oxidative modification of LDL (Esterbauer et al, 1989).
The metal-chelating abilities of UA also allow it to act as a sacrificial antioxidant to
prevent the metal-catalysed oxidation ofAA (Abuja et al, 1999). Furthermore, UA can
regenerate AA that been oxidised (Lam et al, 1984; Sevanian et al, 1991) to and
maintain the distinct antioxidant ability of this compound (Sevanian et al, 1985;
Sevanian et al, 1991). Therefore, in view of the various mechanisms underlying
cardiovascular disease, UA could have a beneficial role by chelating redox-active
transition metal ions, thus inhibiting the initiation of metal-catalysed reactions, the
oxidative modification of lipoproteins, and maintaining endogenous antioxidant levels.
1.14.2.2 Radical Scavenger
The radical scavenging ability of UA could confer a degree of protection against
cardiovascular disease and the associated risk factors, such as hypercholesterolaemia,
by preventing the deleterious actions of ROS. Under physiological conditions, 99% of
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UA is present as urate (Simic & Jovanovic, 1989). Consequently, the antioxidant
activity ofUA is attributed the ability of this monoanion to scavenge free radicals via a
one-electron redox process. Substitution of the hydroxy-group at the 8-position, with a
halogen or phenyl group, results in the loss of the antioxidant ability ofUA (Schlotte et
al, 1998). Consequently, the 8-hydroxy-group may be essential for the stabilisation of
the urate monoanion and is an important functional moiety for the antioxidant activity
ofUA (Schlotte et al, 1998). The one-electron oxidation ofUA produces a free radical
metabolite that contains an unpaired electron, located primarily on the five-membered
ring of the purine structure (Maples & Mason, 1988). This free radical is a relatively
stable compound due to the marked delocalisation of the unpaired electrons over the
heterocyclic purine ring structure (redox potential = 0.59V, OH = 2.00V). The one-
electron oxidation of UA by strong oxidants including hydroxyl (OH"), peroxyl, nitrite,
and guanyl radicals produces a UA radical in neutral solution (Maples & Mason, 1988;
Simic & Jovanovic, 1989; Vasquez-Vivar et al, 1996; Santos et al, 1999). UA reacts
with hydroxyl radicals at a rate constant reaction of 7xl09 M'V1 (Becker, 1993) and
significantly prevents the light emission evoked from luminol in the presence of various
OH-generating systems in luminol-enhanced chemiluminescence (Howell &
Wyngaarden, 1960; Becker et al, 1989; Radi et al, 1990). However, whilst UA may be
regarded as a potent antioxidant for oxidants such as OH" and ONOO" (Radi, et al,
2001) it does not react with weaker oxidants such as H2O2 or O2" (Becker et al, 1989;
Kaur & Halliwell, 1989). UA does not attenuate the reduction of cytochrome C
(Becker et al, 1989) or nitrotetrazolium blue by O2 " radicals (Goshima et al, 1986).
UA may only be oxidised in the presence of O2'" if the experimental conditions favour
the secondary generation of OH", for example, if H2O2 to was added to, or formed
from, O2" (Becker et al, 1989).
The UA-derived radical formed upon radical scavenging may further react with other
antioxidants to regenerate UA (Abuja, 1999) and produce weaker oxidants, such as the
ascorbate radical (redox potential = 0.28V) (Maples & Mason, 1988; Simic &
45
Jovanovic, 1989; Sevanian et al, 1991). However, in the absence of redox-partners to
regenerate UA, the UA-derived radical may be further oxidised via two-electron
transfer by oxidants such as H2O2 or HOC1. This forms allantoin and other products,
such as allantoate, parabanic, oxaluric and oxalic acid (Kaur & Halliwell, 1989; Santos
et al, 1999). Therefore, UA could potentially prevent the development of endothelial
dysfunction and cardiovascular disease by scavenging free radicals to reduce oxidative
stress, maintain NO-availability and prevent further oxidative damage to the vascular
system.
1.14.3 The site of action ofUA
Although the EC are a major site of UA production in the cardiovascular system
(Becker, 1993), all tissue compartments, with the exception of the lipid phases, utilise
UA as a replenishable antioxidant (Becker, 1993). UA has access to all extracellular
fluid compartments, such as plasma, lymphatic, cerebrospinal, interstitial, synovial,
intraocular, respiratory tract lining and amniotic fluid (Fleming et al, 1988; Hasegawa
& Kuroda, 1989; Peden et al, 1990; Becker, 1993). Therefore, UA is not as strictly
compartmentalised as enzymatic free radical scavengers, such as SOD and catalase.
The transport of UA across cellular membranes may occur by non-ionic or anionic
modes, although both forms are slow (Lucas-Heron & Fontenaille, 1979; Becker et al,
1989). Nevertheless, UA is avidly taken up into red blood cells, hepatocytes and
cardiomyocytes, implying that it may act as an intracellular scavenger in cells other
than those where it is produced. Therefore, in cardiovascular disease, other cells may
take up the elevated concentrations of UA from the plasma to use as an intracellular
antioxidant and protect against the oxidative stress and damage that are prominent this
disease state. Further investigation is required to provide an increased understanding of
the effect of UA upon vascular function. This would allow a clearer interpretation of
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the potential role of the increased serum UA concentrations in endothelial dysfunction
and cardiovascular disease.
1.15 Methodological approaches to assessing endothelial
function
The study of isolated blood vessels eliminates the influence of surrounding tissue cells.
This provides an understanding of the influence of the pharmacological properties of
the vascular system upon blood flow. Comparing the reactivity of the blood vessels
with and without endothelium is the only method that can demonstrate the involvement
of EC in vascular function. For ethical reasons, the only technique that may be used to
truly demonstrate endothelium-dependency in humans is the use isolated human blood
vessels. However, the ability of EC to control the tone of vascular smooth muscle
rapidly diminishes after death (Vedernikov et al, 1990), meaning that arteries must be
isolated as early as possible and used immediately. This makes experiments difficult to
plan and very restrictive. Therefore, the majority of isolated vessel studies are
performed on animal models such as rabbits or rodents.
1.15.1 Perfusion myography
Resistance arteries within the microcirculation are chiefly responsible for the regulation
of blood flow and capillary pressure (Furness & Marshall, 1974). Small arteries and
arterioles are major determinants of peripheral vascular resistance, blood pressure and
blood flow. Blood vessel control in the microcirculation also determines perfusion of
the surrounding tissue. It has previously been suggested that alterations in the vascular
structure and function of these vessels may have a prominent role in various
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pathological conditions such as hypertension and congestive heart failure (Dunn &
Gardiner, 1995). Therefore, an understanding of the physiological factors involved in
the control of vascular tone in resistance arteries is essential. As a result of the
causative or consequential implications of these arteries in vascular disease, the in vitro
study of isolated resistance blood vessels is vital in investigating the aetiology of
pathological conditions such as hyperuricaemia, hypertension and cardiovascular
disease. However, due to their small size, the techniques used to perform in vitro
studies on isolated resistance arteries are not as straightforward as the techniques used
to study larger vessels such as the aorta.
Due to the difficulty in accurately measuring the biochemical generation ofNO by the
endothelium, a functional approach has been adopted. This is performed by assessing
changes in vasomotor function in response to endothelium-dependent vasodilators, such
as ACh, or by inhibiting NO synthesis. The methods most commonly used for
examining the physiological and pharmacological properties of isolated resistance
arteries are wire myography and perfusion, or pressurised, myography. Mulvany and
Halpern developed the wire myography technique for the study of isolated resistance
arteries. This involved the mounting of arterial ring preparations in an organ bath
chamber by passing two wires through the lumen. Vasoactive responses were measured
by recording the isometric force exerted by the vessels upon the wires (Mulvany &
Halpern, 1976). This technique has since been modified to produce a method that
better replicates physiological conditions for the study of isolated resistance vessels
(Mulvany & Halpern, 1977; Duling et al, 1981; Sipkema & Westerhof, 1989; Halpern
& Kelley, 1991; Hoogerwarf et al, 1992). In 1990 Van Bavel et al developed the
technique of perfusion or pressurised myography (Van Bavel et al, 1990). This
technique differs from wire myography as the vessel is mounted on size-matched
cannula, perfused with an intraluminal solution and pressurised. The vasoactive
responses are then measured as changes in intraluminal diameter.
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1.15.2 The advantages of perfusion myography
Perfusion myograph may be more appropriate than techniques such as wire myography
for the study of vascular and endothelial function in resistance arteries. The in vitro
conditions under which experiments are performed alter the ability of agonists to
induce vasoactive responses in isolated vessel preparation. The use of perfusion
myography allows studies to be conducted in an experimental environment that mimics
those found in vivo. Perfusion myography allows proportionately longer intact vessel
segments to be mounted when compared to the ring segments commonly used in wire
myography. This technique also allows longitudinal stretching of the mounted arterial
segment to restore it to its physiological in vivo length, as the arteries undergo marked
physical retraction upon dissection (Coats & Hillier, 1999). Longitudinal stretching of
the arteries also increases the media surface area, thus increasing the availability and
access of vasoactive drugs to the VSMC (Buss et al, 1994; Coats & Hillier, 1999).
Furthermore, this technique allows the arteries to be pressurised to passive or 'normal'
in vivo conditions, which for the Wistar Kyoto rat (WKY) is 60mmHg (Halpern &
Kelley, 1991). Pressurisation allows the arteries to assume a natural cylindrical shape
as found in vivo. The pressurisation also allows the arteries under examination to more
closely replicate the vasoactive responses produced in vivo, as pressure elevation
significantly increases the sensitivity of WKY vessel concentration-responses to PE
(Halpern & Kelley, 1991). It has previously been demonstrated in rat small mesenteric
arteries that maximal sensitivity to methoxamine, an a-adrenoceptor agonist, occurs
when transmural pressure is approximately 60mmHg or above (McPherson, 1992).
This suggests that transmural pressure is a major influence on arterial function.
However, in the wire myograph system the vessels may not be pressurised, but rather
are stretched between two wires to place them under isometric tension instead. This
results in the 'flattening' of the arterial ring segments and the loss of the natural
cylindrical shape. Therefore, as a result of the influence exerted by transmural
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pressure upon vasoactive responses, the technique used in these studies arguably
provides a better model for assessing vascular function. Another advantage of this
technique is that the cannulation of isolated vessels does not impose mechanical
deformation upon the endothelium and vascular wall, and the endothelium is untouched
upon cannulation. Therefore, there is less danger of endothelial disruption during
mounting. This may occur with wire myography, as the wires on which the ring is
mounted may damage the vascular wall. Endothelial damage would enhance
vasoconstriction, impair endothelium-dependent vasodilatation, and have a significant
influence upon any results produced
The use of perfusion myography also allows agents to be perfused through the vascular
lumen and/or superfused abluminally through the organ bath. This may offer a more
physiological method of study and may prevent the agents from interacting directly
with the VSMC. Moreover, it may also prevent any interaction or inactivation of the
vasoactive agents with any test solution, such as UA solution or LDL. Perfusion
myography also prevents the contamination of the perfusate by the buffers or
vasoactive agents, thus allowing the uncontaminated perfusate to be collected for
analysis.
Finally, examining alterations in luminal or vascular diameter of the cannulated arteries
may directly assess vascular function, rather than interpreting changes in the isometric
force placed upon the wires on which an arterial ring segment is mounted. Therefore,
assessment of the results produced using perfusion myography may be easier and of
greater physiological relevance (Halpern & Osol, 1985).
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1.16 Aims of Thesis
The role of UA in cardiovascular disease is still one of great debate. Several large
population studies have identified the value of UA in predicting the risk of
cardiovascular events. As a result, research has been conducted to determine possible
mechanisms by which UA may have a direct or indirect effect upon the cardiovascular
system. The specific role ofUA has been difficult to identify because of its association
with established cardiovascular risk factors. Currently, it is unclear whether UA has a
protective or damaging effect in cardiovascular disease. Increased understanding of the
effect of UA on the vascular system and the association of UA with elevated LDL
concentrations may allow a clearer interpretation of the importance of increased serum
UA concentrations in cardiovascular disease and the associated risk factors. This thesis
aims to determine the role of UA in cardiovascular disease by investigating the direct
action of UA upon endothelial and vascular function and examining the association
between elevated UA and LDL in relation to their effects on the endothelium. In this
way, this thesis will seek to investigate whether UA may exert a beneficial or harmful
effect upon vascular function in isolated arteries exposed to conditions representative of
those that predispose to the development of cardiovascular disease in vivo.
The general hypotheses of this thesis are:
■ Direct exposure to elevated concentrations of UA is injurious to the
endothelium and directly induces endothelial dysfunction, implying that UA has a
direct causal role in development of cardiovascular disease and may be an independent
risk factor in man.
■ In conditions such as hypercholesterolemia, which predispose to the development
of cardiovascular disease, elevated UA concentrations prevent the development of
vascular dysfunction. Thus, the association between UA and other cardiovascular risk
factors may represent a compensatory defence mechanism that serves to prevent and
protect against the onset of cardiovascular disease.
The succeeding chapters aim to investigate these, and further elucidate the potential
role of UA on endothelial function and dysfunction, by demonstrating that:
■ The direct luminal exposure to increasing concentrations of UA impairs ACh-
mediated vasodilatation in isolated rat mesenteric arteries.
■ LDL will impair endothelial function in the perfusion myograph model using
isolated rat mesenteric arteries.
■ UA will mitigate the deleterious effects of LDL on endothelial function and will be
able to do so as efficiently, on a molar basis, as other physiological radical-scavenging
antioxidants.
■ The beneficial effects of UA on LDL-induced endothelial dysfunction relate not






2.1 Low-Density Lipoprotein solutions
2.1.1 Isolation of LDL
Venous blood samples were collected from healthy, non-smoking males following an
overnight fast. Plasma was separated in heparinised tubes (Li Heparin 500 U/10 ml) by
centrifugation at 1000 g for 10 minutes at 4°C, within 20 minutes of venepuncture.
Lipoprotein sub-fractions were then isolated by a double spin rapid ultracentrifugation
procedure similar to the methods described by other studies (Chung et al, 1980; Jacobs
et al, 1990; MacDowell et al, 1995; Fontana et al, 1999; Woodburn et al, 1999). The
density of the plasma was adjusted to 1.25g/ml by the addition of 2.823g of KBr to
7.65ml plasma. This was added to an 8ml Beckman polyallomer ultracentrifugation
tube and over-layered with 0.35ml of 0.9% w/v NaCl solution (density=1.006g/ml).
Ultracentrifugation was then performed in a Beckman Optima Ultracentrifuge (TL-100)
at 420,000 g for 90 minutes at 5°C, using a Beckman 26° fixed angle rotor (MLA-80).
The yellow lipoprotein layer was then removed by aspiration. This was added to a fresh
8ml Beckman ultracentrifugation tube and layered with an equal volume of KBr
solution (density=1.21g/ml, 301mg KBr per ml lipoprotein). The tube was filled with
0.9% w/v NaCl and sealed. Ultracentrifugation was then performed, using the same
equipment as before, at 420,000 g for 240 minutes at 5°C (Woodburn et al, 1999). The
LDL sub-fractions were extracted by aspiration, placed on ice and purified immediately.
Isolation of the lipoprotein sub-fractions was carried out in the presence of a control
tube containing Sudan Black, which stained the lipids to allow visualisation of the
lipoprotein bands (Chapman et al, 1981; Gehrisch et al, 1989). This ensured that the
LDL was extracted from the correct area of the ultracentrifuge tube. The separation of




Figure 2.1. The separation of lipoprotein subfractions following density-gradient
ultracentri fugation.
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2.1.2 Purification of LDL
Small molecules, such as KBr, and water soluble antioxidants, such as AA and UA,
were removed from the crude LDL sub-fractions by size exclusion chromatography
using a Sephadex PD-10 column (Pharmacia Biotech, Bucks., UK) primed with
phosphate-buffered solution (PBS, 0.01M, pH 7.4). LDL sub-fractions (1ml) were
added to the column, followed by 1.5ml PBS and the elutant discarded. A further 2ml
of PBS was added, and the elutant containing the purified LDL sub-fraction was
collected. The purified LDL sub-fractions were then immediately placed on ice and the
protein concentration assessed, or stored at -80°C as stock solutions for later use.
2.1.3 Determination of LDL protein concentration
The protein concentrations of the purified LDL samples were determined using a
commercial kit a based on the Lowry precipitation assay (Sigma Chemical Company,
Dorset, U.K.), which involved a spectrophotometry method with bovine serum albumin
(BSA) as a standard (Lowry et al, 1951). This assay has been widely used in other
studies to assess isolated lipoprotein concentrations (Frostegard et al, 1991; Lewis et al,
1997; Schlotte et al, 1998; Fontana et al, 1999; Santos et al, 1999).
2.1.3.1 Preparation of solutions
The Lowry reagent solution was prepared by adding 40ml of deionised water to a bottle
of modified Lowry Reagent provided with the commercial kit. Folin & Ciocalteau's
Phenol Reagent (FCPR) working solution was prepared by transferring 18ml of reagent
solution to an amber glass bottle. The original reagent bottle was then rinsed with 80ml
of deionised water and the rinsing added to give the working solution. The BSA protein
standard solutions were prepared by adding 4.94ml deionised water to the vials
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provided, giving a standard concentration of 400pg/ml. This solution was then
refrigerated until required.
2.1.3.2 Procedure
Protein standards were prepared by diluting the protein standard solution with deionised
water to a volume of 0.5ml in appropriately labelled eppendorf tubes, to give the
following concentrations:








Samples of LDL were added to appropriately labelled tubes and diluted to a volume of
0.5ml:




50pl deoxycholate solution (DOC) was added to each standard and sample. After 10
minutes, 50pl trichloroacetic acid solution (TCA) was added to the standard and sample
solutions. These were centrifuged for 10 minutes at 16,000 g to pellet the precipitates.
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These pellets were dissolved with 0.5ml Lowry Reagent Solution and transferred to
fresh tubes. The original tubes were rinsed with 0.5ml of de-ionised water and the
rinsing added to the respective fresh tube. The solutions were allowed to stand at room
temperature for 20 minutes, before 0.25ml of FCPR working solution was added to each
tube. The tubes were then left to stand at room temperature for 30 minutes to allow the
colour to develop. The absorbance of the standards was then measured vs. the blank
(0pg/ml protein) at a wavelength of 595nm and a calibration curve constructed. The
absorbance of the LDL samples was measured and the protein concentration determined
using the calibration curve.
2.2 Functional studies using perfused isolated rat mesenteric arteries
2.2.1 Preparation of the rat mesenteric artery
Adult male WKY rats (250-300g) were obtained from the Biomedical Research Facility,
Western General Hospital, Edinburgh, where they were maintained on standard chow
and water. The animals were killed by cervical dislocation and the mesenteric bed
immediately removed and pinned out in a silicone coated Petri dish (Sylgard, Dow-
Corning, UK) containing cold Krebs-Ringer solution (Appendix 1).
Third order vessels of the superior mesenteric artery are found after the third arterial
branch, a section of this artery (5-6mm in length, 250-350pm in diameter) (McPherson,
1992) was carefully dissected and cleaned of adhering perivascular fatty tissue under a
dissection microscope (Zeiss, UK). To prevent damage to the artery, the adhering fat
was carefully pulled away from the vessel to expose the connective membrane; this was
cut to allow the removal of all adhering fat from the artery. The artery was then
excised.
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Care was taken to ensure that it was possible to differentiate between the two ends of
the artery upon removal. This enabled the artery to be mounted in the correct
orientation in the myograph, allowing any flow through the lumen to occur in the same
direction as that of blood in vivo i.e. proximal to distal.
2.2.2 Mounting the isolated artery
The dissected artery was carefully transferred to a 10ml arteriograph chamber (Living
Systems Instrumentation, Burlington, Vermont, USA) (Figure 2.2) containing
oxygenated (95% O2/ 5% CO2) Krebs-Ringer solution. The arteriograph chamber
contained two glass microcannulae, one of which was fixed (the efferent cannula) and
another that was mounted on a manipulator (the afferent cannula) to facilitate
positioning of the artery. The proximal end of the artery was mounted on the afferent
cannula and secured using three knots of single strands of 4.0 silk suture that had
previously been looped onto the cannula. The afferent cannula then attached to a
miniature peristaltic pump connected to a pressure servo unit (P/S200, Living Systems
Instrumentation, Burlington, Vermont USA) to facilitate the delivery and flow of the
intraluminal solution through the arterial lumen (Figure 2.3). The artery was perfused
slowly with Krebs-Ringer solution to remove any residual blood, ensuring that the intra¬
luminal pressure did not rise above 4-5mmHg to prevent endothelial damage. Once the
arterial lumen was cleared of blood, the distal end was attached to the efferent cannula
by the same means as before. If the dissected artery was not cannulated within 10
minutes a new vessel was dissected.
A stopcock was attached to the distal cannula and closed to allow the vessel to be
pressurised. An intraluminal pressure of 60mmHg was achieved by slowly introducing
Krebs-Ringer solution to the vascular lumen using the peristaltic pump. This was





















Figure 2.3. Arteriograph chamber containing isolated mesenteric artery.
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is the physiological in vivo pressure in the animal model used (WKY) (Halpern &
Kelley, 1991). Any buckling that developed in the vessel upon pressurisation was
carefully removed by gently stretching the vessel using the micrometer attached to the
proximal cannula. For the purpose of these experiments, the mounted arteries were
stretched to 120% of their resting length to provide optimal experimental conditions
(Coats & Hillier, 1999). Once pressurised, the artery was checked for leaks by
changing the pressure servo from automatic to manual mode. If the pressure remained
constant the mounted artery had no leaks. If the pressure fell, there was a leak in the
vessel and perfusion circuit. If this occurred, the ties were further tightened or the
artery removed, discarded and another vessel mounted.
The arteriograph chamber was then placed on an inverted stage microscope (Nikon
TMS-F, Japan) with a monochrome TV camera (Burle, USA) attached to a viewing tube
(Halpern & Osol, 1985), to allow the mounted arteries to be visualised on a television
monitor (Burle, USA). The arteriograph chamber was connected to an oxygenated
Krebs-Ringer reservoir. The mounted artery was superfused with this solution at a flow
rate of lOml/min"1 (Watson Marlow 505S; Falmouth UK) with a circulating volume of
30ml. The conditions within the arteriograph chamber were kept constant to maintain
the vessel environment at 37°C + 0.5 and pH 7.4 + 0.5. The temperature of the
superfusate was maintained by passing the solution through a glass heat exchanger,
which was warmed with circulating water from a water bath (40°C) and a Peltier heat-
exchange unit (MHE-1, Moor Instruments, Millwey, Axminter, Devon, UK). The
temperature was measured using a digital thermometer held in close proximity to the
mounted vessel and the pH was monitored using a basic pH meter (Dewar Instrument
Company, USA).
2.2.3 General experimental protocol
For the purposes of this thesis, the term 'luminal perfusion' means that the vascular
lumen was fdled with a solution, pressurised and maintained in a non-flow state. This
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was performed by opening the stopcock on the distal cannula and perfusing the arterial
lumen with the intraluminal solution. The stopcock was then closed, luminal perfusion
halted and the artery maintained in a non-flow state at an intraluminal pressure of 60
mniHg throughout the experiments. The vessels were allowed a 60 minute equilibration
period before being contracted with high K+ Krebs-Ringer solution (NaCl: 4.7mM; KC1
118mM) (Appendix 1), added extraluminally to the arteriograph via the Krebs-Ringer
reservoir. The chamber was then washed for 10 minutes with Krebs-Ringer buffer to
remove the high K+ Krebs-Ringer solution and dilate the artery to its resting diameter.
This process was repeated at 15 minute intervals until successive contractions remained
constant, to ensure the vessel was responsive and maximal constriction was produced.
Following contraction with high K+ Krebs-Ringer solution, the artery was washed with
Krebs-Ringer solution and allowed to relax for 30 minutes. Concentration-response
curves to phenylephrine (PE) (lxlO^-SxlO^M) were then performed. The drug was
added cumulatively to the Krebs-Ringer reservoir and the arteries superfused with the
modified solution. The arteries were exposed to each concentration of drug for 10
minutes and luminal diameter was measured immediately prior to the next drug
addition. Contractions were then expressed as a 'percentage ofmaximal constriction to
high K+ Krebs-Ringer solution', and concentration-response curves constructed.
After washout and a 30 minute equilibration period, the arteries were preconstricted
using ECgo PE. The vessels were allowed to equilibrate for 15 minutes and
concentration-response curves to ACh (1x10"9-5x10"4M) and SNP (1x10"9-5x10"4M)
performed, in a random order, by extraluminal cumulative addition, as previously
described. Changes in intraluminal diameter were measured and expressed as
'percentage return towards resting luminal diameter' following preconstriction to PE.
All concentration-response curves and 'best-fit' lines were produced using a non-linear
regression analysis package (Biograph Version 1.0, Strathclyde University, UK).
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Cumulative concentration-response curves were performed using a continuous
reperfusion circuit. These experiments could be performed by switching off the
superfusate and adding drugs directly to the arteriograph chamber. However, this
method has several disadvantages; the O2 within the chamber is consumed, resulting in
anaerobic conditions, and a rapid and sustained decline in the chamber temperature
occurs, both of which affect the vascular response to the vasoactive agents. Therefore, a
continuous reperfusion circuit was used to maintain optimal conditions with in the
vessel chamber.
2.2.4 Endothelial denudation
The most common approach to removing the endothelium in isolated blood vessels is to
rub the inner surface with a small wire or hair (Osol et al, 1989; Megson et al, 1997).
Resistance arteries are small and fragile making this technique difficult to apply.
Chemical or enzymatic methods are difficult to control and may damage the adjacent
VSMC, thus it cannot be determined if any alteration in vascular response is exclusively
due the removal of the EC or the result of smooth muscle damage. An alternative
method used for denuding the EC of resistance arteries is to perfuse the lumen with an
air bubble (Ralevic et al, 1989; Bjorling et al, 1992; Falloon et al, 1993). For the
purpose of this thesis, endothelial denudation of the mesenteric arteries was achieved
using the 'air bubble technique' as described by Falloon et al (1993).
To do this, the pressure within the vessel was slowly reduced and the stopcock on the
distal cannula opened. An air bubble of about one inch in length was introduced into the
tubing attached to the proximal cannula. This was slowly moved down the tubing at a
flow rate that produced an intraluminal pressure of 30-35mmHg. A series of 10-15 air
bubbles were passed through the lumen of the vessel. To ensure any endothelial debris
was removed, the flow ofKrebs-Ringer solution through the lumen was continued for 2-
3 minutes after all the air had passed. The stopcock was then closed and the pressure
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within the vessel restored to 60mmHg. Endothelial denudation was confirmed by the
failure of sub-maximally constricted vessel to respond to ACh (10 pM).
2.3 Functional studies using isolated rat aortic segments
2.3.1 Preparation of aortic ring segments
Adult male WKY rats (250-300g) were obtained from the Biomedical Research Facility,
Western General Hospital, Edinburgh, where they were maintained on standard chow
and water. The animals were killed by cervical dislocation. The aorta was immediately
removed and pinned out in a silicone coated Petri dish (Sylgard, Dow Corning, UK)
containing cold Krebs-Ringer solution. The isolated aorta was carefully cleaned of all
adhering connective tissue and divided into 2 ring segments (2-3mm), one ofwhich was
then denuded.
The vessel rings were suspended between two intraluminal wires in a 10ml organ bath
(Multi Tissue Bath System 700MO, Danish Myo Technology A/S, Copenhagen,
Denmark) to record alterations in isometric tension. The aortic rings were bathed in
oxygenated (95% (V 5% CO2) Krebs-Ringer solution at 37°C and placed under a
resting tension of 1.5g by increasing the tension applied to the vessels in stepwise
increments. The vessels were allowed to equilibrate for 60 minutes.
2.3.2 General experimental protocol
The aortic rings were contracted three times with high K+ Krebs-Ringer solution (NaCl:
4.7mM; KC1: 118mM) to obtain maximum contraction. Following washout and an
equilibration period, the rings were exposed to increasing concentrations of PE (lxlO"8-
1x10~5M). The drug was added cumulatively to the organ bath and the aortic rings were
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exposed to each concentration of drug for 5 minutes. A concentration-response curve
was constructed and a suitable concentration chosen to produce 80% contraction (ECso)-
The vessels were washed with Krebs-Ringer solution and allowed to equilibrate before
g
being preconstricted with ECgo PE. Concentration-response curves to ACh (1x10" -
1x10"5M) were performed by cumulative addition as previously described. Changes in
tension were measured and expressed as 'percentage return towards resting tension'
prior to preconstriction with PE. Following washout, the aortic rings were allowed to
relax. Test solutions were added to the organ bath and, following a 20 minute
equilibration period, the rings were preconstricted with ECgo PE and vasodilatation to
1x10"5M ACh examined. Alterations in tension from the myography were processed by
a MacLab/4e analogue digital converter and displayed through Chart™ software.
2.3.3 Endothelial Denudation
When required, aortic ring segments were denuded of their endothelium prior to
mounting in the wire myograph system. Following dissection, the luminal surface of
the aortic ring segment was rubbed to remove the endothelium (Megson et al, 1997).
Endothelial denudation was confirmed by the failure of sub-maximally constricted
vessels to respond to ACh (10 pM).
2.4 Determination of the oxidative status of LDL
The lipoprotein samples used in these studies are typical of the LDL found in human
circulation (See Chapter 5). This should be unoxidised LDL as it is isolated from fresh
human plasma and immediately used or stored at -80°C. To prevent auto-oxidation,
0.3mM EDTA was added to the solutions (Jacobs et al, 1990; Hayashi et al, 1994).
However, to ensure that oxidative modification did not occur during the course of the
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experiments, the oxidative status of the LDL samples before and after luminal perfusion
was measured. This was performed using a commercial colourimetric assay kit (CN
Biosciences, Nottingham, U.K.) that used a spectrophotometric method to measure 4-
Hydroxynonenal (4-HNE) and malondialdehyde (MDA) as indices of lipid peroxidation
(Esterbauer & Cheeseman, 1990). These have previously been used as indices of lipid
peroxidation in several other studies examining the oxidative status of LDL in vitro
(Jacobs et al, 1990; Janero, 1990; Frostegard et al, 1991; Galle et al, 1995; Pritchard et
al, 1995; Schlotte et al, 1998; Vergnani et al, 2000).
OH CH(OH)CH CH CH CH CH
MDA 4-HNE
Figure 2.4. The molecular structure of the aldehydes MDA and 4-HNE, which are used
as an index to assess the oxidative status of the LDL samples in these experiments.
2.4.1 Preparation of solutions
18ml of 10.3mM N-methyl-2-phenylindole in acetonitrile was diluted by the addition of
6ml of 100% methanol. This was stored at 4°C. 200pl LDL samples were collected
before and after perfusion through the vascular lumen, and immediately stored at -80°C.
When performing the assay, samples were placed on ice and stored at 4°C.
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2.4.2 Procedure
A working solution of 4-HNE was prepared by adding lml of lOmM 4-HNE solution to
99ml of Krebs-Ringer buffer, to give a final concentration of lOOpM. Standards were
then formed by adding 0-5Opl of the working solution to Krebs-Ringer buffer to give a
final volume of 200pl. This process was repeated using 10mM MDA solution to
prepare MDA standards.
650pl of diluted N-methyl-2-phenylindole solution was added to a clean glass test-tube.
200pl of the standard were added to this solution and mixed by vortexing for 3-4
seconds. 150pl ofmethanesulphonic acid (15.4M) was added to the tube, the tube sealed
tightly and the solution mixed. This solution was incubated in a water bath maintained
at 45°C + 1°C for 40 minutes. The standard samples were placed on ice and allowed to
cool. The absorbance of the standards was then measured at 586nm and plotted against
the corresponding aldehyde concentration to produce a calibration curve.
This experimental procedure was repeated using the LDL samples and the absorbency
measured. This was compared to the calibration curve to determine the 4-HNE and
MDA concentration in the LDL samples. This concentration was then multiplied by 5
to account for dilution during the assay. The concentration ofMDA and 4-HNE present
in the LDL samples before and after addition to the isolated vessels were compared and
the percentage change in lipid peroxidation products calculated.
2.5 Analysis of Results
Techniques used for the analysis of the results for the individual studies are given in the
'Methods' section of the corresponding chapter. For the studies of mesenteric vessels all
results are given as mean + SEM of 8 independent experiments. For the studies of aortic
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rings 6 independent experiments were performed. Statistical differences in
concentration-response curves were analysed using a 2-factor ANOVA with replication
and Bonferroni correction. The best fit concentration-response curves, and the
concentration of agonist causing 50% (EC50) responses for vasoconstriction and
dilatation, were calculated using a non-linear regression analysis package (Biograph
Version 1.0, Strathclyde University, UK). Estimated EC50 data were analysed using
one-way ANOVA with Bonferroni correction. All other results were analysed using
paired Student's /-test. The P-values quoted in the chapters are accepted as statistically
significant when P<0.05. The statistical significance is indicated in the relevant figures,
and the symbols used to represent points of significance are given in the corresponding
figure legend.
2.5 Drug and Reagents
Key
Dilution
H20: Diluted in water
fEO/Kr.: Diluted in water, then Krebs-Ringer buffer
Kr.: Diluted in Krebs-Ringer buffer
Li2C03 vehicle: Diluted in Li2C03 vehicle solution
Meth.: Diluted in 100% methanol
Sal.: Diluted in saline






Prepared on the day of use
Stored at 4°C and used within 1 week of preparation
Stored at 4°C and used within 1 month of preparation
Used within 3 months of preparation as advised
Used within 6 months of preparation as advised6 months:
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Drug Dilution Storage Source
ACh Kr day Sigma
AA H20 /Kr day Sigma
BSA H20 day Sigma
DOC solution 3 months Sigma
FCPR H20 3 months Sigma
GSH H20 /Kr day Sigma
Indomethacin sal. month Sigma
Krebs buffer salts H20 day BDH
Li2C03 H20/Dextrose month Sigma
solution
Li2C03 vehicle Kr day -
Lowry reagent H20 6 months Sigma
L-NAME Kr week Sigma
MDA solution day CN Biosciences
Methanesulphonic acid solution month CN Biosciences
N-methyl-2-phenylindole
In acetonitrile Meth. day CN Biosciences
PBS H20 day Pharmacia
Biotech
PE Kr day Sigma
SOD Kr day Sigma
SNP Kr day Sigma
TCA solution 6 months Sigma
UA Li2C03 vehicle month Sigma
UA solution Kr day -
4-HNE solution day CN Biosciences
A detailed description of the preparation of the various LDL, antioxidant and vehicle
solutions is provided in the 'Methods' section of the relevant chapters.
All compressed gases were supplied by Linde.
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Company Locations
BDH - Merck Ltd., Lutterworth, U.K.
CN Biosciences - Nottingham, U.K.
Linde - Linde Gas UK Ltd., West Bromich, U.K.
Sigma - Poole, U.K.
Pharmacia Biotech - Amersham Biosciences, Bucks., U.K.
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CHAPTER 3
EXAMINATION OF THE ROLE OF NO IN THE
VASCULAR FUNCTION OF ISOLATED RAT
MESENTERIC ARTERIES
3.1 INTRODUCTION
It is well established that NO has a central role in ACh-induced endothelium-dependent
vasodilatation in large vessels (Bellan et al, 1993; Shimokawa et al, 1996; Cohen et al,
1997). For example, chronic treatment with L-NAME caused a 10-fold reduction in
cGMP and prevented ACh-induced vasodilatation in isolated rat aorta (Arnal et al, 1992;
Henrion et al, 1996). However, the role ofNO in vasodilatation to ACh in isolated rat
mesenteric arteries is more controversial. In these arteries, muscarinic agonists such as
ACh can stimulate the release of an uncharacterised EDHF that is neither prostacyclin
nor NO (Chen et al, 1989; Taylor & Weston, 1988; Garland & MacPherson, 1992;
Garland et al, 1995). Consequently, endothelium-dependent vasodilatation of isolated
resistance arteries can be mediated by both NO and EDHF (Henrion et al, 1997). NO
may not be the primary mediator of endothelium-dependent vasodilatation in isolated
rodent arterioles, as L-NAME reduces vasodilatation to ACh by less than 50% (Dora et
al, 1997). Similarly, this NOS inhibitor only caused a slight and non-significant
reduction in the concentration-dependent vasodilatation to ACh isolated rat mesenteric
arteries (Garland & MacPherson, 1992). Similarly, the COX inhibitor, indomethacin,
which prevents the generation of prostacyclin, did not impair ACh-mediated
vasodilatation (Garland & MacPherson, 1992; Henrion et al, 1997), although it
significantly reduced dilatation in chronic L-NAME-treated vessels (Henrion et al,
1997). It has previously been demonstrated that agonist-mediated vasodilatation in rat
mesenteric arteries is primarily due to the release of EDHF and the resultant
hyperpolarisation of the VSMC (Dora et al, 1997; Edwards et al, 1998). It has been
suggested that K+ is the EDHF, and primary EDRF, released in rat mesenteric arteries
following agonist stimulation with ACh (Wu et al, 1993; Edwards et al, 1998).
Therefore, whilst the use of perfusion myography arguably provides the most favourable
model for assessing vascular function, the role of NO in ACh-induced vasodilatation in
resistance arteries is uncertain. For that reason, the role of NO in the vascular function
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of this experimental model must be investigated. This chapter aims to clarify the role of
NO, prostacyclin, and subsequently, EDHF in isolated rat mesenteric arteries, by
examining the effect of arterial perfusion with L-NAME and indomethacin on the
vasoactive responses to PE, ACh and SNP. This chapter also intends to validate the use
of perfusion myography in future studies examining the effect of various substances on
NO-mediated vascular function. This will be achieved by demonstrating that:
1). NO is the major vasodilator released by the endothelium in response to ACh,
demonstrated by the abolition of the vascular response to ACh by L-NAME, an
eNOS inhibitor.
2). Inhibition of endothelial prostacyclin generation by indomethacin, will not have any
significant effect upon vascular function in the isolated arteries.
3.) Perfusion myography using third order rat mesenteric arteries stimulated/activated




Adult male Wistar Kyoto rats (250-300g) were killed, the mesenteric beds removed, and
a segment of a third order arterial branch mounted in the perfusion myograph chamber
as described in Chapter 2 (Section 2.2).
3.2.2 Experimental protocol
Concentration-response curves to PE, ACh and SNP were performed, as described in
Chapter 2 (Section 2.2), when perfused with lOOpM L-NAME, lOpM indomethacin,
lOOpM L-NAME + lOpM indomethacin, or control Krebs-Ringer buffer. This
procedure was also repeated on endothelial denuded vessels perfused with Krebs-Ringer
solution.
3.2.3 Intraluminal Solutions
ImM indomethacin stock solution was prepared by dissolving 0.179g in 500ml saline.
Working solution (lOpM) was prepared by diluting 1ml of the stock solution in 99ml
Krebs-Ringer buffer on the day of use. 100pM L-NAME solution was prepared daily by
dissolving 0.135g L-NAME in 500ml Krebs-Ringer solution to give a ImM solution,
then adding 1ml of this to a further 9ml of Krebs Ringer.
75
3.2.4 Statistical Analysis
Statistical analysis was performed to determine any significant difference in the results




3.3.1 Vasoconstrictor response to PE in the presence of L-NAME
and/or indomethacin
The maximal response obtained when the intact lumen was perfused with Krebs-Ringer
solution was 101.2 + 2.5%, and 101.3 + 2.1% when the endothelium was removed (Fig
3.1). Perfusion with lOpM indomethacin, lOOpM L-NAME, orlOOpM L-NAME +
lOpM indomethacin produced maximal responses to PE of 96.6 + 1.2%, 99.4 + 3.5%
and 98.6 + 3.3%, respectively. Vasoconstriction was significantly greater when all
responses to 5xl0"8 (P<0.05) and lxl 0"7 PE (P<0.01) were compared to the
physiological control.
3.3.2 Endothelium-dependent vasodilatation in the presence of L-
NAME and/or indomethacin
ACh produced a maximal vasodilatation of 100.5 + 2.1% in endothelium-intact arteries
perfused with physiological Krebs-Ringer solution (Fig 3.2). Vasodilatation when
perfused with lOOpM L-NAME (maximal = 42.3 + 3.2%) or 100pM L-NAME + lOpM
indomethacin (maximal = 36.3 + 3.6%) were similar, but significantly lower than the
responses when perfused the physiological control or 10pM indomethacin only (1x10" -
5xl0"4, P<0.01). Vasodilatation to ACh when perfused with lOpM indomethacin was
similar to the physiological control. All responses produced by endothelium-intact
arteries were significantly greater than those obtained following endothelial denudation
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Figure 3.1. The effect of luminal perfusion with L-NAME and/or indomethacin on
vasoconstriction to PE in isolated rat mesenteric arteries: a.) lOOpM L-NAME, b.)
lOpM indomethacin, and c.) lOOpM L-NAME + 10pM indomethacin compared to
intact or denuded vessels perfused with Krebs-Ringer solution. *p<0.05 vs. intact
vessels (2-factor ANOVA with replication and Bonferroni correction, n=8). d.)
compares the effect of L-NAME, indomethacin, and L-NAME + indomethacin. All
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Figure 3.2. The effect of luminal perfusion with L-NAME and/or indomethacin on
vasodilatation to ACh in isolated rat mesenteric arteries: a.) lOOpM L-NAME, b.)
lOpM indomethacin, and c.) lOOpM L-NAME + lOpM indomethacin compared to
intact or denuded vessels perfused with Krebs-Ringer solution. *p<0.01 vs. intact
vessels, **p<0.01 vs. denuded vessels (2-factor ANOVA with replication and
Bonferroni correction, n=8). d.) compares the effect of L-NAME, indomethacin, and
L-NAME + indomethacin. *p<0.01 vs. indomethacin (2-factor ANOVA with
replication and Bonferroni correction, n=8). All values are the mean + SEM.
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3.3.3 Endothelium-independent vasodilatation to SNP in the presence
of L-NAME and/or indomethacin
All responses to SNP were similar when the vessels were perfused with Krebs-Ringer
solution, lOpM indomethacin, lOOpM L-NAME, lOOpM L-NAME + lOpM
indomethacin or following endothelial denudation (Fig 3.3).
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Figure 3.3. The effect of luminal perfusion with L-NAME and/or indomethacin on
vasodilatation to SNP in isolated rat mesenteric arteries: a.) lOOpM L-NAME, b.)
10pM indomethacin, and c.) IOOjiM L-NAME + lOpM indomethacin compared to
intact or denuded vessels perfused with Krebs-Ringer solution, d.) compares the effect




Luminal perfusion with L-NAME (lOOpM) and/or indomethacin (10pM) only enhanced
vasoconstriction to PE at lower concentrations. Perfusion with L-NAME significantly
inhibited vasodilatation to ACh in isolated rat mesenteric arteries. Indomethacin did not
significantly alter the response to ACh. The inhibition of ACh-induced vasodilatation
following luminal perfusion with L-NAME + indomethacin was not significantly
different from the inhibition produced when perfused with L-NAME only.
Vasodilatation to SNP was unaffected by luminal perfusion with L-NAME and/or
indomethacin.
3.4.1 The effect of L-NAME and/or indomethacin on vasoconstriction
to PE
PE is a sympathomimetic amine that causes vasoconstriction by acting directly upon
VSMC. PE-mediated vasoconstriction occurs via the activation of the ai-adrenoceptors,
although blood vessels also possess a2-receptors that may cause vasoconstriction. These
G-protein-coupled receptors are coupled to PLC, which converts PIP2 to IP3, causing the
9+
release of stored intracellular Ca . This combines with calmodulin to activate MLCK,
which phosphorylates myosin allowing it to interact with actin and initiate the
contractile process. Activation of these receptors constricts arteries, arterioles, and
veins resulting in increased peripheral resistance, reduced venous capacity, and
consequently, increased arterial blood pressure
Vasoconstriction to PE was largely unaffected by perfusion with the various solutions in
the current studies. The constriction produced was calculated and expressed as a
percentage of the maximum achieved with KC1. However, it should be noted that the
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vasoconstriction to KC1 was also performed in the presence of the various test solutions.
Consequently, this could mask any changes that the various solutions had on the
maximal responses produced. Nevertheless, at lower concentrations, endothelial
denudation or luminal perfusion with L-NAME and/or indomethacin significantly
enhanced vasoconstriction (Fig 3.1). It has previously been reported that the
suppression of NO by L-NAME can enhance agonist-induced vasoconstriction
(Moncada et al, 1991) and augment vasoconstriction to PE in rat mesenteric arteries
(Dora et al, 2000). The results produced following endothelial denudation or the
inhibition of NOS activity suggest that the endothelium and NO synthesis confer a
degree of protection against agonist-induced vasoconstriction. This may occur as a
compensatory defence mechanism to prevent exaggerated vasoconstriction and disorders
such as vasospasm (Dora et al, 1997).
3.4.2 The role of NO in endothelium-dependent vasodilatation to ACh
Due to difficulties in assessing the biochemical generation of NO, research into the role
of the endothelium and NO in the vasculature is conducted using a functional approach.
Studies using larger vessels such as the aorta are commonly performed using wire
myography. In such vessels, vasodilatation and repolarisation to ACh can be fully
accounted for by NO, with little contribution from EDHF (Cohen et al, 1997).
Perfusion myography is technically demanding but may better reflect the in vivo
properties of arteries when assessing the impact of various conditions on endothelial
function in vitro (Halpern & Kelley, 1991; Buss et al, 1994; Coats & Hillier, 1999).
However, studies performed by this method use smaller resistance arteries and the role
of NO in ACh- and agonist-induced vasodilatation in these arteries is questionable.
Therefore, before this experimental model could be regarded as a suitable technique for
the assessment NO-mediated vascular function, it had to be demonstrated that NO was
the primary vasodilator released in response to ACh. The interpretation of the vascular
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responses to ACh is complicated (Chowienczyk et al, 1993; Chowienczyk et al, 1995).
ACh acts on the G-protein-coupled M2 or M3 muscarinic receptors on the EC to
stimulate the release of EDRF, and can induce endothelium-dependent smooth muscle
relaxation that is associated with membrane hyperpolarisation (Bolton et al, 1984; Chen
et al, 1989; Feletou & Vanhoutte, 1988; Brayden 1990; McPherson & Angus, 1991;
Garland & McPherson, 1992; Rand & Garland, 1992). However, in the rat aorta and
pulmonary artery, oxyhaemoglobin (ox-Hb) or methylene blue impair vasodilatation but
do not block this hyperpolarisation. This indicates that a distinct EDHF is released from
the EC at the same time as NO, although the latter is the cause of the endothelium-
dependent vasodilatation (Chen et al, 1989; Taylor & Weston, 1988; Garland &
McPherson, 1992).
In rabbit and rat aortic rings, ACh-induced vasodilatation is almost exclusively mediated
by the endothelial release ofNO (Bellan et al, 1993; Shimokawa et al, 1996). However,
in smaller vessels, such as rat mesenteric arteries, vasodilatation to ACh may be
produced by NO-independent EDHF-mediated increases in VSMC membrane potential
(Waldron & Garland, 1994; Shimokawa et al, 1996; Dora et al, 1997; Dora et al, 2000).
This could account for more than 75% of the vasodilatation induced (Waldron &
Garland, 1994). In canine mesenteric arteries, ACh induces cell membrane
hyperpolarisation in VSMC by the endothelial release of a diffusible substance. This is
NO-independent and has been was attributed to the release of EDHF (Komori et al,
1988). It has previously been reported that NO had little or no involvement in ACh-
induced dilatation in rat mesenteric arteries of a similar size and breed to those used in
the current study (WKY), as treatment with L-NAME only caused a slight decrease in
vasodilatation (Garland & McPherson, 1992).
However, the results of this study contradict these findings. The current study
demonstrates that luminal perfusion of the isolated rat mesenteric artery with lOOpM L-
NAME solution produces a maximal ACh-mediated vasodilatation 42.3%. This is a
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reduction of 57.7% when compared to the physiological control. L-NAME is an 1-
arginine analogue that binds within the active site of eNOS to make the haem iron
unreactive to oxygen and prevent the oxidation 1-arginine and the formation of NO
(Abu-Soud et al, 1994). The current results indicate that approximately 60% of
vasodilatation to ACh occurred via the generation and release of NO. These results
imply that NO is the primary EDRF released to this agonist in the experimental model
used. This is supported by previous studies that demonstrated a significant impairment
of ACh-induced vasodilatation in isolated rat mesenteric arteries following acute and
chronic L-NAME (Plane et al, 1992; Dowell et al, 1996). Several other studies have
also demonstrated that the inhibition NO synthesis markedly impairs, but does not
abolish ACh-induced vasodilatation in rat mesenteric arteries (Moore et al, 1990; Khan
et al, 1992; Le Marquer-Domagala & Finet, 1997; Kimura & Nishio, 1999). The
removal of NO by haemoglobin (Hb) and methylene blue also markedly attenuated
vasodilatation to ACh in this experimental preparation (Furchgott et al, 1987, Randall &
Hilley, 1988). The contradictory results produced between this study and those previous
could be due to the experimental size of isolated vessels used (Dora et al, 2000), as the
relative contributions of NO to in vitro vasodilatation by ACh may vary in vessels of
different sizes from the rat mesenteric vascular bed (Flwa et al, 1994).
Nevertheless, the results of the current study suggest that NO is the primary EDRF
released following agonist stimulation with ACh in preconstricted rat mesenteric
arteries. These results support the use of perfusion myography, with this isolated vessel
preparation, to examine NO-mediated vascular function. This experimental model
allows isolated vessel studies to be conducted under conditions that are more reflective
of those found in vivo when compared to the use of isometric ring or strip preparations.
The experimental advantages that this technique offers for assessing vascular function
have previously been cited in Chapter 1 (Section 1.14.2).
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3.4.3 The role of prostacyclin in endothelium-dependent
vasodilatation to ACh
23"Activation of EC by ACh increases intracellular Ca and activates PLA. This liberates
arachadonic acid from membrane phospholipids, which can then be metabolised to
prostacyclin via the enzyme COX-1, a constitutive enzyme found in most cells.
Indomethacin is a COX inhibitor that is relatively selective for COX-1. This prevents
the conversion of arachadonic acid to cyclic endoperoxides, thus preventing the
biosynthesis of vasoactive prostaglandins or thromboxanes. The inability of
indomethacin (lOpM) to inhibit dilatation demonstrates that COX-derived mediators
such as prostacyclin do not make a significant contribution to ACh-mediated
vasodilatation in the current study. This is in agreement with other studies that have
reported the failure of indomethacin to inhibit vasodilatation to ACh (Chen et al, 1989;
Feletou & Vanhoutte, 1998). ACh-induced vasodilatation in rabbit aortic ring segments
(Andrews et al, 1987) and rat small mesenteric arteries were unaffected by lOpM
indomethacin (Garland & MacPherson, 1992). However, whilst acute indomethacin
(lOpM) did not significantly alter the responses in this experiment, it caused a
significant reduction in flow-induced dilatation in chronic L-NAME-treated isolated rat
mesenteric arteries (Henrion et al, 1997). Therefore, COX-prostacyclin may have a
greater role in endothelium-dependent vasodilatation following the inhibition or
abolition of NO. Nevertheless, the anti-platelet properties of prostacyclin are thought to
have a greater contribution to its role in human physiology than its vasoactive
capabilities (Radomski et al, 1987; Luscher & Barton, 1997).
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3.4.4 Implication for the role of EDHF in endothelium-dependent
vasodilatation to ACh
Perfusion of the arteries with L-NAME + indomethacin inhibits the synthesis of both
NO and COX-derived mediators. Therefore, the results produced indirectly imply that
EDHF accounts for approximately 36% of ACh-induced vasodilatation in this
experimental model. It has been demonstrated that ACh stimulates vasodilatation via
endothelium-dependent increases in VSMC K+ conductance and raising external K+
concentrations will reduce dilatation to ACh by 50% (Chen et al 1989). However, the
current study suggests that ACh-mediated vasodilatation of the rat mesenteric artery
primarily depends on the stimulated release ofNO by NO synthase. Nevertheless, while
the results demonstrate that EDHF is not the primary EDRF released in this
experimental model, they do imply that it makes a significant contribution to ACh-
induced vasodilatation in the current experimental model. This EDHF may be released
to ACh to act synergistically with NO and produce vasodilatation via different
mechanisms in isolated rat mesenteric arteries (Waldron & Garland, 1994).
3.4.5 Endothelium-independent vasodilatation to SNP
Denudation or perfusion of the isolated arteries with L-NAME and/or indomethacin had
no significant effect upon vasodilatation when compared to the physiological control.
SNP is an exogenous NO-donor and acts directly upon the VSMC to produce
vasodilatation by mimicking the action of endogenous NO (Ignarro et al, 1981). SNP
releases NO that enters directly into the VSMC where it may either form a reactive
nitrosothiol intermediate or act alone to activate intracellular sGC and increase in cGMP
levels. This decreases intracellular Ca2+ and activates PKG to prevent VSMC
constriction and induce vasodilatation. There was no significant alteration in the
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responses to SNP compared to the physiological control, demonstrating that, as
expected, eNOS- and COX-inhibitors had no significant effect upon dilatation to this
agent.
3.4.6 Summary
ACh caused concentration-dependent vasodilatation in isolated rat small mesenteric
arteries previously constricted with PE. This was totally abolished by endothelial
denudation. The significant reduction of the vascular response (>50%) to ACh by L-
NAME (lOOpM), an eNOS inhibitor, demonstrates that NO is the major vasodilator
released by the endothelium to ACh in rat mesenteric arteries. The contribution of
prostacyclin to vasodilatation in this experimental model is minimal, as the response to
ACh is not inhibited following luminal perfusion with indomethacin (10pM). The
remainder of the endothelium-dependent vasodilatation most likely occurs via
hyperpolarisation to EDHF, based on the residual dilatation produced to ACh following
luminal perfusion with L-NAME + indomethacin. Vasodilatation to SNP was
unaffected by prior exposure to L-NAME and/or indomethacin. The results of this study
establish NO as the major vasodilator released by the endothelium in response to ACh
(Fig 3.4). This in turn demonstrates that the experimental model and technique
employed is suitable for the examination ofNO-mediated vascular function.
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Figure 3.4. Relaxation of VSMC to EDRF released from rat mesenteric EC in response
to ACh. NO increases cGMP to activate PKG and oppose agonist-induced increases in
[Ca2+]i. EDHF causes hyperpolarisation, thus preventing voltage-gated Ca2+-channels
from opening and inhibiting the intracellular concentration increase. PGI2 increases
cAMP to activate PKA and inhibit MCLK to inhibit contraction and induce relaxation.
89
CHAPTER 4
THE EFFECT OF LUMINAL PERFUSION WITH URIC
ACID ON ENDOTHELIAL AND VASCULAR FUNCTION
4.1 INTRODUCTION
Having demonstrated the role of NO in mesenteric vascular function in the previous
chapter, the relationship between UA and endothelial dysfunction can now be
investigated. Endothelial dysfunction can promote the onset of cardiovascular disease
by many mechanisms and is characteristically found in the blood vessels of patients
with cardiovascular risk factors such as hypertension, type II diabetes,
hypercholesterolaemia and atherosclerosis (D'Angelo et al, 1978; Ross, 1993; Blann et
al, 1995; Celermajer, 1997; Wilkinson & Cockroft, 1998).
These disease states are frequently accompanied by an elevation in the serum UA level
(Lehto et al, 1998; Ward, 1998; Fang & Alderman, 2000; Alderman, 2002). However,
the role of this elevated UA in cardiovascular disease has yet to be established. Several
studies suggest that UA is an independent risk factor for the development of
cardiovascular disease (Bengtsson et al, 1998; Brand et al, 1985; Bonora et al, 1996;
Fang & Alderman, 2000; Fessel, 1980; Lehto et al, 1998; Liese et al, 1999; Persky et al,
1997; Ward, 1998; Johnson et al, 2003), whilst others have concluded that this
relationship is secondary to the association between UA and other cardiovascular risk
factors such as obesity, hypertension, hypercholesterolaemia and increased triglyceride
levels (Reunanen et al, 1982; Iribarren et al, 1996; Wannamethee et al, 1997; Culleton
et al, 1999; Alderman, 2001; Alderman, 2002).
Evidence regarding the causal role of UA in endothelial dysfunction remains
inconsistent (Alderman, 2002). The functional impairment of the endothelium provides
a potential means by which UA could directly contribute to the pathogenesis of
cardiovascular disease. Elevated serum UA may constitute a novel risk factor for
endothelial dysfunction. Impaired endothelial-dependent vasodilatation is present in
hyperuricaemic patients in the absence of any overt cardiovascular disease (Kato et al,
2005) and increasing serum UA concentrations, even in the physiological range, reduce
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flow-mediated dilatation in healthy human subjects (Edrogan et al, 2005). Clinical
studies performed using angiography (Crouse et al, 1987) or carotid ultrasound
(Schneidau et al, 1989; Vigna et al, 1992) demonstrated a linear relationship between
elevated UA concentrations and cardiovascular disease. The infusion of UA into the
brachial artery of healthy volunteers impairs endothelium-dependent vasodilatation
(Waring et al, 2000), and reducing serum UA concentrations has been reported to
prevent the development of degenerative vascular disease (Emerson, 1979). This may
also restore endothelium-dependent vasodilatation in hyperuricaemic patients
(Farquharson et al, 1999; Mercuro et al, 2004; Baldus et al, 2005). Furthermore, in
vitro and in vivo studies have demonstrated that UA can impair endothelial NO
production, thus inhibiting endothelium-dependent vasodilatation (Kanellis & Kang,
2005; Khosla et al, 2005). In pre-eclampsia, a disease characterised by endothelial
injury, the plasma UA concentration correlates with the increased markers for
endothelial damage such as thrombomodullin and endothelin-1 (Clark et al, 1992; Hsu
et al, 1993; Garrone & Broso, 1997; Leyva et al, 1998). Therefore, UA could be
directly injurious to the endothelial lining of the vascular system and, as a result, could
have a direct role in the pathogenesis of cardiovascular disease.
This chapter investigates whether acute UA elevation has a deleterious action on the
endothelium by examining the direct effect of acute luminal exposure to various
concentrations of UA upon vascular function. The hypotheses for this study are:
1). UA is an independent risk factor with a direct role in the pathogenesis of
cardiovascular disease, hence the reported correlation between elevated UA
concentrations and cardiovascular mortality.
2). UA is injurious to the endothelium and directly induces endothelial dysfunction,
thereby inhibiting the vascular response to endothelial-dependent vasodilatory
agents, such as ACh, to cause severe functional impairment.
92
The extent of endothelial injury is related to the concentration of UA to which the
vessel is exposed. This effect will be concentration-dependent and manifest at
physiological concentrations seen in human extracellular fluids.
Although UA is sparingly soluble in aqueous solution, it can be delivered directly





Adult male WKY rats (250-300g) were killed, the mesenteric beds removed, and a
segment of a third order arterial branch mounted in the perfusion myograph chamber as
described in Chapter 2 (Section 2.2).
4.2.2 Experimental protocol
Concentration-response curves to PE, ACh and SNP were performed, as described in
Chapter 2 (Section 2.2), when perfused with 200pM, 400pM or 600pM UA solution,
control Krebs-Ringer buffer, or the vehicle LCCO3 solution.
4.2.3 Intraluminal Solutions
UA stock was made using Li2C03 solution as the vehicle. The vehicle Li2C03 stock
was made by dissolving 1.6mg/ml Li2C03 in a mixture of distilled water: 5% dextrose
solution (1:4). 2g/ml of UA were then dissolved in the vehicle solution to give a stock
solution of 11.9mM. 16.6ml/l, 33.3ml/l and 49.9ml of stock were then added to Krebs-
Ringer solution to give 200pM, 400pM and 600pM UA solution respectively. For the
purpose of the control vehicle solution, 49.9ml/l of Li2CC>3 stock was added to Krebs-
Ringer solution. This was used as it was the concentration of Li2C03 present in the
600pM UA solution (216pM).
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4.2.4 Statistical Analysis
Statistical analysis was performed to determine any significant concentration-dependent
difference between the results obtained for the various UA solutions, and any significant
difference when compared to the physiological control and vehicle Li2C03 solutions. To
determine the effect of the vehicle solution on vascular function, the results for the
Li2C03 solution and the physiological Krebs-Ringer buffer were compared.
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4.3 RESULTS
4.3.1 The effect ofUA on vascular contractility to PE
All responses to PE were similar when the vessels were perfused with 200pM, 400pM
or 600pM UA, physiological control or L^CCE vehicle solution (Fig. 4.1).
4.3.2 The effect of UA on endothelium-dependent responses to ACh
The concentration-dependent responses to ACh were similar when the arterial lumen
was perfused with 200pM, 400pM or 600pM UA solution (Fig. 4.2). The responses
were also similar to those obtained when the arteries were perfused with the vehicle
Li2C03 solution. The ACh-induced vasodilatation when perfused with the various
concentrations of UA appeared to be reduced when compared with the physiological
control. However, only the reduced response to 1x10"6M ACh when perfused with
200pM UA was found to be statistically significant fP<0.03). There was no statistically
significant difference in the calculated EC50 values (Table 4.1).
4.3.3 The effect of UA on endothelium-independent vasodilatation to
SNP
Concentration-dependent vasodilatation to SNP was similar when the arteries were
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Figure 4.1. The effect of luminal perfusion with UA on vasoconstriction to PE in
isolated rat mesenteric arteries: a.) 200pM UA, b.) 400pM UA, and c.) 600pM UA
compared to Krebs-Ringer or Li2C03 solution, d.) compares the effect of each
concentration ofUA. All values are the mean + SEM (n=8).
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Figure 4.2. The effect of luminal perfusion with UA on vasodilatation to ACh in
isolated rat mesenteric arteries: a.) 200pM UA, b.) 400pM UA, and c.) 600pM UA
compared to Krebs-Ringer or LiiC03 solution, d.) compares the effect of increasing
concentrations of UA. All values are the mean + SEM (n=8). *p < 0.03 vs. Krebs-
Ringer solution (2-factor ANOVA with replication and Bonferroni correction).
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Intraluminal Solution ECso Maximal Dilatation
Krebs-Ringer 107.4 ±30.2nM 105.9 ±3.6%
Li2C03 197.5 ±44.8nM 100.3 ±2.5%
200pM UA 155.5 ±30nM 101.4 ± 1.6%
400pmM UA 178 ± 58.2nM 100.7 ± 1.4%
600pM UA 125.6 ±37.6nM 100.3 ±2.3%
Table 4.1. The effect of luminal perfusion with UA on vasodilatation to ACh in
isolated rat mesenteric arteries: Calculated mean EC50 and maximal response values, +
SEM, for concentration-dependent vasodilatation to ACh in isolated rat mesenteric
arteries when perfused with the above intraluminal solutions. There was no statistically
significant difference in the mean EC50 values (P>0.05; One-way ANOVA with
Bonferroni correction, n=8).
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Figure 4.3. The effect of luminal perfusion with UA on vasodilatation to SNP in
isolated rat mesenteric arteries: a.) 200pM UA, b.) 400pM UA, and c.) 600pM UA
compared to Krebs-Ringer or L^CC^ solution, d.) compares the effect of increasing
concentrations ofUA. All values are the mean + SEM (n=8).
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4.4 DISCUSSION
Perfusion of the arterial lumen with increasing concentrations of UA (200pM, 400pM
and 600pM) had no effect upon the vasoconstriction to increasing concentrations of PE,
endothelium-dependent vasodilatation to ACh, or endothelium-independent
vasodilatation to SNP, when compared to the physiological control or vehicle control
responses.
4.4.1 The effect ofUA on vascular function
Many cardiovascular risk factors are accompanied by endothelial dysfunction, which
may be characterised by excessive vasoconstriction or vasospasm (Galle et al, 1990;
Cox & Cohen 1996). However, acute luminal exposure to UA at physiological and
elevated concentrations does not directly potentiate vasoconstriction to PE. This
suggests that UA does not impair vascular dysfunction and may provide limited
evidence that increased concentrations ofUA are not injurious to the vascular system.
It was hypothesised that UA is injurious to the endothelium and directly impairs
endothelium-dependent vasodilatation. However, in the current study, vasodilatation to
ACh was similar when the isolated arteries were perfused with increasing
concentrations of UA, the vehicle L^CCb solution, or physiological Krebs-Ringer
solution (Fig. 4.2). This demonstrates that acute luminal perfusion with increasing
concentrations UA, to a level that is greater than that found in human plasma, does not
attenuate endothelium-dependent vasodilatation to ACh, or induce vasoconstriction to
this agonist, as may occur in endothelial dysfunction (Ludmer et al, 1986; Zeiher et al,
1991; Zeiher et al, 1993). These results provide evidence that acute endothelial
exposure to increasing concentrations ofUA does not directly impair vascular function.
The failure of UA to induce vascular dysfunction is further demonstrated by the
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vasodilatation produced to SNP when the arteries were perfused UA solution or
physiological Krebs-Ringer solution. All the concentration-dependent responses were
similar, confirming that UA does not exert a direct inhibitory effect upon the relaxation
ofVSMC. These findings negate the hypotheses that UA directly induces the functional
impairment of the endothelium and demonstrate that UA is not cytotoxic or directly
injurious to the endothelium. Consequently, they do not support a causal link between
elevated UA concentrations and endothelial or vascular dysfunction. This is in accord
with a recent clinical study which reported that acute exposure to high concentrations of
UA did not impair forearm vascular function in healthy men (Waring et al, 2004).
The current results conflict with several studies which concluded that elevated UA
concentrations caused endothelial dysfunction (Farquharson et al, 1999; Mercuro et al,
2004; Baldus et al, 2005; Edrogan et al, 2005; Kanellis & Kang, 2005; Kato et al, 2005;
Khosla et al, 2005). However, these studies did not examine the direct effect ofUA on
vascular function and the results produced may be misleading. Kato et al and Edrogan
et al both demonstrated the impairment of endothelial-dependent vasodilatation in
hyperuricaemic patients and concluded that UA causes this endothelial dysfunction
(Edrogan et al, 2005; Kato et al, 2005). This conclusion may be speculative, as whilst
these studies demonstrate a correlation between hyperuricaemia and endothelial
dysfunction, it cannot be concluded if UA is the direct cause of this dysfunction.
Similarly, a number of the studies based their conclusions upon the restoration of
endothelial function following the lowering of in vivo UA concentrations in
hyperuricaemic patients (Farquharson et al, 1999; Mercuro et al, 2004; Baldus et al,
2005; Khosla et al, 2005). This restoration was achieved by the therapeutic reduction of
UA levels with allopurinol or oxypurinol, which inhibit XO activity. These studies did
not examine the direct action ofUA on vascular function, but rather studied the effects
of inhibiting XO-mediated UA generation. XO is a prominent source of ROS
(Engerson et al, 1987; Ohara et al, 1993; Anker et al, 1997; Leyva et al, 1997; Culleton
et al, 1999) and the stoichiometry of the XO reaction produces an excess of free radicals
over UA (Becker et al, 1991). These free radicals reduce NO availability and impair
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NO-mediated vasodilatation (Huie & Padmaja, 1993; Beckman & Koppenol, 1996).
Consequently, interpretation of the results produced is not straightforward, as the
restoration of endothelial function by XO-inhibitors could be attributed to the inhibition
of excess generation of XO-mediated free radicals (Farquharson et al, 1999; Doehner et
al, 2002; Farquharson et al, 2002). The current study used exogenous UA to examine
the direct effects on vascular function, thus the results produced were not complicated
by XO-mediated free radical generation. This could potentially explain the conflicting
results produced in this in vitro study when compared to previous in vivo studies in
hyperuricaemic patients.
4.4.2 Li2C03
UA is insoluble in hydrophobic media and sparingly soluble in aqueous media.
Physiological concentrations in human blood are near saturation (415pM).
Consequently, poor solubility has impaired the in vivo and in vitro study of UA on
vascular function, however this has recently been overcome (Waring et al, 2000). In the
present study, concentrations of UA near to and above the level of saturation were
required. Dissolution of UA in L^CCb solution allowed the preparation of such
concentrations (Waring et al, 2000). To minimise the L^CC^ present in the perfusing
solutions, and any influence this could have upon vascular function, high concentrations
ofUA were dissolved in the vehicle solution and then further diluted with physiological
Krebs-Ringer solution.
The results obtained in this study demonstrate no significant influence of any of the
interventions, or vehicle on endothelium-dependent dilatation to ACh. Therefore, it
seems unlikely that the Li2C03 vehicle was an important influence on the effects ofUA
in this study. This is supported by the calculated mean EC5o values, which are similar
when the vessels are perfused with the vehicle solution compared to the physiological
control. This is in agreement with a clinical study that demonstrated that Li^CCX
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provided a safe and suitable vehicle for the in vitro administration of UA in humans
(Waring et al, 2002).
However, the results produced do not agree with previous studies that have
demonstrated the variable impact of lithium and Li2C03 on vascular function in isolated
vessel preparations. However, such studies have used higher concentrations of Li2CC>3
and longer durations of exposure than this study. Li2CC>3 could potentially impair
vasodilatation to ACh by inhibiting the formation of IP3 (Drummond, 1987), which is
responsible for the release of intracellular Ca2+ from the endoplasmic reticulum in EC.
Similarly, lithium could also reduce vasodilatation by inhibiting cGMP synthesis
(Kanba et al, 1991). In contrast, it has been reported that lithium can enhance eNOS
activity and NO-mediated vasodilatation via the endothelial accumulation of cystolic
2+Ca (Marsden et al, 1990), or by inducing a transient increase in IP3 (Berridge et al,
1982). Dehpour et al demonstrated that the alteration of endothelial function by Li2CC>3
was dependent upon the chronicity of exposure, with prolonged exposure to lithium
enhancing ACh-mediated vasodilatation (Dehpour et al, 2000). However, in the current
study, the EC of the isolated vessels were only acutely exposed to the perfusing Li2CC>3
solution. Dehpour et al. also reported that the effect of lithium was concentration-
dependent, as 2mM lithium significantly increased ACh-induced dilatation in isolated
rat aorta, while 500pM significantly reduced vasodilatation (Dehpour et al, 1995).
However, incubation of the aorta with 500pM lithium did not alter the dilatory response
to less than 10"6M ACh (Dehpour et al, 1995). The current study is in partial agreement
with this as luminal perfusion with the Li2C03 vehicle solution had no effect upon
vasodilatation to ACh at any concentration studied. This may be because the
concentration of lithium in the vascular lumen in our studies was low (216pM).
Similarly, the inhibitory action of lithium upon IP3 and cGMP synthesis only occurs at
concentrations (1.5mM) far greater than those used in the present study (Kanba et al,
1991).
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4.4.3 The association of UA with cardiovascular disease
An epidemiological link between elevated UA and cardiovascular events has been
established for several years (Becker, 1993; Waring et al, 2000). Evidence regarding
the association between elevated plasma UA concentrations and the development of
cardiovascular disease is inconsistent (Jossa et al, 1994). Therefore, it remains unclear
whether UA has a causative or protective role in this condition. Several epidemiological
studies have reported that UA is an independent risk factor for this disease state (Fessel,
1980; Brand et al, 1985; Bonora et al, 1996; Persky et al, 1997; Bengtsson et al, 1998;
Lehto et al, 1998; Ward, 1998; Liese et al, 1999; Fang & Alderman, 2000;), whilst
others have reported that the link does not persist after correcting for other risk factors
(Reunanen et al, 1982; Iribarren et al, 1996; Wannamethee et al, 1997; Culleton et al,
1999; Wannamethee, 2005). The latter findings are in agreement with the results
produced in the present study, as UA does not have a direct effect upon vascular and
endothelial dysfunction following acute exposure in isolated vessels. This does not
support the hypothesis that elevated UA directly contributes to the pathogenesis of
cardiovascular disease via the impairment of vascular function. Rather, it suggests that
the epidemiological association of elevated UA with increased cardiovascular risk may
be mediated by other means. The strong association between UA and cardiovascular
risk may be misleading, as elevated UA may be present to combat the pathogenesis of
this disease or may simply be a non-causal marker for existing damage or other
cardiovascular risk factors.
4.4.3.1 The potential indirect causative role ofUA in cardiovascular disease
The present study has demonstrated that short-term exposure to elevated UA is not
directly injurious to the endothelium and does not induce endothelial dysfunction;
however an indirect causative role for UA in this condition cannot be discounted. There
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is extensive clinical and experimental evidence to suggest that UA can indirectly impair
endothelial function by other means. Biochemical and in vitro data indicate that UA
can react to form radical species and induce various pro-oxidant effects in the vascular
wall which could impair endothelial function (Vasquez-Vivar et al, 1996; Abuja, 1999;
Bagnati et al, 1999; Santos et al, 1999). This could not be examined in the present study
as the vessels were not placed under oxidative stress. In vitro and in vivo findings
suggest that UA may contribute to endothelial dysfunction by inducing antiproliferative
effects on endothelium and impairing NO production (Kanellis & Kang, 2005).
Elevated concentrations of UA may cause chronic inflammation through the activation
of various blood components, such as leukocytes (Duff et al, 1983; Hutton et al, 1985;
Leyva et al, 1998; Mazzali et al, 2002; Kanellis et al, 2003), which can have a
deleterious effect upon the endothelium. UA can enhance platelet adhesion,
aggregation, (Mustard et al, 1963; Newland, 1975; Ginsberg et al, 1977) and lysis
(Ginsberg et al, 1977). Platelet and leukocyte activation promotes peroxide and O2'"
radical liberation from these cells (Boogaerts et al, 1983; Falasca et al, 1993). This can
increase oxidative stress within the vascular wall and reduces NO availability.
Therefore, UA may indirectly impair NO-mediated vascular function by the activation
of various cells in the blood. These more chronic effects in vivo could not be addressed
by the current study as there were no blood components present in the vascular lumen.
4.4.3.2 UA as marker for other risk factors or existing damage
The association between cardiovascular disease and elevated UA could occur as a non¬
specific marker for other cardiovascular risk, such as hypercholesterolaemia,
hypertension, disordered glucose metabolism, obesity, or as a marker for existing
damage (Reunanen et al, 1982; Iribarren et al, 1996; Wannamethee et al, 1997; Culleton
et al, 1999; Alderman, 2001; Alderman, 2002). For example, the link between elevated
serum UA and cardiovascular disease may arise through a non-causal relationship with
insulin resistance syndromes, in which cardiovascular risk is caused by other factors. In
this state, insulin-mediated glucose metabolism is impaired but the renal effects remain
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(Perry et al, 1995; Muscelli et al, 1996). As insulin concentrations are greater in this
condition, there is enhanced renal insulin activity, and as such, reduced UA clearance
resulting in increased serum UA concentrations (Perry et al, 1995; Muscelli et al, 1996).
The association could also occur as elevated serum UA may be a marker for tissue
ischaemia. Under conditions of tissue ischaemia and hypoxia, there is a significant
increase in the synthesis and circulating concentration of adenosine to relax the VSMC
(Fredholm & Sollevi, 1986; Raatikainen et al, 1994). Flowever, the adenosine
synthesised locally by the VSMC is rapidly degraded by the EC to UA (Nees et al,
1985; Jarasch et al, 1986; Becker, 1993). Therefore, elevated serum UA may be a
marker of underlying ischaemia and or hypoxia. Similarly, the association between
elevated serum UA and increased cardiovascular risk may be secondary to the increased
XO activity that occurs under increased oxidative stress (Castelli et al, 1995). NO
exerts a potent dose-dependent inhibition on XO (Fukahori et al, 1994; Rinaldo et al,
1994; Hassoun et al, 1995). This inhibition is removed in oxidative stress and
endothelial dysfunction and XO activity is enhanced (Sobey et al, 1992; Sobey et al,
1993), resulting in increased UA generation.
4.4.3.3 Association of UA with cardiovascular disease as protective role
The inability of UA to impair vascular function in the current study suggests that UA
does not have a direct harmful effect upon endothelial function. Alternatively, the
association between elevated UA, endothelial dysfunction and cardiovascular disease
could occur as UA has a variety of potential protective effects, as outlined in Chapter 1.
UA is an established antioxidant and the elevated concentrations present in
cardiovascular disease may occur as a compensatory mechanism in the face of chronic
risk factors or established vascular disease. For example, elevated UA levels are
frequently associated with hypercholesterolaemia (Wannamethee et al, 1997), in which
there is an increased generation of O2" and ROS within the vascular wall (Ohara et al,
1993). UA may be present in greater concentrations in this disease state to prevent the
oxidative damage caused by these free radicals. This potentially beneficial role for
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elevated UA in conditions of cardiovascular risk could explain why humans have
greater concentrations of UA compared to other species, as a positive correlation exists
between plasma UA and species life-span (Ames et al, 1981; Becker, 1993). It has
previously been suggested that the high levels of UA present in human physiology are
not harmful to the body but are the result of an evolutionary process to provide an
effective protective mechanism against radical-induced oxidative damage (Ames et al,
1981). As the current study has demonstrated that UA does not directly impair vascular
function, further studies should focus upon investigating the potentially protective
effects of UA upon endothelial and vascular function.
4.4.4 Study Limitations
Possible limitations of this investigation include the duration of arterial exposure to UA.
The isolated vessels were only acutely exposed to the UA solutions (approximately 7
hours). However, patients at risk of developing cardiovascular disease, or those with
hyperuricaemia, may be exposed to elevated concentrations of UA in the plasma for
extensive periods of time. Therefore, it is possible that the onset of vascular or
endothelial dysfunction by UA may take longer the time scale for this study would
allow. Indeed, it has been suggested that chronic exposure to blood containing
hyperuricaemic concentrations of UA may trigger initial damage within the intimal
layer of the vessel wall (Rathmann et al, 1993; Persky et al, 1997). Furthermore, in
vitro studies examining the effect of incubation with elevated UA concentrations upon
the structural and functional integrity of HUVEC in culture reported that the extent of
endothelial injury was correlated to UA concentration and the duration of incubation
(Kuhne et al, 1999). Another possible limitation of this study is the presence of Li2C03
as the vehicle solution. However, as previously mentioned, the concentration within the
arterial lumen in these studies was relatively low (216pM) and exposure to the vehicle
solution had no significant effect on the vascular responses. Finally, any alterations in
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the maximum vasoconstrictor responses may have been hidden, as the data was
calculated in relation to the maximum response to KC1, which was also performed in the
presence of the various test solutions.
4.4.5 Summary
This study demonstrated that perfusing the lumen of isolated rat mesenteric arteries with
increasing concentrations of UA did not potentiate vasoconstriction or reduce
endothelial-dependent vasodilatation. This demonstrates that acute exposure of the
endothelium to UA does not induce severe functional impairment and is not directly
cytotoxic or injurious to the EC. On the basis of this study, it is hypothesised that the
UA does not have a direct causal role in endothelial dysfunction. Therefore, the
correlation between elevated UA concentrations and the pathogenesis of cardiovascular
disease does not occur by the direct impairment of endothelial function. However, the
relationship could be due to either the indirect actions ofUA upon the endothelium, the
production of free radicals by XO, or increased generation of UA as a compensatory
mechanism to combat conditions of increased oxidative stress. As a result, it is believed
that examining the effect of UA on endothelial function secondary to other established
risk factors, such as high concentrations of LDL, will help to further elucidate the role
of elevated UA in cardiovascular disease.
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CHAPTER 5
THE EFFECT OF LUMINAL EXPOSURE TO LDL ON
ENDOTHELIAL AND VASCULAR FUNCTION
5.1 INTRODUCTION
The previous chapter demonstrated that elevated concentrations of UA do not directly
impair vascular function. This elevation in serum UA concentrations frequently
accompanies hypercholesterolaemia (Wannamethee et al, 1997), an established
cardiovascular risk factor (Goldstein & Brown, 1977; Steinberg, 1983; Martin et al,
1986), in which endothelial dysfunction is prevalent (Chowienczyk et al, 1992). This
dysfunction is attributed to LDL-induced damage to the endothelium. However,
evidence regarding the role of LDL in the development of endothelial dysfunction
remains inconsistent, and must be clarified before the relationship between UA, LDL
and vascular function can be examined.
The oxidative modification of LDL to ox-LDL was previously regarded as a key
process in the development of endothelial dysfunction (Steinberg et al, 1989;
Esterbauer et al, 1992; Cox & Cohen, 1996). The harmful properties of LDL are
commonly attributed to the action of ox-LDL (Cox & Cohen, 1996; Dart & Chin-
Dusting, 1999; Rosendorff, 2002) and the deleterious effects of ox-LDL on NO-
mediated vascular function are widely established (Hein & Kuo, 1998; Vergnani et al,
2000; Mukherjee et al, 2001; Chan et al, 2003; Fleming et al, 2005). However, the role
of unmodified LDL in vascular and endothelial dysfunction is less clear, as in vitro
studies performed to elucidate the direct effects of LDL on endothelial function have
produced conflicting results. Several studies have reported that LDL does not impair
vascular function in isolated vessel preparations (Kugiyama et al, 1990; Yokoyama et
al, 1990; Simon et al, 1990; Plane et al, 1992; Galle et al, 1994; Galle et al, 1995; Chan
et al, 2003), while several have demonstrated that LDL significantly reduces NO-
availability and impairs vasodilatation (Andrews et al, 1987; Jacobs et al, 1990; Tomita
et al, 1990; Galle et al, 1991; Hein & Kuo, 1998; Fontana et al, 1999; Vergnani et al,
2000).
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The mechanism by which LDL could impair endothelium-dependent vasodilatation also
remains uncertain, but is likely arise due to the decreased release of, or the increased
inactivation of, endothelium-derived NO. These may occur due to LDL-induced
increases in ROS and oxidative stress within the vascular wall (Gryglewski et al, 1986;
Ohara et al, 1993). It has been reported that a three-fold increase in ROS occurs in
hypercholesterolemia, which coincides with a decrease in vascular relaxation (Ohara et
al, 1993; Ohara et al, 1995). This may be prevented by SOD, the major tissue defence
against O2 ", which restores NO-mediated vascular function in in vitro models of
hypercholesterolemia (Mugge et al, 1991; White et al, 1994; Hien & Kuo, 1998).
This restoration implies a central role for O2 ~ in the deleterious actions of LDL on
endothelial function. The endothelial generation of O2" may be enhanced by LDL via
the direct impairment of endothelial 1-arginine metabolism and the resultant effects this
has upon eNOS activity (Pritchard et al, 1995; Pritchard et al, 2002; Stepp et al, 2002).
Consequently, LDL could have a causative role in cardiovascular disease by increasing
oxidative stress within the EC, which in turn reduces NO availability, thus inducing
endothelial dysfunction.
This chapter aims to clarify the contradictory literature and investigate the role of LDL
in endothelial dysfunction. This chapter will use perfusion myography to examine the
effect of acute luminal exposure to LDL upon vascular function in isolated rat
mesenteric arteries. This chapter will also examine the effect of supplementation of the
LDL solutions with L-NAME, 1-arginine and SOD. This chapter aims to establish the
effect of LDL on vascular function, and the possible mechanisms of action, by
demonstrating that:
1.) Luminal exposure to LDL in a perfusion myograph model induces vascular
dysfunction in a concentration-dependent manner.
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2.) LDL induces vascular dysfunction by impairing NO-dependent vasodilatation in
this experimental model, which is not augmented by the prevention ofNOS activity
with L-NAME.
3.) The inhibition of vascular function is mediated by impaired 1-arginine metabolism
and increased oxidative stress within the vascular wall. This can be reversed by
supplementation with 1-arginine or the dismutation of O2 ~ by SOD.
4.) The inhibitory effects of LDL upon endothelium-dependent vasodilatation are fully
reversible.
5.) LDL does not require oxidative modification to ox-LDL to induce endothelial




LDL was isolated, purified, and the protein concentration determined using a
commercial kit based on the Lowry precipitation assay (Sigma Chemical Company,
Dorset, U.K.), as previously described (Chapter 2).
5.2.2 The effect of LDL on vascular function
Segment of third order branches of the rat mesenteric artery were excised, mounted and
concentration-responses curves to PE, ACh and SNP performed when the lumen was
perfused with LDL solution (250, 500 or lOOOpg/ml) or control Krebs-Ringer solution.
This was also repeated on endothelial denuded vessels perfused with Krebs-Ringer
solution.
5.2.3 The reversibility of the inhibitory action of LDL on
endothelium-dependent vasodilatation
The arteries were prepared as before and the lumen perfused with Krebs-Ringer
solution. Following constriction with high K+ Krebs solution, cumulative
concentration-response curves to PE were performed. The arteries were washed,
allowed to relax, and then preconstricted with ECgo PE (l-5pM). ACh concentration-
response curves (1x10"7-1x10"5M) were then performed. The stopcock attached to the
distal cannula was then opened to allow the arterial lumen to be slowly perfused with
LDL solution (250, 500 or lOOOpg/ml). The stop-cock was closed and the vessel re-
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pressurised to 60mmHg. The vessels were allowed a 60-minute equilibration period,
preconstricted with PE, and ACh concentration-response curves repeated. The lumen
was then perfused slowly with Krebs-Ringer solution for 10 minutes to remove all LDL
solution and ensure the lumen was completely perfused with physiological buffer. The
arteries were re-pressurised to 60mmHg and, allowed a 60-minute equilibration period,
preconstricted, and ACh concentration-response curves repeated.
5.2.4 The effect of L-NAME upon the action of LDL on vascular
function
Arteries were prepared and mounted as before. The lumen was perfused with 250pg/ml
LDL solution, 100pM L-NAME solution, 250pg/ml LDL + lOOpM L-NAME solution,
or Krebs-Ringer buffer, and concentration-response curves to PE, ACh and SNP
performed.
5.2.5 The effect of SOD upon the action ofLDL on vascular function
The experimental preparation and protocol (5.2.2) was repeated when the arterial lumen
was perfused with 250pg/ml LDL solution, 250pg/ml LDL + 150U/ml SOD solution or
Krebs-Ringer buffer.
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5.2.6 The effect of 1-arginine supplementation upon the action of LDL
on vascular function
The experimental preparation and protocol (5.2.2) were repeated when the arterial
lumen were perfused with 250pg/ml LDL solution, 250pg/ml LDL + ImM 1-arginine
solution or Krebs-Ringer buffer.
5.2.7 Intraluminal Solutions
LDL solutions were prepared daily from stock by dilution with Krebs-Ringer solution
to give a final intraluminal lipoprotein concentrations of 250, 500 and lOOOpg/ml. To
prevent the oxidative modification of LDL, 0.3mM EDTA was added to the solutions.
ImM L-NAME stock solution was prepared by dissolving in Krebs-Ringer solution.
Working solutions were prepared daily by dilution with Krebs-Ringer to give a final
concentration of lOOpM. L-NAME-supplemented LDL solutions were prepared daily
by diluting stock LDL solution with Krebs-Ringer buffer and stock L-NAME solution
to give a final intraluminal lipoprotein concentration of 250pg/ml and L-NAME
concentration of 1 OOpM. 1 OmM 1-arginine solution was prepared daily by dissolving
1.74mg/ml 1-arginine in Krebs-Ringer buffer. This was then used to dilute the stock
LDL solution, along with Krebs-Ringer buffer, to give an 1-arginine concentration of
ImM and lipoprotein concentration of 250pg/ml. SOD protein was dissolved daily in
250pg/ml LDL solution to give a final SOD concentration of 150U/ml.
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5.2.8 Lipid Peroxidation
Samples of the intraluminal LDL and supplemented solutions were collected before and
after luminal perfusion to measure the extent of LDL lipid peroxidation and examine
any changes in oxidative status. The hydroxynonenal (4-HNE) and malondialdehyde
(MDA) concentrations of the intraluminal solutions were determined using a
commercial colorimetric assay kit (CN Biosciences, Nottingham, U.K.).
5.2.9 Statistical Analysis
The statistical significance of the impairment of vascular function by LDL was
determined by comparing the results obtained for the various concentrations of LDL
with the physiological control responses. These were also compared with each other to
demonstrate that the inhibitory effects of LDL were concentration-dependent. The
reversibility of the effect of LDL upon endothelial function was analysed by
determining any statistical significance in endothelium-dependent vasodilatation
before, during and after luminal perfusion with LDL solution. Statistical analysis was
performed to determine the effect of LDL supplementation with L-NAME, SOD or 1-
arginine on vascular function when compared to LDL or the physiological control. The
effect of the LDL supplementation with L-NAME was also compared to the vascular
responses when perfused with L-NAME only. Statistical analysis was performed using
a paired Student's t-test to compare the oxidative status of the intraluminal LDL
solution before and after luminal perfusion.
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5.3 RESULTS
5.3.1 The effect of LDL on vascular function
5.3.1.1 The effect of LDL on vascular contractility
PE produced concentration-dependent vasoconstriction in mesenteric arteries perfused
with Krebs-Ringer solution, with a maximal response of 96.6 + 3.5% (Fig 5.1). All
maximal responses were similar when perfused with the various intraluminal solutions.
All concentrations of LDL produced similar results. However, 250pg/ml (5xl0"7-lxl0"
6, P<0.01), 500pg/ml (5x10"7-1x10~6, P<0.01) and lOOOpg/ml LDL (5xHF8-lxl(F6,
P<0.01) significantly enhanced vasoconstriction when compared to the control and
denuded artery responses. Nevertheless, there was no statistically significant difference
in the calculated EC50 values (Table 5.1).
5.3.1.2 The effect of LDL on endothelium-dependent vasodilatation
ACh produced concentration-dependent vasodilatation with a maximal response of
106.1 + 2.9% in arteries perfused with Krebs-Ringer solution (Fig 5.2). Endothelial
denudation abolished the dilatory responses to ACh (lxlO^-SxlO"4, P<0.001).
250pg/ml LDL (1x10"9-5x10"4, P<0.01), 500pg/ml LDL (lxlO^xlO"4, P<0.03), and
1000|ig/ml LDL (lxlO^-SxlO"4, P<0.01) significantly reduced vasodilatation when
compared to the physiological control, producing maximal responses of 42.6 ± 2.1%,
33.6 + 3.7% and 21.7 + 2.3%, respectively. However, these responses were
significantly greater than the responses in endothelial denuded arteries (250pg/ml:
1x10"8-5x10~4 P<0.05; 500pg/ml: lxlO^-SxlO"4, P<0.01; lOOOpg/ml: 5xl0"7-5xl0"4,
P<0.04). The inhibition of vasodilatation by LDL was concentration-dependent.
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Figure 5.1. The effect of luminal perfusion with LDL on vasoconstriction to PE in
isolated rat mesenteric arteries: a.) 250pg/ml LDL, b.) 500pg/ml LDL, and c.)
lOOOpg/ml LDL compared to intact or denuded vessels perfused with Krebs-Ringer
solution. *p<0.05 vs. intact vessels, **p<0.05 vs. denuded vessels (2-factor ANOVA
with replication and Bonferroni correction, n=8). d.) compares the effect of the various
concentrations of LDL. All values are the mean + SEM (n=8).
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Table 5.1. The effect of luminal perfusion with LDL on vasoconstriction to PE in
isolated rat mesenteric arteries: Calculated mean EC50 and maximal response values, +
SEM, for concentration-dependent vasoconstriction to PE when perfused with the
above intraluminal solutions. There was no statistically significant difference in the
mean EC50 values (P>0.05; One-way ANOVA with Bonferroni correction, n=8).
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Figure 5.2. The effect of luminal perfusion with LDL on vasodilatation to ACh in
isolated rat mesenteric arteries: a.) 250pg/ml LDL, b.) 500pg/ml LDL, and c.)
lOOOpg/ml LDL compared to intact or denuded vessels perfused with Krebs-Ringer
solution. *p<0.03 vs. intact vessels, **p<0.04 vs. denuded vessels (2-factor ANOVA
with replication and Bonferroni correction, n=8). d.) compares the effect of the various
concentrations of LDL. *p<0.01 vs. 1000pg/ml LDL, **p<0.01 vs. 500pg/ml LDL (2-
factor ANOVA with replication and Bonferroni correction, n=8). All values are the




















5.3.1.3 The effect of LDL on endothelium-independent vasodilatation to SNP
Vasodilatation to SNP was similar following luminal perfusion with Krebs-Ringer
solution, 250, 500 or 1000pg/ml LDL (Fig. 5.3), producing maximal dilatory responses
of 100.9 ± 1.3%, 99.7 ± 1.5%, 99.7 ± 1.8% and 96.9 ± 4.4%, respectively. The
vasodilatation in endothelium denuded arteries was also largely similar and produced a
maximal dilatation of 100 + 2.1%. However, 250pg/ml (Ixl0"7-lxl0~6, P<0.02),
500pg/ml (lxlO"6, P<0.01) or lOOOpg/ml LDL (lxlO"6, P<0.01) did reduce dilatation
to SNP when compared to vasodilatation in denuded arteries.
5.3.2 The reversibility of the inhibitory action of LDL on
endothelium-dependent vasodilatation
Luminal perfusion with 250, 500 or lOOOpg/ml LDL significantly attenuated
concentration-dependent vasodilatation to ACh when compared to the dilatation prior
to perfusion with LDL (Fig. 5.4). This was completely reversible, as vasodilatation to
ACh was restored following LDL washout and reperfusion with Krebs-Ringer solution.
5.3.3 The effect of L-NAME upon the inhibitory action of LDL on
endothelium-dependent vasodilatation
Perfusion with 100pM L-NAME significantly reduced vasodilatation to ACh when
compared to Krebs-Ringer buffer (1x10"8-5x10~4, P<0.02; Fig 5.5). The maximal
dilatation was 44.9 + 3.2%. Perfusion with 250pg/ml LDL + lOOpM L-NAME
produced a maximal dilatation of 38.6 + 3.5%. These dilatations to ACh were largely
similar to the responses for 250pg/ml LDL (5xl(T6, P<0.02) or lOOpM L-NAME
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Figure 5.3. The effect of luminal perfusion with LDL on vasodilatation to SNP in
isolated rat mesenteric arteries: a.) 250pg/ml LDL, b.) 500pg/ml LDL, and c.)
1000p.g/ml LDL compared to intact or denuded vessels perfused with Krebs-Ringer
solution. *p<0.02 vs. denuded vessels (2-factor ANOVA with replication and
Bonferroni correction, n=8). d.) compares the effect of the various concentrations of




Figure 5.4. The reversibility of the impaired endothelium-dependent vasodilatation to
ACh in isolated rat mesenteric arteries perfused with LDL: before, during, and after
luminal perfusion with a.) 250pg/ml LDL, b.) 500pg/ml LDL, and c.) 1000pg/ml LDL.

























- 250pg/ml LDL + lOOpM L-NAME
- Krebs-Ringer solution
*
Figure 5.5. The effect of L-NAME on vasodilatation to ACh in isolated rat mesenteric
arteries perfused with LDL: 250pg/ml LDL, Krebs-Ringer solution, 100pM L-NAME
and 250pg/ml LDL + lOOpM L-NAME. *p<0.01 vs. Krebs-Ringer solution, **p<0.02
vs. 250pg/ml LDL, ***p<0.02 vs. lOOpM L-NAME (2-factor ANOVA with replication
and Bonferroni correction, n=8). All values are the mean + SEM (n=8).
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(5x10"4, .P<0.02) but significantly reduced when compared to the physiological control
(Ixl0"s-5xl0~4, PO.Ol).
5.3.4 The effect of SOD upon the action of LDL on endothelium-
dependent vasodilatation
250pg/ml LDL + 150U/ml SOD significantly attenuated concentration-dependent
8 -4
vasodilatation to ACh when compared to the physiological responses (1x10" -5x10 ,
P<0.01; Fig 5.6), and the maximal vasodilatation was 46 + 3.6%. Luminal perfusion
with 250jig/ml LDL + 150U/ml SOD did not significantly alter the vasodilatation to
ACh when compared to arterial perfusion with 250pg/ml LDL only.
5.3.5 The effect of 1-arginine supplementation upon the action of LDL
on vascular function
Perfusion with 250pg/ml LDL + ImM 1-arginine significantly increased ACh
8 _4
concentration-dependent vasodilatation when compared to LDL only (1x10" -5x10 ,
P<0.01; Fig 5.7), producing a maximal vasodilatation of 84.2 + 4.8%. However, this
vasodilatation was still significantly lower than the physiological control responses
(5x10"7-5X10"4 P<0.04).
5.3.6 Lipid peroxidation
There was no significant alteration in MDA and 4-HNE concentrations solutions
following luminal perfusion (Fig. 5.8).
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■ - 250pg/ml LDL
A - 250pg/ml LDL + 150U/ml SOD
o - Krebs-Ringer solution
Concentration (M)
Figure 5.6. The effect of SOD on vasodilatation to ACh in isolated rat mesenteric
arteries perfused with LDL: 250pg/ml LDL, Krebs-Ringer solution, 250pg/ml LDL +
150U/ml SOD. *p<0.01 vs. Krebs-Ringer solution (2-factor ANOVA with replication
and Bonferroni correction, n=8). All values are the mean + SEM (n=8).
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Concentration (M)
100- ■ - 250|ig/ml LDL
A - 250(ig/ml LDL + ImM 1-arginine
o - Krebs-Ringer solution
Figure 5.7. The effect of 1-arginine on the action of LDL on vasodilatation to ACh in
isolated rat mesenteric arteries: 250pg/ml LDL, Krebs-Ringer solution, 250|ig/ml LDL
+ ImM 1-arginine. *p<0.01 vs. 250pg/ml LDL, **p<0.04 vs. Krebs-Ringer solution (2-
factor ANOVA with replication and Bonferroni correction, n=8). All values are the
mean + SEM (n=8).
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250 LDL 500 LDL 1000 LDL
Figure 5.8. Alterations in lipid peroxidation product levels: a.) Concentration ofMDA
and 4-HNE present in 250pg/ml, 500pg/ml and 1000pg/ml LDL solutions before and
after luminal perfusion, b.) Mean percentage change in the concentration of MDA and
4-HNE following luminal perfusion. All values are mean + SEM (n=8).
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5.4 DISCUSSION
The results show that luminal perfusion with LDL inhibits vascular function in isolated
rat mesenteric arteries, resulting in the marked attenuation of endothelium-dependent
vasodilatation to increasing concentrations of ACh. Vasodilatation to SNP was not
significantly affected. The effects of LDL were similar to those of L-NAME, and
supplementation of LDL with L-NAME did not augment vasodilatation LDL-induced
impairment of vasodilatation to ACh. This impairment was reversible upon washout,
and could be largely reversed by 1-arginine supplementation, but was not affected by
SOD.
5.4.1 The effect of LDL on vascular function
Protein and cholesterol constitute approximately 20% and 33% of the weight LDL,
respectively (Lewis et al, 1997; Abuja, 1999). Therefore, lmg/ml LDL contains 200pg
LDL protein/ml and 330pg LDL cholesterol/ml (Esterbauer et al, 1991; Lewis et al,
1997; Bagnati et al, 1999). Consequently, the LDL samples used in this study (250, 500
and lOOOpg/ml protein) equate to 1.25, 2.5 and 5mg/ml LDL, and should contain
approximately 412.5, 825, and 1650pg/ml, or 1.65mg/ml, LDL cholesterol respectively.
Hypercholesterolaemic patients have a total cholesterol concentration greater than
2.4mg/ml (6mmol/l) (Chowienczyk et al, 1992; Ting et al, 1997; Wilkinson &
Cockroft, 1998), and LDL cholesterol greater than 1.6mg/ml (Ting et al, 1997; Homig
et al, 1998). Similarly, hypercholesterolaemic patients have a plasma LDL protein
concentration of approximately 2mg/ml or greater (Jacobs et al, 1990), while the
physiological concentration is approximately lmg/ml (Lees et al, 1970; Schonfeld et al,
1974; Beghin et al, 2000). As a result, the concentrations of LDL used in the present
study are relevant to human physiology and pathophysiological conditions.
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Luminal perfusion with LDL enhanced vasoconstriction to PE in a concentration-
dependent manner when compared to the physiological control. However, the maximal
response was only increased by approximately 10% at the highest concentration of
LDL used, whilst there was no significant difference in any of the calculated EC50
values. It has previously been demonstrated that LDL has little direct constrictor effect
upon isolated blood vessels in the absence of preconstriction, but may constrict vessels
that have been pretreated with a contractile agonist (Galle et al, 1990; Simon et al,
1990; Murohara et al, 1994). This is likely to be mediated by the inhibition of basal
NO release from the EC, which occurs to prevent excessive vasoconstriction (Bullock
et al, 1986; Moncada et al, 1991; Dora et al, 1997; Dora et al, 2000).
ACh-induced endothelium-dependent vasodilatation was impaired by LDL. This
inhibition was LDL concentration-dependent, with lOOOpg/ml causing approximately
78% inhibition (Fig. 5.2). The failure of L-NAME to significantly enhance the
inhibition of vasodilatation when added to the 250pg/ml LDL solution demonstrated
that the prevention of NOS activity did not augment the inhibition of endothelium-
dependent vasodilatation by LDL (Fig 5.5). This suggests that all endothelial NO-
dependent vasodilatation was impaired, and implies that the deleterious action of LDL
is largely caused by the impairment of endothelial NO production and may be mediated
via an inhibitory action upon eNOS. Conversely, the results produced may also suggest
that LDL impairs endothelium-mediated NO-independent vasodilatation. It has
previously been demonstrated (Chapter 3) that NO accounts 58% of vasodilatation in
this experimental model. However, luminal exposure to higher concentrations of LDL
(500 and lOOOpg/ml) caused a 66% and 78% reduction in vasodilatation to ACh,
respectively, suggesting that LDL may also impair vasodilatation to other EDRF's.
This is supported by the failure of ImM 1-arginine to fully restore vasodilatation to
ACh, demonstrating that there is a component of the LDL-induced inhibition of
endothelium-mediated vasodilatation that is independent of the NO system. It has been
demonstrated that the role of prostacyclin as an EDRF in this experimental model is
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minimal (Chapter 3). Therefore, the NO-independent inhibition is likely to be caused
by the impairment of EDHF-mediated vasodilatation.
There was no significant reduction in vasodilatation to SNP when the arterial lumen
was perfused with LDL compared to the physiological control (Fig 5.3). This is in
agreement with numerous studies that have demonstrated that FDF does not alter
vasodilatation to exogenous nitrosovasodilators, such as SNP and GTN (Andrews et al,
1987; Jacobs et al, 1990; Fewis et al, 1997; Hein & Kuo, 1998; Fontana et al, 1999;
Jiang et al, 2001; Ji et al, 2003). However, FDF reduced dilatation to SNP when
compared to vasodilatation in denuded arteries (Fig 5.3, Table 5.3). This may initially
appear surprising, but could occur as the inhibitory effects of FDF are mediated via the
endothelium. For example, LDF may promote the excess endothelial generation of O2 '
which could potentially impair endothelium-independent vasodilatation to SNP by
inactivating the NO released. Endothelial denudation would remove this and enhance
the endothelium-independent vasodilatation produced.
5.4.2 Mechanism of action of LDL on vascular function
The results of the current study have demonstrated that FDF impairs endothelial NO-
dependent vasodilatation. It is unlikely that the effects of FDF are mediated by the
endocytosis of FDF, as FDF inhibits ACh-mediated vasodilatation in aortic rings from
Watanabe hereditary hyperlipidaemic rabbits (Bruckdorfer et al, 1988) which lack the
functional high affinity receptors required for the endocytosis and degradation of LDF
(Baker et al, 1984). The current study supports this, as these receptors are fully
saturated at LDL concentrations of lOOpg/ml in rabbits and rodents (Baker et al, 1984;
Jacobs et al, 1990). However, increasing the concentration of LDL from 250pg/ml, at
which the receptors should already be saturated in the rodent model used, to 500gg/ml
and 1000pg/ml increased the level of inhibition induced.
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The inhibitory action of all concentrations of LDL upon endothelium-dependent
vasodilatation was reversible upon washout and reperfusion with physiological Krebs-
Ringer solution (Fig 5.4). These results support the hypothesis that the inhibitory effect
of LDL occurs via a direct impairment of NO-availability rather than a cytotoxic or
injurious effect upon the EC. This may endorse an in vivo study that reported an
improvement in impaired vasodilatation to ACh in hypercholesterolaemic patients
following LDL apheresis (Tamai et al, 1997). The reversible nature of the inhibition
also implies that the deleterious action of LDL is not mediated by the intemalisation of
LDL in the EC or accumulation in subendothelial space (Brown & Goldstein, 1979;
Baker et al, 1984), as this LDL would not be washed out and the inhibition would not
be reversed.
The relatively rapid nature of the inhibition also suggests that the LDL does not exert
its inhibitory action by undergoing oxidation to ox-LDL as this requires prolonged
exposure to transition metals or EC (Jacobs et al, 1990). Examination ofMDA and 4-
HNE in the lipoprotein samples before and after luminal perfusion implies that the LDL
did not undergo further oxidative modification during the course of these experiments,
and should therefore have been representative of unmodified LDL.
The four sites were LDL is most likely to exert an effect are shown in Fig. 5.9. It is
unlikely that the inhibitory action of LDL is mediated by a kinetic phenomenon or
effect, for example the binding of the LDL to ACh, as the technique used would not
allow the LDL and ACh to come into contact and interact (Fig 5.9 (1)). The failure of
LDL to impair vasodilatation to SNP establishes that LDL does not inactivate NO
within the extracellular space (Fig 5.9 (3)) or alter VSMC function (Fig 5.9 (4)). This
suggests that the inhibitory action of LDL is endothelium-specific (Ezaki et al, 1994).
Therefore, it is highly likely that LDL inhibits NO-mediated vasodilatation by altering
physiological eNOS activity (Fig 5.9 (2)).
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ACh
Figure 5.9. Potential sites where LDL may impair endothelium-dependent
vasodilatation to ACh: 1) LDL may prevent the interaction between ACh and the M 2/3-
receptor. 2) LDL may alter eNOS activity. 3) LDL may promote the inactivation of NO
following the generation and release from EC. 4) LDL may inhibit the mechanism by
which NO opposes agonist-induced increases in [Ca2+]i to inhibit contraction and
induce relaxation.
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5.4.3 The role of 02'~ in LDL-induced vascular dysfunction
The current study has demonstrated that acute luminal exposure LDL impairs NO-
mediated vasodilatation. However, numerous studies have demonstrated that eNOS
activity and NO production are in fact enhanced in hypercholesterolaemic models or by
exposure to LDL (Minor et al, 1990; Galle et al, 1991; Schaefer et al, 1993; Liao et al,
1995; Pritchard et al, 1995; Allen et al, 1998; Vidal et al, 1998). Under these
conditions, endothelial NO may undergo enhanced oxidative degradation (Ohara et al,
1993; Ohara et al, 1995; Pritchard et al, 1995; Vergnani et al, 2000). This is commonly
attributed to a LDL-induced imbalance in eNOS activity that increases eNOS-mediated
O2 " generation. Hypercholesterolaemic rabbits generate 3 to 5 fold more O2 " than
control animals (Ohara et al, 1993; Ohara et al, 1995). When produced in close
proximity, O2" reacts readily with NO to decrease NO availability. It was therefore
hypothesised that the inhibition of vasodilatation by LDL is a result of increased
oxidative degradation ofNO due to O2 ~ generation within the vascular wall.
The current study examined the role of O2 ~ in LDL induced vascular dysfunction by
supplementing 250pg/ml LDL solution with exogenous SOD. SOD is the major tissue
defence against the harmful effects of 02 . Endogenous SOD and SOD mimetics
facilitate the dismutation of O2 "(Kasten et al, 1994; Kasten et al, 1995; Mian & Martin,
1995) at a rate of 2xl09M~V (Huie & Padmaja, 1993). The potential restoration of
vasodilatation by the addition of SOD to the LDL solution would demonstrate the role
of O2" in the impairment of vascular function. However, supplementation with SOD
had no significant effect upon the response to ACh in the current study.
This could suggest that O2 ~ generation is not involved in the inhibitory action of LDL.
However, there are several other possible explanations for this finding. NO is rapidly
inactivated by O2" at a diffusion-limited rate (Huie & Padmaja, 1993), and although the
reaction rates are similar, the reaction between of O2 ~ and NO is over 3 times faster
than the dismutation of O2" by SOD (Ducroq, 1999). As a result, the reaction between
excessive concentrations of O2 " and NO is likely to occur before the reaction with
SOD. Furthermore, exogenous SOD is unable to permeate cellular membranes and
dismute intracellular sources of O2" (Laight et al, 1998). SOD can reverse the
inhibition of ACh-mediated vasodilatation caused by the extracellular generation of O2"
in both rat (Mian & Martin, 1995) and rabbit aorta (Abrahamsson et al, 1992;
MacKenzie & Martin, 1998), but cannot prevent the inhibition caused by DECTA
(Mian & Martin, 1995; Laight et al, 1998), which inhibits endogenous Cu-Zn SOD to
generate intracellular oxidative stress (Heikkila et al, 1976). Therefore, the exogenous
SOD used to supplement the LDL solution would only be able to exert an extracellular
action, which could explain the negative results produced. These agree with a previous
study that demonstrated the inability of exogenous SOD to restore endothelial function
following acute exposure to LDL in vitro (Plane et al, 1993).
It has previously been concluded, using exogenous SOD in vivo, that endothelial
dysfunction in hypercholesterolaemic patients is not due to increased extracellular NO
breakdown by O2 " (Garcia et al, 1995). The failure of exogenous SOD to restore
vasodilatation may indirectly suggest that LDL-induced endothelial dysfunction is
caused by the intracellular inactivation of NO. This has previously been demonstrated
by the cell permeable SOD mimetic, manganese (III) tetra is (l-methyl-4-pyridyl)
porphyry (MnTMPyP), which can react with O2 " at a rate constant of 1x109M"V
(Faulkner et al, 1994), and restores vasodilatation in aortic rings (Fontana et al, 1999)
or isolated conduit arteries exposed to LDL (Hein & Kuo, 1998).
Nevertheless, the current study does not support the hypothesis that exogenous SOD
can restore endothelial function following luminal exposure to LDL. However, this
does not discount the hypothesis that LDL-induced vascular dysfunction is due to
increased oxidative stress within the vascular wall, as the ability of exogenous SOD to
combat this may have impaired by an inability to gain endothelial intracellular access.
136
Consequently, it is suggested that LDL-induced vascular dysfunction is mediated by the
intracellular generation ofOf" and resultant inactivation ofNO.
The generation of O2" may be attributed an imbalance in eNOS activity caused by the
impairment in 1-arginine metabolism (Pritchard et al, 2002; Stepp et al, 2002). In an
arginine-depleted environment, eNOS still accepts electrons from NADPH and
becomes electron rich. Under these conditions eNOS activity uncouples and utilises
molecular O2 as a principal substrate to produce O2" (Mayer et al, 1991; Klatt et al,
1993; Griffith & Steuhr, 1995; Pritchard et al, 1995), making eNOS a further source of
oxidative stress (Shinozaki et al, 1999). Huk et al previously proposed that LDL
reduced 1-arginine availability, resulting in a conformational change in eNOS that
promoted the generation of O2" from O2 (Huk et al, 1997). Previous studies have
demonstrated that 1-arginine supplementation can prevent LDL-induced increases in
endothelial O2 " generation and enhance NO-availability (Pritchard et al, 1995; Huk et
al, 1997; Vergnani et al, 2000). This is in accord with the current study, which
demonstrates that the inhibitory action of LDL can be reversed by supplementation
with ImM 1-arginine. This implies that LDL-induced endothelial dysfunction could
occur, in part, via the inhibition of the utilisation of 1-arginine by eNOS.
The restorative action of 1-arginine supplementation may be specific for LDL-induced
endothelial dysfunction, as this improves vascular function in hypercholesterolaemia
(Creager et al, 1992; Clarkson et al, 1996; Wolf et al, 1997; Yin et al, 2005), but not in
hypertension or insulin-dependent diabetes mellitus (MacAllister et al, 1995). The Km
of eNOS for 1-arginine is in the order of 1-lOp.M (Vallance, 1998; Bult et al, 1999;
Hobbs et al, 1999) and the cellular 1-arginine concentration ranges from 40pM to ImM,
respectively (MacAllister et al, 1995). Therefore, the supply of cellular 1-arginine is
excessive and should not be rate-limiting for the formation of NO. However, the
restoration of NO-mediated vasodilatation in the present study could occur as
supplementation increases the intracellular 1-arginine concentration and shifts the
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equilibrium towards the removal of the excess 1-arginine, resulting in increased NO
formation and availability.
There are several possible means by which LDL could impair 1-arginine metabolism.
The inhibition may be due to the formation ofADMA, an endogenous eNOS inhibitor,
which accumulates at high levels in the plasma of hypercholesterolemic animals (Yu et
al, 1994; Bode-Boger et al, 1996). This competes with 1-arginine as a substrate for
eNOS to prevent NO formation. Supplementation with 1-arginine may increase the
intracellular concentration to sufficient levels to compete with this, restore eNOS
activity and normalise NO production (Boger et al, 1997). Alternatively, LDL could
increase EC membrane rigidity through the donation of cholesterol (Pritchard et al,
1991). This would alter the lipid dynamics of the membrane, which may impede the
binding, internalisation, and availability of 1-arginine to eNOS. The resultant
generation of O2 ~ could further impede the internalisation of 1-arginine, as the primary
means of 1-arginine transport into EC, the system y+ transporter (Ogonowski et al,
2000), is impaired by oxidants and oxidative stress (Patel et al, 1996; Ogonowski et al,
2000). Nevertheless, the demonstrated restoration of endothelial function by 1-arginine
suggests that LDL impairs intracellular 1-arginine availability. This is likely to cause
eNOS uncoupling and the endothelial generation of O2", which in turn increases
oxidative stress and reduces NO availability (Fig 5.10).
5.4.4 Tissue preparation
Contradictory results have been reported with regards to the effect of LDL upon
isolated vessel preparations. This may be due to the techniques applied, as the action of
LDL upon vascular function in vitro could be dependent upon the experimental
preparation used. Galle et al. reported that incubation with LDL did not impair
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Figure 5.10. The proposed mechanism of LDL-induced endothelial dysfunction. From
the experiments performed in this chapter, it is hypothesised that LDL impairs 1-
arginine metabolism to cause an imbalance in eNOS activity. This inturn increases
eNOS-generated O2 which then inactivates endothelial NO to reduce NO
bioavailability and impair NO-mediated vasodilatation.
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endothelium-dependent vasodilatation in intact rabbit femoral artery segments, but did
significantly inhibit the responses in arterial ring preparations (Galle et al, 1991).
Similarly, several other in vitro studies have demonstrated the impairment of
endothelium-dependent vasodilatation using ring or strip preparations (Andrews et al,
1987; Tomita et al, 1990; Takahashi et al, 1990; Jacobs et al, 1990; Plane et al, 1993;
Lewis et al, 1997; Fontana et al, 1999). The immersion of ring or strip preparations in
the LDL solution allows the lipoprotein to act directly upon the smooth muscle layers,
allowing rapid infiltration into the vessel wall. Consequently, the impaired
vasodilatation may not be exclusively attributable to the action of LDL upon the
endothelium, but could result from an action of the LDL directly upon the VSMC.
Up to this point, the majority of in vitro vessel studies examining LDL have immersed
ring preparations mounted under isometric conditions (See above). Perfusion
myography is more technically demanding and time-consuming than wire myography,
but may provide the optimal technique for assessing the impact of LDL on endothelial
function. This technique allows the vessels to be exposed to LDL exclusively via the
endothelial surface under physiological pressures, thus removing any influence
produced by the direct interaction of LDL with VSMC. As a result, the inhibition of
endothelium-dependent vasodilatation observed in this study may be directly attributed
to an action upon the endothelium and mitigates any direct contractile effect of LDL on
VSMC. Furthermore, this technique also prevents any interaction or inactivation of the
vasoactive agents, such as PE or ACh, with the LDL solution. Therefore, the
conditions used in this study may better replicate the in vivo interaction between LDL,
EC and vascular function when compared to experimental models used by other
studies.
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5.4.5 The Oxidative Status of LDL
It is has previously been demonstrated that LDL does not require oxidative
modification to induce endothelial dysfunction (Chowienczyk et al, 1992; Drexler &
Zeiher, 1991; Zeiher et al, 1991). The current results appear to support this, but in
order to attribute the impairment of vascular function to the action of unoxidised LDL it
must be ensured that there was no oxidative modification of the LDL. Such a change
could alter the effect upon vascular function (Liao & Clark, 1995) and eNOS
expression (Liao et al, 1995; Hirata et al, 1995). The LDL used in these experiments
may have undergone minor degrees of oxidation in vitro or prior to the experiments
being performed, due to variations in the initial oxidative state, the antioxidant content
of the LDL samples, or spontaneous oxidation. This could explain any observed
variation in the responses to the vasoactive agents in the individual experiments.
However, throughout the experiments special care was taken to avoid any oxidative
modification. The lipoprotein should have been representative of unmodified LDL as it
was collected from fresh blood samples, and there is little direct evidence that ox-LDL
exists within circulation (Frei et al, 1988; Bowry et al, 1992; Bowry & Stocker 1993).
Furthermore, the LDL subfractions were immediately frozen at -80°C following
isolation and purification.
It is also unlikely that the oxidative modification of LDL would have occurred in vitro
during these experiments, as this requires prolonged exposure to transition metals or EC
within the vascular wall (Jacobs et al, 1990; Cox & Cohen, 1996). 0.3mM EDTA was
also added to the LDL to prevent any oxidation ex vivo and in vitro. This is an
established technique that prevents oxidative modification (Jacobs et al, 1990; Hayashi
et al, 1994), without altering vascular function to endothelium-dependent or
independent vasodilators (Green et al, 1999). Supplementation with EDTA is
extensively used in studies examining the effect of LDL in isolated vessels and has no
effect upon the vascular responses produced (Andrews et al, 1987; Jacobs et al, 1990;
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Galle et al, 1991; Plane et al, 1993; Hayashi et al, 1994; Lewis et al, 1997; Fontana et
al, 1999; Vergnani et al, 2000). The reversibility of the induced endothelial
dysfunction also suggests that the lipoprotein used was not oxidised, as ox-LDL
produces an inhibition that is partially or completely irreversible (Jacobs et al, 1990;
Simon et al, 1990; Plane et al, 1992). However, without adequate detection or analysis
of the oxidative state of the LDL, the observed effects cannot be attributed to LDL.
Therefore, MDA and 4-HNE concentrations were measured as indices of lipid
peroxidation (Esterbauer & Cheeseman, 1990). There was no significant alteration in
the concentration of these before and after the experiments were performed,
demonstrating that modification did not occur.
5.4.6 Study Limitations
As previously, the maximum constriction to KC1 was performed in the presence of the
various test solutions rather than Krebs-Ringer only. This could have masked any
effect the test solutions had on the maximal vasoconstriction to PE. Another limitation
of the current study is that only one endothelium-dependent vasodilator, ACh, was
used. The inhibitory effect of LDL may be concentration-dependent, as lower
concentrations selectively inhibit ACh-mediated dilatation but at higher concentrations
this selectivity is less apparent (Flavahan, 1992). For example, at concentrations of
200|ig/ml or greater, LDL may inhibit vasodilatation to several agonists (Lewis et al,
1997). Therefore, while it has been demonstrated that acute luminal perfusion with
LDL inhibits endothelial function in isolated mesenteric arteries, it cannot be
determined if the effects are selective for ACh or generalisable to other agonists.
Another limitation is the addition of human LDL to rodent tissue. Previous studies
have used a similar method to examine the effects of LDL, although the arteries used
were from a different species of rat (Sprague-Dawley) (Lewis et al, 1997). The
concentrations of LDL used to perfuse the isolated arteries in this study were relevant
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to the rodent model used, as the plasma LDL concentration in WKY rat is
approximately 240pg/ml (Kitts et al, 1998). Finally, this study can only speculate that
the action of LDL occurs via the intracellular inactivation ofNO by O2 " as exogenous
SOD, which exerts an extracellular action, failed to restore vasodilatation. The
experiments should be repeated using a SOD-mimetic, such as MnTMPyP, before a
definitive conclusion can be made regarding the role and site of action of O2 ~ in LDL
induced endothelial dysfunction.
5.4.7 Summary
The current study demonstrates that luminal exposure to various concentrations of LDL
in a perfusion myograph model induces endothelial dysfunction in a concentration-
dependent manner. This is caused by the inhibition of NO-mediated vascular function,
as demonstrated by the experiments using L-NAME. The restoration of vascular
function by 1-arginine supplementation implies that this inhibition is due to the
impairment of 1-arginine availability following acute endothelial exposure to LDL.
This is likely to result in an uncoupling in eNOS activity, which causes eNOS to
generate O2", and in turn, reduce NO availability and inhibit NO-mediated
vasodilatation. The inhibition of vasodilatation by LDL is reversible and demonstrates
that LDL is not cytotoxic or directly injurious to EC. These results suggest a causal
role for LDL in cardiovascular disease and demonstrate that it does not require
oxidative modification to induce endothelial dysfunction. This deleterious action of
LDL has been demonstrated using perfusion myography and intact arterial segments,
rather than immersed strips or ring preparations. Use of this technique removed any
direct influence that the addition of LDL may have had upon the VSMC, to better
replicate the in vivo interaction of LDL with endothelial and vascular function.
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CHAPTER 6
THE EFFECT OF URIC ACID ON VASCULAR
DYSFUNCTION INDUCED BY LDL
6.1 INTRODUCTION
Hypercholesterolaemia is strongly associated with vascular dysfunction (Zeiher et al,
1993; Anderson et al, 1995; Wilkinson & Cockroft, 1998). The mechanism that
produces this is attributed to lipoprotein-induced damage of the endothelial lining of the
blood vessels. The capacity of LDL to induce vascular dysfunction was established in
the previous chapter, using isolated rat mesenteric arteries mounted in a perfusion
myograph. The inhibition of vascular function was attributed to the onset of endothelial
dysfunction, mediated by the impairment of 1-arginine availability (Chapter 5). This
increases eNOS-generated free radical production and oxidative stress within the
vascular wall (Pritchard et al, 1995; Shinozaki et al, 1999), which reduces NO
availability and prevents NO-mediated vasodilatation (Huie & Padmaja, 1993). This
increased oxidative stress also potentiates the oxidative modification of LDL to further
enhance the development of endothelial dysfunction and cardiovascular disease
(Steinberg et al, 1989; Esterbauer et al, 1992).
The human body has an extensive antioxidant defence system to protect against this.
Several of these antioxidants may protect against the development of endothelial
dysfunction (Plane et al, 1993; Brown & Goodman, 1998; Fontana et al, 1999). UA is
an established hydrophilic antioxidant in human physiology (Ames et al, 1981; Cross et
al, 1992; Becker, 1993; Maxwell et al, 1997), and the potent radical scavenging ability
(Maxwell et al, 1997; Nyyssonen et al, 1997; Nieto et al, 2000) of this compound could
confer several advantages in conditions of increased oxidative stress, such as LDL-
induced endothelial dysfunction. UA could potentially prevent the deleterious actions
of LDL upon vascular function by scavenging the free radicals generated within the
vascular wall, to maintain NO-availability and protect endothelium-dependent
vasodilatation. In point of fact, elevated UA levels are frequently associated with
hypercholesterolaemia (Wannamethee et al, 1997).
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However, the potential role of increased serum UA concentrations in this
pathophysiological condition remains unclear. For example, under certain conditions
UA can prevent (Davies et al, 1986; Schlotte et al, 1998; Abuja, 1999; Bagnati et al,
1999), or promote (Schlotte et al, 1998; Abuja, 1999; Bagnati et al, 1999; Patterson et
al, 2003) the oxidative modification of LDL and enhance oxidative-damage (Vasquez-
Vivar et al, 1996; Santos et al, 1999). Several epidemiological studies have shown that
elevated UA, rather than conferring a physiological advantage, is associated with the
development of cardiovascular disease (Fessel, 1980; Brand et al, 1985; Bonora et al,
1996; Persky et al, 1997; Bengtsson et al, 1998; Ward, 1998; Liese et al 1999; Fang &
Alderman, 2000).
Nevertheless, it has been demonstrated in this thesis (Chapter 4) that physiological and
supraphysiological concentrations ofUA do not directly impair vascular function. This
suggests that UA does not directly contribute to the development of cardiovascular
disease, or pathophysiological conditions that predispose to this, by the induction of
endothelial dysfunction. Therefore, it is logical to investigate a potential protective role
for UA in cardiovascular disease, by examining the ability of UA to mitigate the
harmful effect of LDL upon vascular function.
The aim of this chapter is to examine the effect of UA supplementation upon LDL-
induced vascular dysfunction, following acute luminal exposure, in isolated rat
mesenteric arteries. The following hypotheses are examined in this chapter:
1). UA is a powerful chain-breaking antioxidant that protects against the inhibitory
effects of LDL on endothelial function by scavenging free radicals to reduce
oxidative stress and increase NO-availability within the vascular wall.
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2.) The ability of UA to prevent the inhibitory action of LDL is concentration-
dependent, as increasing concentrations of UA confer greater protection upon
vasodilatation.
3.) The effect of UA on LDL-induced endothelial dysfunction results from its ability to
increase the availability of endothelium-derived NO and will not be apparent in the




LDL was isolated, purified and the protein concentration determined using a
commercial kit based on the Lowry precipitation assay (Sigma Chemical Company,
Dorset, U.K.), as previously described (Chapter 2).
6.2.2 The effect of UA upon the action of LDL on vascular function
Adult male Wistar Kyoto rats (250-300g) were killed, the mesenteric beds removed, and
a segment of a 3rd order branch of the mesenteric arteries mounted in the perfusion
myograph chamber as described in Chapter 2. Concentration-response curves to PE,
ACh and SNP were performed when perfused with Krebs-Ringer buffer, 250pg/ml LDL
solution, UA-supplemented 250|ig/ml LDL solution (200pM, 400pM or 600pM UA), or
250jig/ml LDL solution supplemented with the vehicle Li2C03 solution.
6.2.3 The effect of L-NAME upon the reversal of LDL-induced
vascular dysfunction by UA
Arteries were mounted and perfused with 250pg/ml LDL solution, 250pg/ml LDL +
400pM UA, 250pg/ml LDL + lOOpM L-NAME, 250pg/ml LDL + 400pM UA +
lOOpM L-NAME, or Krebs-Ringer buffer. The concentration-response curves to PE,
ACh and SNP were then repeated.
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6.2.4 Intraluminal Solutions
LDL solutions were prepared daily from stock by dilution with supplemented Krebs-
Ringer solution to give an intraluminal concentration of 250pg/ml LDL. UA stock was
prepared as previously described. The stock solution was diluted with Krebs-Ringer
solution and used to supplement the LDL solutions to give a final intraluminal LDL
concentration of 250pg/ml and UA concentrations of 200pM, 400pM or 600pM. For
the purpose of the vehicle solution control, L^CCE stock was used to supplement the
250pg/ml LDL solutions to give final intraluminal concentration of 216pM. ImM L-
NAME stock solution was prepared as previously described in Chapter 3. L-NAME
supplemented solutions were prepared daily by diluting stock LDL solution with Krebs-
Ringer buffer, UA solution and stock L-NAME solution to give final intraluminal
concentrations of 250pg/ml LDL, 400pM UA and lOOpM L-NAME.
6.2.5 Lipid Peroxidation
Samples of the intraluminal LDL and UA-supplemented LDL solutions were collected
before and after the concentration-response curves to the vasoactive drugs were
performed to measure the extent of LDL lipid peroxidation and examine any changes in
oxidative status. The MDA and 4-HNE concentrations of the intraluminal solutions
were determined using a commercial colorimetric assay kit (CN Biosciences,
Nottingham, U.K.).
6.2.6 Statistical Analysis
The ability of UA to prevent the effect of LDL upon vascular function was determined
by comparing the results obtained for the various concentrations ofUA with each other,
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with LDL only, with the physiological control responses. The effect of the L^CC^
vehicle solution on LDL was analysed by comparing the vascular responses to those
obtained when the vessels were perfused with LDL only. The significance of L-NAME
upon the reversal of LDL induced vascular dysfunction by UA was analysed by
comparing the vascular responses when perfused with LDL + UA + L-NAME to the
responses when perfused with LDL + UA, LDL + L-NAME, LDL only or the
physiological control. Statistical analysis was also performed using paired Student's t-




6.3.1 The effect ofUA upon the action of LDL on vascular function
6.3.1.1 The effect of UA upon the action of LDL on vascular contractility to PE
PE produced concentration-dependent vasoconstriction in arteries perfused with
physiological Krebs-Ringer solution, giving a maximal response of 99.1 + 2.3% (Fig
6.1). 250pg/ml LDL enhanced vasoconstriction to PE at concentrations from lxl0"7 to
lxlO"6 (.PO.Ol). The concentration-dependent responses to PE were similar when
perfused with the physiological solution or the UA-supplemented LDL solutions.
However, supplementation of LDL with 200pM (Ixl0"7-lxl0"5, P<0.01), 400pM (1x10"
8-lxl0"5, P<0.03) and 600pM UA (Ixl0"8-lxl0"5, P<0.03) significantly reduced
vasoconstriction when compared to LDL alone. Supplementation with Li2C03 had no
effect upon vasoconstriction when compared to LDL, but significantly increased
vasoconstriction when compared to the physiological control (5xl0"8-lxl0"6, P<0.04).
6.3.1.2 The effect of UA upon LDL-induced endothelial dysfunction
ACh produced concentration-dependent vasodilatation with a maximal response of
101.5 + 2.3% in the physiological control. Perfusion with LDL markedly impaired this
(P<0.01; Fig 6.2) and produced a maximal dilatation of 41.1 + 4.3%. Supplementation
of the perfusing LDL solution with 200pM, 400pM or 600pM UA significantly
increased the concentration-dependent responses to ACh, when compared to LDL only
(1x10"7-5x10"4, PO.Ol), and produced maximal vasodilatations of 62.2 + 4.8%, 69.5 +
1.3% and 74.4 + 3.4%, respectively. However, the vasodilatation was still significantly
8 4lower than the physiological control (1x10" -5x10" , PO.Ol). Supplementation with
600pM UA produced greater restoration of vasodilatation than 400pM, which produced
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Figure 6.1. The effect of UA on vasoconstriction to PE in isolated rat mesenteric
arteries perfused with LDL: a.) 200pM UA, b.) 400pM UA, and c.) 600p,M UA or
LbCOa solution compared to Krebs-Ringer solution or 250pg/ml LDL. *p<0.03 vs.
250pg/ml LDL, **p<0.04 vs. Krebs-Ringer solution (2-factor ANOVA with replication
and Bonferroni correction, n=8). d.) compares the effect of each concentration of UA.
*p<0.01 vs. LDL + 400pM UA, **p<0.02 vs. LDL + 600pM UA (2-factor ANOVA
with replication and Bonferroni correction, n=8). All values are mean + SEM (n=8).
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Figure 6.2. The effect of UA on vasodilatation to ACh in isolated rat mesenteric
arteries perfused with LDL: a.) 200pM UA, b.) 400pM UA, and c.) 600pM UA or
LLCO3 solution compared to Krebs-Ringer solution or 250pg/ml LDL. *p<0.01 vs.
250pg/ml LDL, **p<0.01 vs. Krebs-Ringer solution (2-factor ANOVA with replication
and Bonferroni correction, n=8). d.) compares the effect of each concentration of UA.
*p<0.05 vs. LDL + 400pM UA, **p<0.02 vs. LDL + 600pM UA (2-factor ANOVA
with replication and Bonferroni correction, n=8). All values are mean + SEM (n=8).
153
greater vasodilatation than 200pM UA (5x10"6-lxl0"5, /><().05). Supplementation of
LDL with Li2C03 had no effect upon the inhibitory action of LDL, and vasodilatation
8 4
was significantly reduced when compared to the physiological control (1x10" -5x10" ,
P<0.01).
6.3.1.3 The effect of UA upon the action of LDL on endothelium-independent
vasodilatation to SNP
Concentration-dependent vasodilatation to SNP was similar when the arteries were
perfused with the physiological, LDL, or supplemented LDL solutions (Fig 6.3).
However, the supplementation of LDL with 200 and 400pM UA significantly enhanced
vasodilatation to lxlO"7 (P<0.03), and lxlO"7 and 5xl0"7 SNP (P<0.03) respectively,
when compared the LDL only,.
6.3.2 The effect of L-NAME upon the reversal of LDL-induced
endothelial dysfunction by UA
Arterial perfusion with LDL + 400pM UA + 100pM L-NAME significantly impaired
the concentration-dependent vasodilatation to ACh when compared to the physiological
control (lxlO^-SxlO"4, PO.01; Fig 6.4) or LDL + 400pM UA (5xl0"7-5xl0"4, P<0.01),
producing a maximal dilation of 39.7 + 5.5%. However, the vasodilatation produced
was similar to that obtained in the presence of LDL + 100pM L-NAME or LDL only. .
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Figure 6.3. The effect of UA on vasodilatation to SNP in isolated rat mesenteric
arteries perfused with LDL: a.) 200pM UA, b.) 400pM UA, and c.) 600pM UA or
Li2C03 solution compared to Krebs-Ringer solution or 250pg/ml LDL. *p<0.03 vs.
250pg/ml LDL, **p<0.03 vs. Krebs-Ringer solution (2-factor ANOVA with replication
and Bonferroni correction, n=8). d.) compares the effect of each concentration of UA.






Figure 6.4. The effect of L-NAME on vasodilatation to ACh in isolated rat mesenteric
arteries when perfused with LDL and UA: a.) The effect of LDL + 400pM UA +
lOOpM L-NAME is compared to LDL + 400pM UA, 250pg/ml LDL or Krebs-Ringer
solution. *p<0.01 vs. Krebs-Ringer solution, **p<0.01 vs. LDL + 400pM UA (2-
factor ANOVA with replication and Bonferroni correction, n=8). b.) The effect of LDL
+ 400pM UA + lOOpM L-NAME is compared to LDL + lOOpM L-NAME, All values
are the mean + SEM (n=8).
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6.3.3 Lipid peroxidation
There was no significant alteration in the MDA and 4-HNE concentrations of the LDL
and supplemented LDL solutions following luminal perfusion. This suggests that there
was no change in the oxidative status of the LDL during the experiments (Fig 6.5).
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Figure 6.5. Alterations in lipid peroxidation product levels: a.) Concentration ofMDA
and 4-HNE present in 250pg/ml LDL, LDL + 200pM UA, LDL + 400pM UA and LDL
+ 600pM UA solutions before and after luminal perfusion, b.) Mean percentage change
in the concentration of MDA and 4-HNE following luminal perfusion. All values are
mean + SEM (n=8).
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6.4 DISCUSSION
In the previous chapter it was demonstrated that ACh-mediated vasodilatation is
reduced in rat mesenteric arteries when they are exposed to 250pg/ml LDL. The results
produced in this series of experiments demonstrate that supplementation of the LDL
solution with increasing concentrations of UA restores endothelium-dependent
vasodilatation to ACh in a concentration-dependent manner and prevents the
potentiation and attenuation of the vasoactive responses to PE and SNP respectively.
Furthermore, the restoration of endothelial function by UA can be prevented by L-
NAME.
6.4.1 Mechanism of action of UA upon LDL-induced vascular
dysfunction
The previous chapter demonstrated that luminal perfusion with LDL impaired NO-
mediated vasodilatation to ACh in rat mesenteric arteries. This is thought to occur due
to the stimulation of O2" production in the vascular wall (Ohara et al, 1993; Vergnani et
al, 2000). This reacts rapidly to inactivate NO and can also directly impair eNOS
activity (Peterson et al, 1999), thus preventing the vasoactive actions of NO. Various
pathophysiological conditions associated with elevated lipoproteins levels are
accompanied by increased UA concentrations (Wannamethee et al, 1997).
In this study, UA improved the deleterious effects of LDL on endothelial function in a
concentration-dependent manner. This was NO-dependent and could be prevented by
the inhibition of eNOS by L-NAME. The significance of these results is that the
concentrations used are equivalent to those that LDL would be exposed to in plasma in
various in vivo conditions (200-600pM). This suggests that elevated UA in vivo could
provide greater protection against the inhibitory effects of LDL on vascular function and
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prevent the subsequent development of cardiovascular disease. This may be a potential
reason for the continual generation and release of this antioxidant from the vascular
endothelium, and the excessive concentrations found in pathophysiological conditions
such as hypercholesterolaemia (Wannamethee et al, 1997).
The oxidation of LDL is known to enhance its deleterious effects on endothelial NO
production (Vergnani et al, 2000), however, there was no evidence of any significant
oxidation of the luminal LDL during our control experiments. This does not rule out
mild degrees of oxidation, particularly in particles entering the vessel wall, but argues
against the effect of UA being due to an antioxidant action causing a significant
retardation of the oxidation of LDL. Instead, it may suggest that UA acts to attenuate
the direct action of LDL upon NO-mediated vascular function. There are four possible
sites of action were UA may impair the inhibitory action of LDL. UA could act
independent of its antioxidant ability to directly prevent the uptake of LDL into the EC.
Moreover, it could prevent the deleterious action of LDL upon 1-arginine uptake and
metabolism which causes the imbalance in NOS enzymatic activity and resultant
generation of excess CV. However, this seems highly unlikely, as there is no evidence
of an interaction between UA and LDL uptake or the impairment of 1-arginine
availability, in the literature. Therefore, it is more probable that the restoration is a
direct result of the antioxidant properties ofUA. The two most probable sites were UA
can prevent the LDL-induced inhibition of NO-mediated endothelial-dependent
vasodilatation are shown in Figure 6.6. UA could prevent LDL-induced endothelial
dysfunction by scavenging eNOS-generated O2" to impair the inactivation of NO, thus
restoring vascular function (Fig 6.6). Similarly, it is possible that UA could scavenge
ONOO", produced by the rapid reaction between NO and O2" within the EC (Fig 6.6).
However, while the latter would prevent further oxidative damage to the endothelium, it
may not necessarily restore NO-mediated vasodilatation.
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Figure 6.6. The proposed sites where UA may prevent LDL-induced inhibition of
NO-mediated endothelial-dependent vasodilatation. It is hypothesised that UA
scavenges either O2 ~ or ONOO" to restore endothelial NO-bioavailability.
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6.4.2 UA and 02
UA is a potent antioxidant and may be capable of reacting with and inactivating O2 ~
(Ames et al, 1981), although this has been disputed (Becker et al, 1989; Becker, 1993).
The lack of restoration of vasodilatation when L-NAME was added to the UA and LDL
solution demonstrates that the beneficial effects of UA are dependent upon eNOS
activity. It is tempting to speculate that the restoration of vascular function by UA
occurs via a simple antioxidant mechanism that removes O2 ~, generated by uncoupled
eNOS, and improves the availability of NO. In the previous chapter (Chapter 5), the
failure of SOD to prevent the deleterious action of LDL demonstrated that the
inactivation ofNO by O2 " was unlikely to occur in the extracellular space. NO is likely
to be inactivated within the EC in the current experimental model, as the simultaneous
generation of NO and O2 " within close proximity results in the rapid inactivation of NO
at the site of production (Radi, 1998).
The major site ofUA production in the cardiovascular system is the EC. The UA is then
released to plasma and extracellular fluid compartments, such as lymphatic, interstitial
and cerebrospinal (Becker, 1993). UA may readily permeate cellular membranes
(Becker et al, 1989), via ionic and non-ionic means (Lucas-Heron & Fontenaille, 1979),
and is not compartmentalised, as may occur with other radical scavengers. UA is able
to cross cellular membranes (Rroll et al, 1992) and has the potential to act as an
intracellular antioxidant in cells other than those where it is produced. Therefore,
exogenous UA may be able to enter EC and prevent the inactivation of NO by
scavenging O2", thus preventing the inhibition of endothelial NO-mediated
vasodilatation. However, this is unlikely as although it has been reported that UA may
react with O2" react at a rate constant of SxlC^MT's"1 (Santus et al, 2001), NO is a far
more likely reactant for O2 ~, in rapid diffusion-limited reaction with a rate of 6.9x109lVr
V1. Therefore, the ability ofUA to directly scavenge 02~is debatable. Previous studies
have demonstrated that UA does not attenuate the reduction of ferricytochrome C by
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O2 ", generated from allopurinol and XO (Becker et al, 1989), or the reduction of
nitrotetrazolium blue by O2" (Goshima et al, 1986). It has been demonstrated that the
decomposition of UA to allantoin, a product of UA oxidation, only occurs in the
presence of O2 ~ if the reaction conditions favour the secondary generation of OH' i.e. if
H2O2 is added to O2", or, allowed to form from O2" (Becker et al, 1989). As a result, it
has been suggested that UA does not react directly with O2" but rather with secondary
formed intermediates (Becker et al, 1989; Becker, 1993). Therefore, UA is unlikely to
be able to prevent the inactivation of NO by O2". This may suggest that the enhanced
NO-mediated vasodilatation that occurs in the current study is produced via a
restorative, rather than preventative, action ofUA upon NO availability.
6.4.3 UA and ONOO"
The rapid inactivation of NO by O2" leads to the formation of ONOO". This is a potent
oxidant that causes cytotoxicity and cellular damage. It reacts with a variety of
biomolecules such as lipids, proteins, and carbohydrates (Moreno & Pryor, 1992;
Rubbo et al, 1994; Pryor & Squadrito, 1995; Salgo et al, 1995; Evans et al, 1996) and is
implicated in the aetiology of numerous disease processes such as atherosclerosis (Radi,
1998). The half-life of this oxidant is estimated to be less than 100ms (Radi, 1998;
Romero et al, 1999), which allows it to potentially travel 5-20pm across extracellular
and/or intracellular compartments. It can freely permeate membranes (Finklestein &
Cass, 1967), via anion channels (ONOO") and passive diffusion (ONOOH) (Maria et al,
1997; Denicola et al, 1998), and readily accesses hydrophobic compartments within
cells and hydrophobic structures. ONOO" can accumulate in atherosclerotic plaques and
may play an important role in membrane and lipoprotein lipid oxidation reactions.
Furthermore, the life-span of ONOO" may be prolonged in hydrophobic environments,
such as atherosclerotic lesions, than in the aqueous media. This could imply that
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ONOO" undergoes a rapid degradation or inactivation in aqueous media which contains
hydrophilic antioxidants.
UA is a major hydrophilic antioxidant and an endogenous scavenger of ONOO" (Hooper
et al, 1997; Hooper et al, 1998). It is possible that the benefits ofUA on vasodilatation
relate to this well-recognised ability to scavenge ONOO" (Squadrito et al, 2000). This
could prevent potential damage to the endothelium and eNOS (Milstien & Katusic,
1999). The reaction between UA and ONOO" has only been partially characterised but
occurs at a rate of SxlC^M'V1 at pH 7.4 and 37°C (Santos et al, 1999). It has been
demonstrated that UA can be readily oxidised by ONOO" to form intermediates that
may be further oxidised, by ONOO", to metabolites such as allantoin, parabanic acid,
urazole and oxonic acid (Skinner et al, 1998; Santos et al, 1999). Excessive production
of ONOO" decreases UA levels in the environment of the site of ONOO" production and
results in a reduced antioxidant capacity. In the presence of high UA concentrations,
tyrosine nitration by ONOO" is largely inhibited (Sawa et al, 2000). Peroxidation of
plasma lipids (Wayner et al, 1985; Frei et al, 1988) and erythrocyte membrane fatty
acids (Ames et al, 1981; Smith & Lawing, 1983; Miki et al, 1989), and lipid
peroxidation in isolated rabbit kidneys (Green et al, 1986) can also be prevented or
inhibited by UA. However, as with the reaction between UA and O2", it has been
suggested that UA does not react rapidly or directly with ONOO". When present in
relatively high concentrations, as found in the hyperuricaemic conditions associated
with hypercholesterolaemia, UA reacts with secondary intermediates of ONOO"
reactions (Skinner et al, 1998). Furthermore, the scavenging of ONOO" by UA may
also form a UA-derived free radical that can propagate ONOO"-mediated damage
(Vasquez-Vivar et al, 1996) and enhance the oxidative modification of LDL (Santos et
al, 1999).
In relation to the current study, the simple scavenging of ONOO" and subsequent
oxidation ofUA would not restore NO-mediated vasodilatation. This would not prevent
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the inactivation ofNO or necessarily restore NO-availability, although it is biologically
plausible that this reaction could form a UA-based NO donor (Skinner et al, 1998). UA
could also restore endothelium-dependent vasodilatation in the current study by
preventing the inhibition of eNOS by ONOO" (Cosentino & Katusic, 1995; Pasquet et
al, 1996; Milstien & Katusic, 1999). L-NAME prevents the beneficial action ofUA and
demonstrates that the restoration of vasodilatation is mediated via an eNOS-dependent
process. The inhibition of eNOS by ONOO" is irreversible (Pasquet et al, 1996) and is
mediated by the oxidation of the haem thiolate bond in the catalytic site of the enzyme
(Pasquet et al, 1996), or via the oxidation of BH4 (Cosentino & Katusic, 1995; Milstien
& Katusic, 1999). However, the restorative action of UA demonstrates that eNOS
activity is not impaired following endothelial exposure to LDL and could suggest that
UA prevents the deleterious action of ONOO" on eNOS. Therefore, the ONOO"-
scavenging ability of UA has the potential to be involved in the restoration of vascular
function following luminal exposure to LDL. However, further assessment is required
as it remains to be determined if the restoration of vascular function is specific for UA
in this experimental model.
6.4.4 Study Limitations
A limitation of the present study is that the LDL solution is supplemented with
exogenous UA, and as such, the increase in UA concentration is not accompanied by the
radical production that occurs during enzymatic UA production in pathophysiological
conditions. Therefore, this study may not represent the entire in vivo conditions.
Similarly, the vessels did not undergo chronic exposure to UA so there was no
crystallisation or accumulation in the tissue, as occurs in vivo (Boogaerts et al, 1983).
Furthermore, the vessels were not perfused with red blood cells and as such the pro¬
inflammatory effects ofUA (Boogaerts et al, 1983; Duff et al, 1983; Hutton et al, 1985;
Leyva et al, 1998; Mazzali et al, 2001; Mazzali et al, 2002; Kanellis et al, 2003) were
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not demonstrated. These properties may damage the vascular wall and impair vascular
function, thus enhancing the development of endothelial dysfunction and vascular
disease. The results produced also only relate to vascular dysfunction produced using
unmodified LDL. UA may prevent the oxidation of LDL but may induce the further
oxidation of mildly oxidised LDL in vitro. Consequently, it may potentiate the
deleterious action of oxidised LDL on vascular function by enhancing the oxidative
modification of lipoproteins. Therefore, whilst the present study has demonstrated that
UA inhibits endothelial dysfunction to LDL, it could propagate the inhibitory action of
LDL via properties that were not examined in the present study. Another limitation
may be the presence of LiCCb in all the UA solutions. However, it has previously been
established that this vehicle solution does not directly alter vascular function (Chapter
4), and the current study demonstrated that supplementation LDL with L^CC^ did not
prevent the inhibitory action of LDL. This demonstrates that the restorative action of
UA is not influenced by the presence of Li2C03; and defends the use of this solution as a
vehicle for UA in the current study. Finally, the maximum constriction to KC1 was
performed in the presence of the various test solutions rather than Krebs-Ringer only.
Consequently, this could have masked the effect the test solutions had on the maximal
vasoconstriction to PE.
6.4.5 Summary
This study demonstrated that supplementation of LDL solution with UA significantly
restored NO-dependent vasodilatation to ACh in a concentration-dependent manner.
This suggests that elevated UA in plasma may provide greater protection against the
inhibitory effect of LDL upon endothelial function, a key-early event in the subsequent
development of cardiovascular disease. The results of this study may lend further
support to the hypothesis that an evolutionary loss of urate oxidase expression occurred
as increased UA confers a physiological advantage in humans and may be related to
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their prolonged life-span (Ames et al, 1981). UA could confer this physiological
advantage by protecting or restoring endothelium-dependent vasodilatation following
arterial exposure to LDL. However, additional research is required to clarify the
mechanism by which vascular function is restored. Further research should investigate
if the restoration is mediated via UA-specific means or via a generalised action that can
be replicated with other endogenous hydrophilic antioxidants.
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CHAPTER 7
THE EFFECT OF URIC ACID AND OTHER
ENDOGENOUS ANTIOXIDANTS ON LDL-INDUCED
VASCULAR DYSFUNCTION
7.1 INTRODUCTION
In the previous chapter (Chapter 6), it was demonstrated that UA can partially restore
NO-mediated vascular function, in a concentration-dependent manner, following
luminal perfusion with LDL. This is thought to occur due to the antioxidant properties
of UA increasing NO-availability. However, it remains to be determined if the
observed restoration is mediated via a UA-specific mechanism or if it can be achieved
with other endogenous hydrophilic antioxidants, such as ascorbic acid (AA) or
glutathione (GSH).
Several large epidemiological studies have suggested that dietary intake of AA and
plasma AA concentrations are inversely associated with oxidative stress and the
development of vascular disease (Gey et al, 1987; Riemersma et al, 1989; Singh et al,
1994; Singh et al, 1995; Khaw et al, 2001; Knekt et al, 2004). This may mediated by the
ability of AA to effectively scavenge O2" and other ROS (Som et al, 1983; Halliwell &
Gutteridge, 1988; Gotoh & Niki, 1992), as AA is a powerful antioxidant in vitro and in
vivo (Frei et al, 1988; Frei et al, 1989; Frei, 1994). It has previously been demonstrated
that AA can restore endothelium-dependent vasodilatation in endothelium-intact
isolated rabbit aortic rings exposed to LDL (Plane et al, 1993; Fontana et al, 1999).
This antioxidant can also increases the resistance of isolated LDL to oxidative
modification and decreases the rate of oxidation ex vivo, thus preventing any deleterious
effects that may caused by the conversion from LDL to ox-LDL (Esterbauer et al,
1991). Furthermore, AA can also spare other endogenous antioxidants from
consumption, thus providing further protection against the deleterious action of LDL
and increased oxidative stress (Frei et al, 1988; Frei et al, 1989; Retsky et al, 1993).
Therefore, the antioxidant ability ofAA could potentially prevent the deleterious action
of LDL upon NO availability in the isolated rat mesenteric arteries (Chapter 5).
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GSH is also a major endogenous antioxidant in human physiology (Fahey & Sundquist,
1991). It is found in varying concentrations in the body, with high concentrations in
VSMC, EC, platelets and red blood cells (0.5-5mM), but lower circulating levels in
human plasma (2-20pM) (Mills & Lang, 1996; Jones et al, 2000). Intracellular GSH
concentrations are important to maintain the intracellular redox balance and provide
protection against the physiological and pathophysiological formation of ROS (Meister,
1994; Griffith, 1999). Consequently, GSH may maintain NO availability by preventing
inactivation by ROS. It has previously been suggested that increased intracellular GSH
concentrations may be an adaptive mechanism to LDL-induced oxidative stress in EC
(Cho et al, 1999; Moellering et al, 2002; Bea et al, 2003). This implies that increased
GSH concentrations protect against the deleterious action of LDL, and may suggest that
GSH supplementation can prevent LDL-induced vascular dysfunction.
However, although AA and GSH are arguably two of the most recognisable
antioxidants in human physiology, UA is the strongest determinant of plasma
antioxidant capacity (Nyyssonen et al, 1997). The concentration of UA in human
plasma (200-500pM) is 5-10 times greater than the concentration ofAA (20-60pM) and
100 times greater than GSH (>2pM). The concentration of UA is also significantly
greater in humans than in other species (Becker, 1993). When taken in conjunction,
these may suggest that the elevated UA concentrations found in human plasma confer a
greater physiological advantage over the other endogenous antioxidants present (Ames
et al, 1981; Becker, 1993).
This chapter aims to examine and compare the effect of supplementation with
stoichiometric equivalent concentrations of UA, AA and GSH on the responses to
vasoactive drugs when isolated rat mesenteric arteries are perfused with 250pg/ml LDL
solution. This will investigate whether UA confers greater protection than the other
major hydrophilic antioxidants on vascular function in the presence of LDL. This
chapter also aims to determine if the restorative action demonstrated in Chapter 6 is
unique for UA. The hypotheses examined are:
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1.) The beneficial effect of UA on LDL-induced endothelial dysfunction is mediated by
antioxidant potential, and is replicated by elevated concentrations of other major
hydrophilic antioxidants.
2.) At stoichiometric equivalent concentrations UA exerts a greater inhibitory effect
than other endogenous antioxidants on LDL-induced endothelial dysfunction, and
physiological concentrations ofAA and GSH will provide little or no protection.
3.) At lower concentrations, similar to those found in animals that express urate





LDL was isolated, purified and the protein concentration determined using a
commercial kit based on the Lowry precipitation assay (Sigma Chemical Company,
Dorset, U.K.), as previously described (Chapter 2).
7.2.2 Comparison of the effect ofUA and AA
A segment of a third order branch of a mesenteric artery was mounted in the perfusion
myograph chamber. Concentration-response curves to PE, ACh and SNP were
performed when arteries were perfused with Krebs-Ringer buffer, 250pg/ml LDL
solution, UA-supplemented LDL solution (40pM or 400pM), or AA-supplemented LDL
solution (40pM or 400pM).
7.2.3 Comparison of the effect ofUA and GSH
The above experimental protocol was repeated for arteries perfused with 250pg/ml LDL
+ 40pM or 400pM GSH solution, and the results compared to those previously obtained




LDL solutions and UA stock were prepared as previous. The UA stock solution was
diluted with Krebs-Ringer buffer and used to supplement the 250pg/ml LDL solutions
daily, to give final intraluminal UA concentrations of 40pM and 400pM. AA stock
solution was made by dissolving 0.704mg/ml in distilled water to give a stock solution
of 4mM. The stock solution was diluted with Krebs-Ringer buffer and used to
supplement the 250jig/ml LDL solutions daily, to give final intraluminal AA
concentrations of 40pM and 400pM. GSH stock solution was made by dissolving
1.23mg/ml in distilled water to give a stock solution of 4mM. The stock solution was
diluted with Krebs-Ringer buffer and used to supplement the 250pg/ml LDL solutions
daily, to give final intraluminal GSH concentrations of40pM and 400pM.
7.2.5 Lipid Peroxidation
Samples of the intraluminal LDL and antioxidant-supplemented solutions were
collected before and after the concentration-response curves to the vasoactive drugs
were performed, and the MDA and 4-HNE concentrations determined using a
commercial colorimetric assay kit (CN Biosciences, Nottingham, U.K.).
7.2.6 Statistical Analysis
The results achieved when LDL was supplemented with UA were compared to the
results produced when LDL was supplemented with stoichiometric equivalent
concentrations of AA or GSH. These results were also compared to the physiological
control and the results for LDL solution only. Analysis was also performed to
determine if supplementation with 40pM or 400pM antioxidant had a significant
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concentration-dependent effect. Statistical analysis was performed using paired
Student's /-tests to compare the oxidative status of the intraluminal LDL solutions
before and after luminal perfusion.
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7.3 RESULTS
7.3.1 Comparison of the effect of UA and AA upon LDL-induced
vascular dysfunction
7.3.1.1 Comparison of the effect upon vasoconstriction to PE
Supplementation with UA or AA did not have a significant effect on the
vasoconstriction to PE when compared to LDL only (Fig 7.1), although the responses to
1x10" PE were reduced (PO.Ol). Supplementation of the LDL with the antioxidant
solutions produced largely similar results, however, vasoconstriction was reduced when
supplemented with 400pM UA compared to 400pM AA (5xlCT8 - lxlO"7, P<0.04).
There was no statistically significant difference in the calculated EC50 values, as shown
in Table 7.1.
7.3.1.2 Comparison of the effect upon LDL-induced endothelial dysfunction
Perfusion with LDL or LDL supplemented with 40pM UA, 40pM AA or 400pM AA
produced similar concentration-dependent vasodilatation to ACh (Fig 7.2). The
maximal dilatations produced were 44 + 2.8%, 45.6 + 4.2%, 44.7 + 8.3%, and 44.7 +
6.2%, respectively. The supplementation of LDL with 400pM UA produced a maximal
dilatation of 66.7 + 1.9% and significantly enhanced vasodilatation when compared to
LDL only (1x10"7-5x10^, PO.Ol), or LDL supplemented with 400pM AA (lxlO"6-
5x10~4, PO.Ol) or 40pM UA (5xl0"7-5xl0"4, .PO.Ol). However, this was still
significantly lower than the physiological control (1x10"7-5x10~4, PO.05).
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Figure 7.1. Comparison of the effect of UA and AA on vasoconstriction to PE in
isolated rat mesenteric arteries are perfused with LDL: a.) Comparison of LDL +
40pM UA with LDL + 40pM AA. *p<0.03 vs. Krebs-Ringer. **p<0.01 vs. 250pg/ml
LDL (2-factor ANOVA with replication and Bonferroni correction, n=8). b.)
Comparison of LDL + 400pM UA, LDL + 400pM AA. *p<0.01 vs. Krebs-Ringer,
**p<0.01 vs. 250pg/ml LDL, ***p<0.04 vs. LDL + 400pM UA (2-factor ANOVA with
replication and Bonferroni correction, n=8). c.) Comparison of LDL + 40pM or 400pM
UA. d.) Comparison of LDL + 40pM or 400pM AA. All values are the mean + SEM
(n=8).
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Intraluminal Solution ECso Maximal Response
(% of vasoconstriction to KCI)
Krebs-Ringer 240.4 ± 60.9nM 98.3 ±1.7%
250pg/ml LDL 95.4+ llnM 102.9 ±2.2%
250pg/ml LDL + 40pM UA 106.4 ± 27.1nM 99.5 ± 2.9%
250pg/ml LDL + 40pM AA 100.8 ±20.1nM 100.9 ± 1.2%
250pg/ml LDL + 400pM UA 230.1 ±61.7nM 99.7 ± 1.5%
250pg/ml LDL + 400pM AA 145.6 ±34.5nM 101.5 ±3.3%
Table 7.1. Comparison of the effect of UA and AA on vasoconstriction to PE when
isolated rat mesenteric arteries are perfused with LDL: Mean EC50 and maximal
response values, ± SEM, for concentration-dependent vasoconstriction to PE when
perfused with the above intraluminal solutions. There is no statistically significant
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Figure 7.2. Comparison of the effect of UA and AA on vasodilatation to ACh in
isolated rat mesenteric arteries perfused with LDL: a.) Comparison of LDL + 40pM
UA with LDL + 40pM AA. *p<0.01 vs. Krebs-Ringer (2-factor ANOVA with
replication and Bonferroni correction, n=8). b.) Comparison of LDL + 400pM UA
with LDL + 400pM AA. *p<0.01 vs. Krebs-Ringer, **p<0.01 vs. 250pg/ml LDL,
***p<0.01 vs. LDL + 400pM UA (2-factor ANOVA with replication and Bonferroni
correction, n=8). c.) Comparison of LDL + 40pM or 400pM UA. *p<0.01 vs. LDL +
40pM UA (2-factor ANOVA with replication and Bonferroni correction, n=8). d.)
Comparison of LDL + 40pM or 400pM AA. All values are the mean + SEM (n=8).
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7.3.1.3 Comparison of the effect upon the action of LDL on endothelium-
independent vasodilatation to SNP
Perfusion with Krebs-Ringer solution or LDL supplemented with 40pM UA or AA, or
400pM UA or AA produced comparable concentration-dependent vasodilatation to SNP
(Fig 7.3). Supplementation with 400pM UA or AA significantly enhanced
vasodilatation when compared to LDL only (400pM UA: 1x10"8-1x1CT6, P<0.02;
400pMAA: Ixl0"7-lxl0"6, PO.Ol).
7.3.2 Comparison of the effect of UA and GSH upon LDL-induced
vascular dysfunction
7.3.2.1 Comparison of the effect upon vasoconstriction to PE
Vasoconstriction was similar when the arteries were perfused with LDL solution
supplemented with 40pM or 400pM GSH (Fig 7.4). This vasoconstriction was similar
to the responses produced when perfused with LDL and LDL supplemented with UA,
but greater than the physiological control (5xlO"8-lxlCT7; 40pM GSH: P<0.02, 400pM
GSH: /><0.04).
7.3.2.2 Comparison of the effect upon LDL-induced endothelial dysfunction
The concentration-dependent vasodilatation to ACh was comparable when the arteries
were perfused with LDL and LDL supplemented with 40pM or 400pM GSH (Fig 7.5).
Vasodilatation was similar when perfused with 40pM GSH- or UA-supplemented LDL
solution. Supplementation with 400pM GSH markedly reduced vasodilatation when
compared to 400pM UA (1x10"7-5x10 4, P<0.01).
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Figure 7.3. Comparison of the effect of UA and AA on vasodilatation to SNP in
isolated rat mesenteric arteries perfused with LDL: a.) Comparison of LDL + 40pM
UA with LDL + 40pM AA. b.) Comparison of LDL + 400pM UA, LDL + 400pM AA.
*p<0.02 vs. 250pg/ml LDL (2-factor ANOVA with replication and Bonferroni
correction, n=8). c.) Comparison of LDL + 40pM or 400pM UA. d.) Comparison of
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Figure 7.4. Comparison of the effect of UA and GSH on vasoconstriction to PE in
isolated rat mesenteric arteries are perfused with LDL: a.) Comparison of LDL +
40pM UA with LDL + 40pM GSH. *p<0.02 vs. Krebs-Ringer (2-factor ANOVA with
replication and Bonferroni correction, n=8). b.) Comparison of LDL + 400pM UA
with LDL + 400pM GSH. *p<0.04 vs. Krebs-Ringer (2-factor ANOVA with
replication and Bonferroni correction, n=8). c.) Comparison of LDL + 40pM or
400pM GSH. All values are the mean + SEM (n=8).
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Figure 7.5. Comparison of the effect of UA and GSH on vasodilatation to ACh in
isolated rat mesenteric arteries are perfused with LDL: a.) Comparison of LDL +
40pM UA with LDL + 40pM GSH. *p<0.01 vs. Krebs-Ringer (2-factor ANOVA with
replication and Bonferroni correction, n=8). b.) Comparison of LDL + 400pM UA
with LDL + 400pM GSH. *p<0.01 vs. Krebs-Ringer, **p<0.01 vs. LDL + 400pM UA
(2-factor ANOVA with replication and Bonferroni correction, n=8). c.) Comparison of
LDL + 40pM or 400pM GSH. All values are the mean + SEM (n=8).
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7.3.2.3 Comparison of the effect upon the action of LDL on endothelium-
independent vasodilatation to SNP
Perfusion with 40pM or 400pM GSH-supplemented LDL solution produced similar
vasodilatation to SNP. This vasodilatation was comparable to the results produced when
perfused with Krebs-Ringer solution, LDL only, or UA-supplemented LDL solutions
(Fig 7.6).
7.3.3 Lipid Peroxidation
No significant alteration in MDA and 4-HNE concentrations occurred in the LDL and
supplemented LDL solutions following luminal perfusion (Fig 7.7 and 7.8). This
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Figure 7.6. Comparison of the effect of UA and GSH on vasodilatation to SNP in
isolated rat mesenteric arteries are perfused with LDL: a.) Comparison of LDL +
40p,M UA with LDL + 40pM GSH. b.) Comparison of LDL + 400pM UA with LDL +
400pM GSH. c.) Comparison of LDL + 40pM or 400pM GSH. All values are the
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Figure 7.7. Alterations in lipid peroxidation product levels: a.) Concentration ofMDA
present in 250pg/ml LDL and LDL solution supplemented with 40pM UA, 40pM AA,
400pM UA and 400pM AA, before and after luminal perfusion, b.) Concentration of
4-HNE present in 250pg/ml LDL and LDL solution supplemented with 40pM UA,
40pM AA, 400pM UA and 400pM AA, before and after luminal perfusion, c.) Mean
percentage change in the concentration of MDA and 4-HNE following luminal
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Figure 7.8. Alterations in lipid peroxidation product levels: a.) Concentration ofMDA
present in 250pg/ml LDL and LDL solution supplemented with 40pM UA, 40pM GSH,
400pM UA and 400pM GSH, before and after luminal perfusion, b.) Concentration of
4-HNE present in 250pg/ml LDL and LDL solution supplemented with 40pM UA,
40pM GSH, 400pM UA and 400pM GSH, before and after luminal perfusion, c.)
Mean percentage change in the concentration of MDA and 4-HNE following luminal
perfusion. All values are mean + SEM (n=8).
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7.4 DISCUSSION
400pM UA prevented the slight enhancement of vasoconstriction to PE by LDL, but
AA and GSH had no effect. 400pM UA was also the only antioxidant solution to
significantly improve LDL-induced endothelial dysfunction in this model.
Supplementation of LDL with 400pM UA or AA also enhanced vasodilatation to SNP.
7.4.1 The effect of AA upon LDL-induced vascular dysfunction
7.4.1.1 AA and 02 "
The deleterious effect of LDL upon endothelium-dependent vasodilatation has been
widely attributed to the inactivation of NO by O2 " within the EC (Galle et al, 1991;
Pritchard et al, 1995; Dart & Chin-Dusting, 1999; Vergnani et al, 2000). AA is a major
water-soluble antioxidant found in plasma (Frei et al, 1988; Frei et al, 1989; Retsky et
al, 1998) and effectively scavenges O2 ~ (Som et al, 1983; Bendich et al, 1986; Halliwell
& Gutteridge, 1988). The molecular structure of this antioxidant is shown in Figure 7.9.
However, the luminal perfusion with AA at physiological and elevated plasma
concentrations (40 and 400pM, respectively) had no significant effect upon the
deleterious action of LDL on vascular function. This is surprising as it has previously
been demonstrated that intra-arterial infusion of AA in hypercholesterolaemic patients
improves NO-mediated vasodilatation (Ting et al, 1997), although negative results have
also been reported (Gilligan et al, 1994). Similarly, dietary supplementation with AA
improves endothelial function in hyperlipidaemic children (Engler et al, 2003) and
patients with coronary artery disease (Gokce et al, 1999; Tousoulis et al, 2005). It has
also been demonstrated in vitro that high dose AA (ImM) can partially restore acute
lipoprotein induced endothelial dysfunction in rabbit aortic rings immersed in 150pg/ml
LDL (Fontana et al, 1999). Antioxidant therapy with AA may also improve
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oxidative stress, such as hypertension, type II diabetes and smoking (Heitzer et al, 1996;
Levine et al, 1996; Solzbach et al, 1997; Hornig et al, 1998; Raitakari et al, 2000),
although contradictory results have also been reported (Duffy et al, 2001; Darko et al,
2002; Pellegrini et al, 2004; Kinlay et al, 2004; Widlansky et al, 2004; Chen et al,
2006).
The beneficial effects of AA have been attributed to its ability to scavenge O2", as
demonstrated by the ability of AA to restore NO-mediated vasodilatation following the
extracellular generation of O2" by HX/XO or pyrogallol (Dudgeon et al, 1998; Jackson
et al, 1998). However, the ability of exogenous AA to restore NO-dependent
vasodilatation under conditions of intracellular oxidant stress is less certain. Exogenous
AA, at concentrations exceeding the physiological range, was ineffective at protecting
NO-dependent vasodilatation following the inhibition of Cu-Zn SOD by DECTA
(Jackson et al, 1998). This implies that exogenous AA does not exert an intracellular
action. This could explain the ineffective nature of AA supplementation in the current
study. The cellular uptake of exogenous AA across membranes occurs at a slow rate
(Winkler et al, 1994). The intracellular penetration of exogenous AA is limited as it
must undergo extracellular oxidation to DHA, the major transport form of AA, before
intracellular accumulation can occur (Mann & Newton, 1975; Washko et al, 1993).
Once transported into cells, DHA will undergo intracellular reduction to regenerate AA
(Washko et al, 1993). Therefore, the failure of exogenous AA to restore vasodilatation
could result from the inability ofAA to access the EC.
Nevertheless, the ability of exogenous AA to scavenge intracellular endothelial O2" in
the current study should not be discounted. However, the rate of this reaction is 3xl05
M"V (Nishikimi, 1975; Gotoh & Niki, 1992; Tsujimoto et al, 1993), which is 104 times
slower than the reaction rate of ONOO" formation. As a result, the kinetics and reaction
rates favour the reaction between O2'" and NO and it is highly unlikely that AA could
scavenge O2 " within the stimulated EC. Therefore, while the failure of AA to restore
NO-mediated vascular function is initially surprising, the negative results could arise
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from the inability of AA to access the intracellular compartment in sufficient
concentrations to compete with the inactivation of NO by O2". The failure of AA to
prevent LDL-induced vascular dysfunction does not discount the role of O2", but may
further support the hypothesis that the inactivation of NO in this experimental model is
intracellular. This is in agreement with a previous study that examined the effects of
LDL upon vascular function (Fontana et al, 1999)
7.4.1.2 AA and ONOO
It is unlikely that supplementation with exogenous AA would be able to scavenge any
ONOO" formed in this experimental model. Physiological concentrations of AA are
insufficient to scavenge ONOO" in vivo due to the small rate constant for the reaction.
(lxK^M'V1) (Bartlett et al, 1995). The estimated concentrations of AA in human
tissue (90pM in heart) are typically higher than those in plasma (Bergsten et al, 1990),
but are still unlikely to be sufficient to effectively scavenge ONOO" (Bartlett et al,
1995). However, Squadrito et al suggested that supraphysiological concentrations of
AA (5.5mM) could effectively scavenge ONOO" (Squadrito et al, 1995). This
concentration of AA is still significantly greater than the highest concentration used in
the current study. Therefore, it is unlikely that the levels of exogenous AA present in
the arterial lumen would be sufficient to scavenge and protect against ONOO".
7.4.1.3 AA and endothelium-independent vasodilatation
Supplementation of the LDL solutions with 400pM AA produced enhanced
endothelium-independent vasodilatation to SNP when compared to UA, despite the
inability of AA to restore ACh-mediated vasodilatation. This may be related to ability
of AA to potentiate the release of NO from NO-donors such as SNP or S-nitroso-N-
acetylpenicillamine (SNAP), which act through S-nitrosothiols (RSNO) within the
VSMC (Singh et al, 1996). The ability of AA to stimulate the release of NO from
RSNO may account for the direct vasodilator action of this antioxidant in some isolated
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preparations (Dudgeon et al, 1998) and could explain the disagreement between studies
that have demonstrated the restoration of endothelium-dependent vasodilatation by AA
(Ting et al, 1997; Levine et al, 1995; Heitzer et al, 1996; Solzbach et al, 1997; Hornig
et al, 1998; Fontana et al, 1999) and the negative results produced in the current study.
7.4.2 The effect of GSH on LDL-induced vascular dysfunction
Thiols are critical endogenous intracellular antioxidants against ROS and ONOO", and
GSH is the main intracellular thiol (Fahey & Sundquist, 1991; Boesgaard et al, 1993).
The molecular structure of this established antioxidant is shown in Figure 7.9.
Increased intracellular concentrations are a common response to oxidant stress and
prevent oxidative damage by enhancing the capacity to scavenge radical species and
repair oxidised protein thiols and lipid peroxides (Padgett & Whorton, 1997; Griffith,
1999; Lu, 1999; Rahman & MacNee, 2000). GSH is also a reducing cofactor in the
production of NO and is required for full NOS enzymatic activity (Stuehr et al, 1990;
Hofmann & Schmidt, 1995; Harbrecht et al, 1997). Therefore, altering GSH levels
could potentially protect against the deleterious action of LDL on vascular function by
preventing the ROS-mediated inactivation of NO or increasing NO synthesis. The
depletion of intracellular GSH may be related to the oxidative injury that occurs in
hypercholesterolaemia (Ma et al, 1997), and increased intracellular GSH may prevent
LDL-induced endothelial ROS generation (Kuzuya et al, 1989). This close interaction
between GSH and NO availability in the vascular wall made this an interesting
antioxidant to examine and compare with UA. However, unlike UA, the current did
study did not report any reversal of LDL-induced endothelial dysfunction when the
LDL solution was supplemented with exogenous GSH.
The inhibitory action of LDL on vascular function is attributed increased oxidative
stress and the inactivation ofNO by O2" (Chapter 5). The negative results of the current
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study suggest that supplementation of the LDL solution with GSH could not prevent
this inactivation. It is highly unlikely that GSH could directly protect against NO
inactivation due to the rapid rate of the reaction between O2 ~ and NO. However, a
recent study demonstrated that GSH can protect NO from inactivation by ROS (Ford et
al, 2006). It has also been widely demonstrated that GSH can reverse endothelial
dysfunction and improve NO-availability under other conditions of increased oxidative
stress (Cheung & Schultz, 1997; Kevelatis et al, 1997; Kugiyama et al, 1998; Vita et al,
1998; Prasad et al, 1999; Cheung et al, 2000; Nascimento et al, 2003; Schauer et al,
2004). This has been attributed to the antioxidant ability of GSH preventing the
inactivation of NO by ROS. This is supported by the induction of acute oxidative
stress, reduced NO-availability and alterations in vascular function in experimental
models following intracellular GSH depletion (Ghigo et al, 1993; Laursen et al, 2001;
Ganafa et al, 2002; Ford et al, 2006).
Therefore, the failure of GSH supplementation to restore endothelium-dependent
vasodilatation in the current study is initially surprising. However, the beneficial effects
of GSH in the previous studies have been attributed to the intracellular action of the
antioxidant. In the current study, this may have been impeded by the tendency for
exogenous GSH to undergo extracellular breakdown by y-glutamyl transpeptidase
(Chang et al, 1992; Ghigo et al, 1993). As a result, exogenous GSH is unlikely to
penetrate the EC and exert a direct intracellular action in the current experimental model
(Ghigo et al, 1993). Consequently, GSH supplementation in the current study may
only provide an alternative approach to enhancing the extracellular antioxidant status.
It has previously been demonstrated that increasing the extracellular GSH
concentrations protects against the extracellular generation of ROS (Boesgaard et al,
1993; Bilzer et al, 1999). However, in the current experimental model the generation of
O2 ~ and the subsequent inactivation of NO are likely to occur within the EC, as both are
generated in the same cell. The failure of exogenous GSH to restore vascular function
supports the hypothesis.
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The extracellular breakdown of GSH does provide a source of substrate for intracellular
GSH synthesis (Tsan et al, 1989; Hiraishi et al, 1994; Griffith, 1999; Sies, 1999), which
could potentially protect EC against intracellular oxidative injury (Chang et al, 1992).
However, this reconstitution is time-dependent and the failure of GSH to restore
vasodilatation may be due to the relatively short time-scale of the current experiment
when compared to the previous studies. The disparity in the results could also be due to
concentrations of GSH used as it has been demonstrated that supplementation of rat
cells with less than ImM GSH is insufficient to produce a sustained increase in
intracellular concentrations (Visarius et al, 1996). Several of the in vitro studies to
demonstrate a beneficial action of GSH in oxidative stress used greater concentrations
than the current study (>lmM) (Ghigo et al, 1993; Visarius et al, 1996; Cheung &
Schultz, 1997; Kevelatis et al, 1997; Bilzer et al, 1999).
The beneficial effects ofGSH demonstrated in these studies may arise from its ability to
scavenge ONOO" (Wu et al, 1994; Balazy et al, 1998; Radi, 1998; Radi et al, 2001),
9 1 1
rather than O2 ". This reaction occurs with a second-order rate constant of 2-5x10 M" s"
(Quijano et al, 1997; Arteel et al, 1999). Increased GSH concentration may be an
adaptive response to ONOO" (Buckley & Whorton, 2000) and cellular GSH depletion
increases the detection and biological effects of ONOO" (Ma et al, 1997; Radi, 1998;
Radi et al, 2001). GSH can convert this potent free radical into potential NO donors
such as S-nitrosoglutathione (GSNO) and S-nitroglutathione (Wu et al, 1994; Mayer et
al, 1995; Mayer et al, 1998; White et al, 1997). These exhibit physiological effects
similar to those of NO and can induce vasodilatation (Nossuli et al, 1998), which may
account for the restorative action of GSH demonstrated in several studies (Cheung &
Schulz, 1997; Cheung et al, 2000). However, this reaction is inefficient and yields
maximally 1% GSNO (Moro et al, 1994; Mayer et al, 1995). There was no evidence of
such an effect in the current study.
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7.4.3. Comparison of supplementation with UA, AA and GSH
The previous chapter demonstrated that UA improved LDL-induced endothelial
dysfunction at physiological concentrations. To determine if this ability was unique for
UA or could be replicated by other major hydrophilic antioxidants, the beneficial effects
were compared with AA and GSH at equivalent molar concentrations (40 and 400 pM
each). These concentrations were chosen as they approximate the concentrations ofAA
and UA in human plasma. GSH is found in lower concentrations in plasma (2-20pM),
although greater concentrations are present within tissue. The results produced imply
that the restorative action of UA supplementation on LDL-induced endothelial
dysfunction is distinct from its antioxidant ability, as both AA and GSH are potent
antioxidants but have no effect. However, it must be noted that whilst antioxidants have
similar antioxidant potential, the primary mechanisms of action are distinct to each
compound and cannot be extrapolated to other antioxidants. The results support the
hypothesis that UA confers greater protection against the deleterious action of LDL-
induced endothelial dysfunction at stoichiometric equivalent concentrations when
compared to AA and GSH. The failure of UA to prevent LDL-induced endothelial
dysfunction when present in concentrations similar to those of other endogenous plasma
antioxidants (40pM), and those found in animals that express urate oxidase, could have
further implications regarding the increased concentrations of UA in human physiology
and may indirectly imply that elevated UA confers a physiological advantage.
The current study was also performed to help elucidate the mechanism of action by
which UA restores vascular function following acute luminal exposure to LDL.
However, it should also be acknowledged that this study may only have examined the
extracellular action of the exogenous antioxidants, given the question marks over their
ability to readily permeate the cell membrane and access the intracellular compartments.
The proposed sites at which the exogenous antioxidants could prevent LDL-induced
endothelial dysfunction are demonstrated in Figure 7.10. The superiority of 400pM UA
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Figure 7.10. The proposed sites where the exogenous antioxidants may prevent LDL-
endothelial dysfunction. AA and GSH are potent O2" and ONOO" scavengers,
respectively, but may be impeded extracellular breakdown. The superiority ofUA over
the other antioxidants could occur as only UA is able to gain access to the intracellular
environment in sufficient concentrations to restore NO-mediated vasodilatation, or
because UA has a unique biochemical action that is not shared by the other
antioxidants.
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over the other antioxidants suggests a unique ability for UA in the current experimental
model. This could occur as only UA is able to gain access to the intracellular
environment in sufficient concentrations to restore NO-mediated vasodilatation, or
because UA has a unique biochemical action that is not shared by the other antioxidants.
Unlike GSH and AA which undergo extracellular breakdown (Mann & Newton, 1975;
Chang et al, 1992; Ghigo et al, 1993; Washko et al, 1993), UA may readily permeate
cellular membranes (Becker, 1989) and exert an intracellular action (Becker, 1993).
The rapid reaction between O2" and NO within the EC all but negates the ability ofUA
to restore NO-mediated vasodilatation by preventing the intracellular inactivation of
NO. Consequently, supplementation with UA would not prevent the intracellular
formation of ONOO". However, UA is able to scavenge ONOO" (Kooy et al, 1994;
Whiteman & Halliwell, 1996; Kuzkaya et al, 2005). This could mediate the restoration
of vascular function in the current experiments by preventing ONOO" from eNOS
(Pasquet et al, 1996) or by forming a nitrated UA derivative with the potential to induce
vasodilatation (Skinner et al, 1998). The formation of such a vasoactive species may be
the unique biochemical ability demonstrated by UA. However, further investigation is
required before the restorative action of UA can be attributed to the formation of a UA-
derived vasodilator species.
7.4.4 Study Limitations
The current study has several limitations. The major limitation of the current study is
that the acute endothelial exposure to LDL supplemented with exogenous GSH or AA
may only allow the extracellular action of these antioxidants to be examined, as
mentioned above. To demonstrate the intracellular action of AA upon O2" and the
formation of ONOO", this series of experiments could have been repeated using DHA
instead of AA. AA is taken up at a slow rate by EC. However, these cells may rapidly
take up DHA under similar conditions and readily converted to AA, which may
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scavenge intracellular O2" to restore vascular function. Furthermore, it is worth noting
that in the present study the action of AA and GSH may have been impaired by the
presence of substances in the physiological buffer. Bicarbonate may partially inhibit
ONOO'-dependent oxidation of GSH and is present in the Krebs-Ringer solution, thus,
in the current study it may have prevented GSH from scavenging ONOCT to form
GSNO. Similarly, during the current experiments EDTA was added to the intraluminal
LDL solution to prevent the oxidative modification by transition metals. EDTA may be
used as a transition metal ion chelator to chelate Cu2+. It is possible that this may mask
2_|_
the formation of an NO-donor by GSH in the present study, by preventing the Cu -
catalysed release of NO from GSNO. It should also be noted that, as previous, the
maximum constriction to KC1 was performed in the presence of the various test
solutions rather than Krebs-Ringer only, which may have hidden any effect the test
solutions had on the maximal vasoconstriction to PE.
7.4.5 Summary
This study demonstrates the ability of UA, but not the other water-soluble antioxidants,
AA or GSH, to ameliorate endothelial dysfunction induced by luminal perfusion with
LDL. The concentrations of antioxidant used to supplement the LDL solutions in the
current study are typical of those found in plasma for AA (40pM) and UA (400pM).
The superiority of UA over the other major aqueous antioxidants in restoring vascular
function implies that the action of UA may be distinct from its antioxidant ability, as
both AA and GSH are potent free radical scavengers. It is hypothesised that the ability
of UA to restore vascular is not due to the direct inhibition of O2'"- mediated NO
inactivation but rather to alternative mechanisms. One possibility is that UA mediates
the formation of a vasoactive NO-donor species, via the scavenging ONOO" (Skinner et
al, 1998). However, further investigation is required before the demonstrated
restorative action ofUA can be attributed to this.
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CHAPTER 8
INVESTIGATION OF THE POTENTIAL FORMATION OF
A URIC ACID-DERIVED VASODILATOR
8.1 INTRODUCTION
The mechanism by which supplementation of LDL solution with UA partially restores
vascular function (Chapter 6) has still to be determined. However, the apparent
superiority of UA over the other major aqueous antioxidants in restoring vascular
function (Chapter 7) suggests that the action ofUA may be distinct from its antioxidant
ability.
The inhibitory action of LDL is thought to occur due to an imbalance in NOS activity,
resulting in enhanced O2" generation. This inactivates NO in a rapid diffusion-
controlled reaction to yield ONOO" (Pryor & Squadrito, 1995; Beckman & Koppenol,
1996; Kissner et al, 1997). This reduces NO availability and, consequently, inhibits
NO-mediated vasodilatation. There are several potential sites where UA may act to
prevent this inhibition (Chapter 6), but the restoration of vascular function is most likely
to occur via the free radical scavenging ability ofUA. UA could prevent the deleterious
effect of LDL by scavenging O2" to directly reduce oxidative stress and prevent the
inactivation of NO. However, the ability ofUA to directly react with O2" is debatable,
as positive (Santus et al, 2001) and negative results (Becker et al, 1989; Becker et al,
1993) have been reported. It is unlikely that UA could prevent the inactivation of NO
by O2", due to the rapid rate of this reaction.
For that reason, it is suggested that the restorative action ofUA does not occur prior to
the inactivation ofNO but after the formation of ONOO". UA is an efficient scavenger
of ONOO" (Kooy et al, 1994; Whiteman & Halliwell, 1996; Kuzkaya et al, 2005), but
the reaction has only been partially characterised (Uppu et al, 1996; Vasquez-Vivar et
al, 1996; Skinner et al, 1998; Tretyakova et al, 1999). The oxidation ofUA by ONOO"
can produce two partially characterised products, an aminocarbonyl free radical
(Vasquez-Vivar et al, 1996; Santos et al, 1999; Kuzkaya et al, 2005) and a nitrate
derivative that is able to release NO (Skinner et al, 1998). These products have been
detected in human plasma treated with ONOO" (Skinner et al, 1998; Vasquez-Vivar et
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al, 1996), suggesting that they can be produced in vivo and may be involved in the
physiological role of UA. However, the formation of a UA-derived vasoactive species
has yet to be demonstrated in vivo or in intact biological systems in vitro, such as
isolated tissue preparations.
The aim of this study is to demonstrate the formation of a potential UA-derived
vasodilator in the presence of LDL in an intact biological system. This is investigated
by examining the restoration of endothelium-dependent vasodilatation to ACh,
following the addition of UA to rat endothelium-intact aortic ring segments exposed to
LDL in a wire myograph model. The solution from these organ baths will then be
transferred to chambers containing endothelium-denuded ring segments, and the
potential to induce vasodilatation examined. Furthermore, the ability of ox-Hb, an
exogenous NO-scavenger, to reverse any vasodilatation produced in the denuded aortic
rings will also be examined.
To this point, perfusion myography has been used as an experimental model for
assessing vascular function in isolated tissue preparations. However, while this
technique offers several advantages for the in vitro study of vascular function, it does
have disadvantages. For example, the size of the vessels and the manner in which they
are perfused make the collection and transfer of the intraluminal solution difficult. This
is due to dilution of the intraluminal solution upon collection and complications upon
retransfer into the lumen of other arteries. Therefore, wire myography and aortic ring
segments will be used in this study to facilitate the ease of transfer of solutions from the
organ baths containing endothelium-intact to endothelium-denuded vessels. This will
also allow the generation of greater volumes of any UA-derived product that may be
formed under the experimental conditions used.
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The hypotheses tested in this study are:
1). UA restores LDL-induced endothelial dysfunction because of its potential to form
an aqueous endothelium-independent vasodilator following stimulation of healthy
endothelium by ACh in the presence of LDL.
2). This UA-derived vasodilator is an NO donor compound, formed following a reaction
with ONOO", and will be inactivated by the presence of ox-Hb.





LDL was isolated, purified and the protein concentration determined using a
commercial kit based on the Lowry precipitation assay (Sigma Chemical Company,
Dorset, U.K.), as previously described (Chapter 2).
8.2.2 Examination of vasodilator formation
The aorta was removed from adult male WKY rats, prepared as ring segments and
mounted in a wire myograph, as described in Chapter 2 (Section 2.3). Endothelium-
intact and -denuded aortic ring segments were bathed in Krebs-Ringer solution and
concentration-response curves to PE performed. Concentration-response curves to ACh
were then performed to ensure all denuded vessels were unresponsive and all
endothelium-intact rings produced similar responses. After washout, the ring segments
were bathed in 250pg/ml LDL + 200, 400 or 600pM UA. The vessels were
preconstricted with ECgo PE, and ACh (10pM) added to the ring segments to examine
endothelium-dependent vasodilatation.
5 minutes after the addition ofACh, the organ bath containing the endothelium-denuded
ring was drained, the solution present in the endothelium-intact vessel chamber
immediately transferred to the denuded chamber, and any vasodilatation recorded.
Following 5 minutes exposure to the transferred solution, 10pM ox-Hb was added to the
denuded ring segments and the alterations in tension recorded. For control purposes,
the above experiment was repeated when aortic rings were bathed in Krebs-Ringer
solution, 250pg/ml LDL solution, or 200, 400 and 600pM UA solution only, following
completion of the concentration-response curves to PE and ACh.
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8.2.3 Vasodilator stability
Aortic ring segments were prepared as previous and concentration-response curves to
PE and ACh performed. 250pg/ml LDL + 400pM UA were added to the aortic ring
segments, which were then preconstricted with PE (l-3pM) and ACh (lOpM) added.
After 5 minutes exposure to ACh, the intact aortic ring segment was removed from the
myograph chamber. At various time points after removal (0, 3, 7, 15, 30, 60 and 120
minutes), the solution from the intact chamber was transferred to the chamber
containing the denuded ring and vasodilatation measured. The half-life of the UA-
derived dilatory product was calculated using the equation: y = RMax/ (1 + (x/Ec50)*P)
to fit the formed curve (Biograph Version 1.0, Strathclyde University, UK).
8.2.4 Solutions
LDL solutions were prepared as previously described and diluted using Krebs-Ringer
solution to give a final organ bath concentration of 250pg/ml. UA solution was
prepared as previously described and added to the Krebs-Ringer solution or 250pg/ml
LDL solutions to give a final organ bath concentration of 200, 400 or 600pM UA.
8.2.5 Lipid Peroxidation
Samples of the LDL and UA-supplemented solutions were collected before and after the
experiments were performed. The MDA and 4-HNE concentrations of the solutions
were determined using a commercial colorimetric assay kit (CN Biosciences,
Nottingham, U.K.), as described in Chapter 2.
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8.2.6 Statistical Analysis
The results shown are the mean values + SEM of 6 independent experiments. The
statistical significance of the results were analysed using paired Student's t-tests.
Statistical analysis was performed to determine any significant difference in the
vasodilatation produced by the transfer of the various organ bath solutions from the
endothelium-intact aortic ring to the denuded ring segment. Student's Mests were also
used to compare the oxidative status of the test LDL solutions before and after exposure
to the aortic ring segments.
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8.3 RESULTS
8.3.1 Examination of vasodilator formation
8.3.1.1 Assessment of aortic contractility to PE and endothelium-dependent
vasodilatation to ACh
PE (1x10"8-1x10"5M) produced concentration-dependent vasoconstriction in
endothelium-intact aortic ring segments, bathed in physiological Krebs-Ringer solution.
This vasoconstriction was significantly greater in endothelial denuded ring segments at
concentrations of 1x10"8-3x1CT7 PE (p<0.05). Similarly, the EC50 of the denuded ring
segments (45.8 + 6.2nM) was significantly lower than the intact segments (67.1 +
4.8nM) (P<0.01; Paired Student's t-test, n=48). However, the vasoconstriction to
greater concentrations of PE (7xl0"7 to lxlO"5) was similar (Fig. 8.1.).
ACh (1x10"8-1x10"5M) produced concentration-dependent vasodilatation in
endothelium-intact vessels, with a maximal dilatation of approximately 98% towards
resting diameter. All endothelial-denuded vessels were unresponsive to ACh (Fig 8.2.).
8.3.1.2 Endothelium-dependent vasodilatation to ACh in intact aortic ring
segments
In the physiological control, ACh (lOpM) produced vasodilatation of 79.8 + 4.6%.
Dilatation to ACh in the presence of 250pg/ml LDL was significantly reduced (24.3 +
2.7%) (R<0.01). Following the supplementation of LDL with 200pM, 400pM or
600pM UA, ACh produced a vasodilatation of 33.1 + 5.9%, 42 + 2.1% and 48.5 ±
4.7%, respectively. These were significantly greater than the dilatation in LDL only
(/><0.01), but markedly attenuated when compared to the physiological or UA control
(PcO.Ol).
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100 - ■ - Endothelial Intact
▲ - Endothelial Denuded
Concentration (M)
Figure 8.1. The concentration-dependent vasoconstriction to PE in endothelial-intact
and -denuded rat aortic ring segments, prior to the addition of the various LDL and UA
solutions. *p<0.05 vs. intact vessels (2-factor ANOVA with replication and Bonferroni
correction, n=48). All values are the mean + SEM.
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Concentration (M)
Figure 8.2. The concentration-dependent vasodilatation to ACh in endothelial-intact
and -denuded rat aortic ring segments, prior to the addition of the various LDL and UA
solutions. *p<0.02 vs. intact vessels (2-factor ANOVA with replication and Bonferroni
correction, n=48). All values are the mean + SEM.
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8.3.1.3 Endothelium-dependent vasodilatation to ACh in denuded aortic ring
segments
There was no significant vasodilatation to lOpM ACh in the denuded aortic rings,
regardless of whether the segments were bathed in Krebs-Ringer, UA, LDL, or UA
supplemented LDL solutions (Fig 8.3).
8.3.1.4 Investigation into vasodilator formation by examining vasodilatation in
denuded aortic rings
Transferring Krebs-Ringer or 250pg/ml LDL solution from the intact ring segments to
the denuded rings produced relaxation towards resting tension of 0.9 + 1.4% and 3.2 +
4.9%, respectively. Transferring 200pM, 400pM or 600pM UA solution produced
vasodilatation of -0.5 + 2.2%, 2.7 + 2.5% and 1.3 + 2%. The transfer of the of the LDL
solution supplemented with 200pM (Fig 8.4), 400pM (Fig 8.5) or 600pM UA (Fig 8.6)
produced vasodilatation of 21.2 + 1.9%, 33.1 + 6% and 49.2 + 6.6%, respectively.
These were significantly greater than the vasodilatation induced by the transfer of
physiological Krebs-Ringer solution (P<0.01), LDL (P<0.01), or UA only solution
(P<0.01). The vasodilatation produced by the UA-supplemented LDL solutions was
significantly greater when LDL was supplemented with increased UA concentrations
(P<0.01; Fig 8.7).
8.3.1.5 The role of NO in the vasodilatation produced by the solution transfer
lOpM Ox-Hb reversed the vasodilatation induced by the transfer of the LDL solution
supplemented with 200, 400 or 600pM UA. Ox-Fib constricted the vessels to 103.1 +





















□ LDL + 200pM UA
■ LDL + 400pM UA
£3 LDL + 600pM UA
Solution present in myograph chamber
Figure 8.3. Comparison of vasodilatation to ACh in the presence of 250pg/ml LDL +
200pM, 400pM, or 600pM UA in denuded aortic ring segments. All values are the

































B 250pg/ml LDL +
200pM UA
Solution present in myograph chamber
Figure 8.4. Investigation into donor formation by examining vasodilatation in denuded
aortic rings: Comparison of vasodilatation when transferring Krebs-Ringer, 200pM
UA, 250pg/ml LDL, or 250pg/ml LDL + 200pM UA acid from intact aortic rings to
denuded rings. *p<0.01 vs. Krebs-Ringer (paired Student's t-test, n=6), **p<0.01 vs.
200pM UA (paired Student's t-test, n=6), ***p<0.01 vs. 250pg/ml LDL (paired





































B 250pg/ml LDL +
400pM UA
Solution present in myograph chamber
Figure 8.5. Investigation into donor formation by examining vasodilatation in denuded
aortic rings: Comparison of vasodilatation when transferring Krebs-Ringer, 400pM
UA, 250pg/ml LDL, or 250pg/ml LDL + 400pM UA from intact aortic rings to
denuded rings. *p<0.01 vs. Krebs-Ringer (paired Student's t-test, n=6), **p<0.01 vs.
400pM UA (paired Student's t-test, n=6), ***p<0.01 vs. 250pg/ml LDL (paired
































Solution present in myograph chamber
Figure 8.6. Investigation into donor formation by examining vasodilatation in denuded
aortic rings: Comparison of vasodilatation when transferring Krebs-Ringer, 600pM
UA, 250pg/ml LDL, or 250pg/ml LDL + 600pM UA from intact aortic rings to
denuded rings. *p<0.01 vs. Krebs-Ringer (paired Student's t-test, n=6), **p<0.01 vs.
600pM UA (paired Student's t-test, n=6), ***p<0.01 vs. 250pg/ml LDL (paired



















□ LDL + 200pMUA
■ LDL + 400pMUA
E3 LDL + 600pM UA
Solution present in myograph chamber
Figure 8.7. Comparison of vasodilatation when transferring 250pg/ml LDL + 200pM,
400pM, or 600pM UA from intact aortic rings to denuded rings. *p<0.01 vs. 250pg/ml
LDL + 200pM UA (paired Student's t-test, n=6), **p<0.01 vs. 250pg/ml LDL +





Solution present in myograph chamber
Figure 8.8. The role of NO in vasodilatation to the UA-derived vasodilator: Reversal
of vasodilatation, following the transfer of 250|ag/ml LDL + 200gM, 400gM, or 600|iM
UA solution from intact aortic rings to denuded rings, by Ox-Hb. All values are the
mean + SEM (n=6).
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8.3.2 Donor stability
Solution transfer at 0 minutes after the removal of the intact aortic ring resulted in 33.1
+ 6.9% vasodilatation (Fig 8.9). After 15 minutes, the solution transfer produced 23 +
3.9% vasodilatation. Transfer after 120 minutes resulted in 4.2 + 2.3% vasodilatation
(Fig 8.9). The decay of the NO-dependent product formed was exponential and the
calculated half-life was 29.3 + 3.1 minutes at 37°C.
8.3.3 Lipid peroxidation
There was no significant alteration in the MDA and 4-HNE concentrations of the LDL
solutions, suggesting that no change in the oxidative status of the LDL occurred during
the experiments (Fig 8.10).
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Figure 8.9. Examination of the stability of the UA-derived vasodilator: The effect of
time from formation upon vasodilatation in denuded rings following the transfer of







































LDL 200 UA 400 UA 600 UA
Figure 8.10. Alterations in lipid peroxidation product levels: Mean percentage change
in the concentration of MDA and 4-HNE following addition to aortic rings. All values
are mean + SEM (n=6).
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8.4 DISCUSSION
Superfusion of endothelium-intact aortic ring segments with LDL solution significantly
impaired vasodilatation to ACh when compared to the physiological control. However,
supplementation of the LDL solution with UA (200, 400, 600pM) significantly restored
ACh-mediated dilatation in a concentration-dependent manner, as previously
demonstrated in the isolated mesenteric arteries. Superfusion with UA only had no
significant effect upon vasodilatation. Endothelial denudation abolished all
vasodilatation to ACh in the aortic rings, regardless of the superfusing solution.
Following the transfer of the solution from intact vessels to denuded vessels, only the
superfusing solution containing UA and LDL caused significant vasodilatation, all other
solutions (Krebs, LDL and UA only) were ineffective. This vasodilatation was related
to the concentration of UA and could be completely reversed by the addition of ox-Hb
to the organ bath. The half-life of the formed dilatory product was 29.3 + 3.1 minutes at
physiological temperature and pH.
8.4.1 Restoration of Vascular Function by UA
In Chapter 6, 200 to 600pM UA improved the deleterious effects of LDL on endothelial
function in a concentration-dependent manner. The dependency of the benefits of UA
on the release and activity of NO was clarified by the lack of any improvement in
vasodilator response in the presence of L-NAME, an eNOS inhibitor. It has previously
been suggested that UA is an antioxidant capable of reacting with and inactivating O2 "
(Ames et al, 1981; Santus et al, 2001), and it is tempting to speculate that UA restores
vascular function via this simple antioxidant mechanism. This is unlikely, as O2 ~ is far
more likely to react with NO than UA. Instead, it is more probable that the restoration
of vasodilatation relates to the ability of UA to scavenge ONOO" (Squadrito et al,
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2000), which has the potential to further damage the endothelium and eNOS (Milstien et
al, 1999). The apparent superiority of UA over other aqueous antioxidants in the
perfusion myograph model led to the hypothesis that stimulation of intact vessels with
ACh in the presence of LDL and UA led to the formation of a vasodilator in solution.
This was demonstrated in the current study when transferring the supervising solutions
from the endothelial intact rings to the denuded rings, as only the solution containing
both UA and LDL caused dilatation of the denuded vessels. The transfer of the Krebs-
Ringer solution (with and without UA) may also have been expected to induce
vasodilatation, as the technique used was similar to that used by Furchgott and
Zawadski to establish the release of EDRF from EC (Furchgott & Zawadski, 1980).
This group demonstrated that the stimulation of endothelium-intact aortic strips with
ACh could induce vasodilatation in adjacent denuded strips (Furchgott & Zawadski,
1980). Therefore, following EC stimulation with ACh in the current study, the Krebs-
Ringer solution from the intact vessel should contain NO, which could potentially dilate
the denuded vessels upon transfer. However, the failure of this solution to induce
vasodilatation may be due to the relatively short half-life of NO. NO has a half-life of
only a few seconds (Beckman & Crow, 1993; Vallance & Collier, 1994; Denicola et al,
1996) but the solution was not transferred until 5 minutes after EC stimulation, thus any
NO produced may have been consumed or decomposed prior to transfer.
The previous lack of effect of ACh in denuded rings confirmed the abolition of
endothelium-dependent vasodilatation, and proved ACh was not responsible for the
vasodilatation upon transfer. Consequently, vasodilatation of the denuded ring
segments demonstrated the presence of an endothelium-independent vasodilator in the
transferred solution. Therefore, it is concluded that the stimulation of the EC in the
presence of both LDL and UA caused the formation of a vasoactive substance.
However, although the vasodilatation produced is endothelium-independent, the
formation of the dilatory product is endothelium-dependent, as it requires stimulation of
the intact endothelium prior to transfer. This was as shown by the failure of UA to
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restore dilatation in denuded vessels exposed to ACh and LDL. The transfer
experiments also suggest an absolute requirement for UA with LDL, as neither UA nor
LDL alone caused vasodilatation when transferred to the denuded segments. The
dilatation was also related to the concentration of UA, as greater UA concentrations
produced greater dilatation following transfer. This supports the hypothesis that the
vasodilator produced is a derivative ofUA.
8.4.2 Mechanism of action of vasodilating factor
The dilatation of the endothelial denuded aortic rings by the UA-derived vasodilator
was reversed by ox-Hb, an exogenous NO-scavenger (Martin et al, 1985; Joshi et al,
2002). This suggests that the vasodilatation is produced by the release of NO, or a
closely related molecule, in the extracellular environment. However, if NO is released
from the UA-derived vasodilator in such a manner, then it remains unclear why it is not
subjected to the same reduction in availability that apparently occurs in the presence of
LDL alone, via the reaction with O2 This may reflect the increased stability of the
donor in the vessel wall or an altered site ofNO release. For example, the NO may be
released in close proximity to the VSMC, at a site that is removed from any endothelial
O2 ~, allowing it to interact with VSMC before it can be inactivated.
The half-life of the UA-derived vasodilator formed in this study is 29.3 minutes ±3.1
minutes at physiological temperature and pH. It has previously been demonstrated that
ONOO" may react with biological molecules to form a vasodilator species that releases
NO by a thiol and Cu+-dependent mechanism (Moro et al, 1995; White et al, 1997).
However, the release of NO from the UA-derived vasodilator in the current study is
spontaneous. This is in agreement with the findings of Skinner et al, who demonstrated
the release of NO was not accelerated by the addition of Cu2+ or thiols (Skinner et al,
1998).
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Therefore, the results suggest that the UA-derived vasoactive substance formed is an
NO-donating species that produces vasodilatation via the spontaneous release of NO in
the extracellular environment. However, this awaits direct confirmation and can only be
inferred at present. The proposed mechanism of action of the UA-derived vasodilator
factor is demonstrated in Figure 8.11. It is likely that this NO-mediated vasodilatation
occurs via a cGMP-dependent mechanism, but this requires further investigation and
may be answered following the identification of the formed vasodilator.
8.4.3 Formation of the vasodilatory substance
The molecular nature of the vasodilator has not been characterised, but it may be a
nitration product formed by the ability of UA to scavenge LDL-generated ONOO".
ONOO" formation in the vascular wall occurs via the generation of both NO and O2" by
EC (Oury et al, 1993; Van der Vliet et al, 1994). In the current study, the generation of
O2 " and NO occurs from exposure of aortic EC to LDL and ACh, to stimulate NO
production. As both are produced in close proximity and react rapidly, ONOO"
formation within the EC is likely to occur. UA is a potent endogenous scavenger of
ONOO" (Hooper et al, 1997; Hooper et al, 1998) and their interaction has been well
documented. UA may react with ONOO" to form a variety of derivatives (Santos et al,
1999). Oxidation of UA by ONOO" may form two partially characterised products, an
aminocarbonyl free radical intermediate centred on an electron-deficient carbon atom,
which may potentiate harmful effects of ONOO" (Vasquez-Vivar et al, 1996), and a
nitrate derivative which may release NO (Skinner et al, 1998). Although these products
have been detected in human plasma treated with ONOO", their production in vivo has
still to be demonstrated and the reaction between UA and ONOO" remains poorly
characterised (Uppu et al, 1996; Vasquez-Vivar et al, 1996; Skinner et al, 1998;
Tretyakova et al, 1999). However, the formation of a UA-based NO donor is
biologically plausible. The ability of UA to form an NO-mediated vasodilator gives
further support to the hypothesis that UA is found in elevated concentrations in
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LDL J Endulhelium-dependent Ischaemia/Oxidative
Vasodilator Stress
Figure 8.11. The proposed mechanism by which UA restores NO-dependent
vasodilatation following endothelial exposure to LDL. It is hypothesised that UA
scavenges the ONOO", formed within the EC, to produce a nitrated UA-derivative
that spontaneously releases NO, thus restoring endothelial NO-dependent
vasodilatation.
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hypercholesterolaemia, and other pathophysiological conditions, as a defence system to
minimise the deleterious effect of LDL on NO-availability. This may provide a
previously undetermined role for UA in human physiology and the pathophysiology of
cardiovascular disease.
8.4.4 Identification of the vasodilatory substance
The results produced in this series of experiments are similar to those of Skinner et al,
who demonstrated that the addition of UA to human plasma or a physiological buffer
containing ONOO" in vitro produced a nitrated UA product (Skinner et al, 1998). This
nitrated UA product was identified as 2-nitrito-4-amino-5-hydroxyimidazoline. The
proposed molecular structure of this dilatory species is shown in Figure 8.12 (Skinner et
al, 1998). It was demonstrated that this could act as a vasoactive NO-donor and
produce concentration-dependent relaxation of rat aortic ring segments. This
vasodilatation was endothelium-independent and ox-Hb sensitive (Skinner et al, 1998).
The vasoactive species produced in the current study also produced UA-concentration
dependent vasodilatation of denuded rat aortic ring segments and, as has already been
demonstrated, shared several of the characteristics of the UA-derived NO-donor
produced by the Skinner group. However, a discrepancy exists between the results of
the current study and the findings by Skinner et al. Electrochemical quantification
confirmed that the UA/ONOO" reaction resulted in the release of NO from a nitrated
UA-derivative with a decay half-life of 125 minutes (Skinner et al, 1998). The half-life
of the vasoactive species formed in this study (29.3 minutes) was significantly less than
the half-life of the nitrated-UA derivative formed by Skinner et al. However, the
Skinner group performed their studies at 10°C, but the present study was performed at
physiological temperature (37°C). This could account for the difference as a 10°C
decrease in temperature will approximately double the half-life. Therefore, it is
hypothesised that a similar nitrated UA product is responsible for the current results.









Figure 8.12. The proposed molecular structure of the UA-derived vasodilator formed
by the reaction of UA with ONOO" (Skinner et al, 1998). It is proposed that this
compound, 2-nitrito-4-amino-5-hydroxyimidazoline, acts as a NO-donating species
(Skinner et al, 1998), and is responsible for the NO-mediated vasodilatation in the
current study.
224
species prior to addition to isolated vessels, this study demonstrates the formation a UA-
derived vasodilator in aortic ring preparations. These results, when taken in conjunction
with those of previous chapters, could provide the first evidence of a UA-based NO-
donor being formed in an intact biological system.
8.4.5 Physiological Relevance
The formation of a nitrated UA-derivative in vivo could have wide reaching
implications for human physiology and the association between elevated UA
concentrations and pathophysiological conditions predisposing to cardiovascular
disease, such as hypercholesterolaemia. The observation that the UA-derived
vasodilator releases NO in a spontaneous and continuous fashion suggests that it could
play a significant role in the maintenance and restoration of vascular function in human
physiology. The current results provide a mechanism by which the higher
concentrations of UA present in plasma and extracellular fluids could offer an important
biological advantage in human physiology and the pathophysiology of cardiovascular
disease. This may in turn be responsible for the evolutionary loss ofUA breakdown by
urate oxidase, and the increased UA concentrations in human physiology, which are
positively associated with an increase in human life-span (Ames et al, 1981).
8.4.6 Study Limitations
A limitation of this study is the speculation that the effects of LDL on vascular function
resulted in the formation of ONOO", as the formation of ONOO" was not examined. In
addition, whilst the formation of the vasodilator and subsequent dilatation was UA-
concentration dependent, the concentration of ONOO" present was not established, and
as such, the concentration-dependent effect of ONOO" could not be determined.
Furthermore, the effects of LDL concentration upon the formation of the vasoactive
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species were not examined as only one concentration of LDL was present. Similarly,
only one concentration of ACh was used to stimulate the EC. Repeating the
experiments using other concentrations of ACh could help to determine the role of
endothelial stimulation and endothelial-derived NO upon the formation of a UA-derived
vasodilator in isolated vessel preparations acutely exposed to LDL. The current study is
also limited as there is no direct measurement ofNO release; this was demonstrated by
assessing changes in vascular function and the reversal of vasodilatation following
solution transfer by ox-Hb. Finally, EDTA and LECCE were present within the LDL
and UA solutions respectively. However, it has previously been demonstrated that the
presence of these would be unlikely influence the results produced (Chapter 4, 5 and 6).
8.4.7 Summary
The present study concluded that UA can partially restore LDL-induced endothelial
dysfunction via the formation of a UA-derived vasoactive species. The formation of
this vasodilator is UA-concentration-dependent, and occurs following the stimulation of
healthy endothelium by ACh in the presence of LDL. This vasodilator exerts an
endothelium-independent action and the vasodilatation produced is ox-Hb-sensitive,
suggesting that the UA-derived vasodilator is likely to be an NO donor. It is
hypothesised that this is formed by the reaction of UA with ONOO", generated as a
result of EC exposure to LDL. The ability of UA to scavenge ONOO" is well
recognised (Squadrito et al, 2000) and it has previously been demonstrated that the
treatment of human plasma with ONOO" produces a UA derivative that causes
vasodilatation similar to the current study (Skinner et al, 1998). This reference is
widely cited, but the formation of this UA-derived NO-donor has never been
demonstrated in vivo. However, the current study could provide the first evidence for
the formation of such a species in an intact biological system. This UA-derived
vasodilator could play a vital role in human physiology by restoring NO-mediated






UA is the major product of purine metabolism and is found in abundant concentrations
in human extracellular fluid. It is a major hydrophilic antioxidant and is present in
considerably higher concentrations in man than most other species, due to the loss of the
ability to express the enzyme urate oxidase (Ames et al, 1981). This evolutionary
process and the physiological treatment of UA suggest that the human body does not
regard UA as a 'waste product', but may imply that it has a very important
physiological role.
However, there has been substantial clinical and epidemiological evidence reporting a
positive association between UA, cardiovascular disease and various cardiovascular
events, such as stroke and myocardial infarction (Fessel, 1980; Brand et al, 1985;
Bonora et al, 1996; Persky et al, 1997; Bengtsson et al, 1998; Lehto et al, 1998; Liese et
al, 1999; Ward, 1998; Fang & Alderman, 2000). Vascular injury and endothelial
dysfunction are key events in conditions such atherosclerosis, hypertension, diabetes
mellitus and hypercholesterolaemia, which predispose to the development of
cardiovascular disease (D'Angelo et al, 1978; Blann et al, 1995). Increased oxidative
stress is a major factor in the development of this dysfunction, and although UA is an
established antioxidant, these conditions are often accompanied by elevated UA
concentrations (Wannamethee et al, 1997). Consequently, it has been suggested that
UA is an independent risk factor for the development of cardiovascular disease.
However, the specific role ofUA in the pathogenesis of this condition has been difficult
to ascertain, due to the association of UA with other established cardiovascular risk
factors. Therefore, it remains to be determined ifUA has a damaging or protective role
under these circumstances. Increased understanding of the effect of UA in the vascular
system and the relationship between UA and the associated risk factors for
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cardiovascular disease would allow a clearer interpretation of the association between
serum UA concentrations and cardiovascular disease.
This thesis aimed to determine the role ofUA in cardiovascular disease by investigating
the direct action of UA upon endothelial and vascular function and examining the
association between elevated UA and LDL. This was performed using isolated rat
mesenteric arteries in an in vitro perfusion myograph system. Perfusion myography
allowed the UA and lipoprotein solutions to be perfused through the vascular lumen to
mimic the endothelial exposure to these compounds that occurs in plasma in vivo. In
addition, a wire myograph model was used to investigate the potential ability of UA to
form a vasoactive species in isolated rat aortic ring segments exposed to ACh in the
presence of LDL.
9.2 THE USE OF PERFUSION MYOGRAPHY TO ASSESS
VASCULAR AND ENDOTHELIAL FUNCTION
The technique employed for the majority of these studies is more technically demanding
and time consuming than alternative techniques, such as wire myography. However,
perfusion myography is believed to be the optimal technique for assessing the impact of
LDL upon endothelial function as it better replicates the in vivo conditions,
proportionately longer vessel segments can be mounted, there is less danger of
endothelial damage or disruption during mounting, and the vessels can be exposed to
LDL via the endothelial surface under physiological pressures. This experimental
technique was selected for this series of studies as luminal perfusion prevented the
results from being influenced by any direct action of the LDL upon the VSMC. This
technique also allowed the studies to be performed using isolated resistance arteries.
These vessels are major determinants of peripheral vascular resistance, blood pressure,
blood flow and perfusion of the surrounding tissue. The in vitro study of these arteries
is vital to investigating the pathophysiology of cardiovascular disease, as alterations in
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the structure and function of these blood vessels may have a prominent role in the
various pathological conditions that predispose to this disease state (Dunn & Gardiner,
1995).
However, the role of NO in ACh-induced vasodilatation in isolated rat mesenteric
arteries is uncertain. Therefore, the ability of this experimental model to examine NO-
mediated vascular function was investigated in Chapter 3. These results demonstrated
that perfusion with lOOpM L-NAME reduced vasodilatation to ACh by approximately
58%. Perfusion with 10pM indomethacin only reduced vasodilatation by 8%.
Following luminal perfusion with both lOOpM L-NAME and lOpM indomethacin, the
vasodilatation produced was only 36% of the physiological response. It is hypothesised
that this residual vasodilatation was produced via hyperpolarisation to EDHF. It was
therefore concluded that NO was the major EDRF released in response to ACh in this
experimental model under physiological conditions, and as such, perfusion myography
using rat mesenteric arteries was suitable for the examination of NO-mediated vascular
function.
9.3 UA AND ENDOTHELIAL DYSFUNCTION
Chapter 4 examined the direct interaction ofUA with vascular and endothelial function.
It has previously been suggested that elevated UA concentrations may be directly
injurious to the endothelial lining of the vascular system, thus precipitating a causal role
in vascular and cardiovascular disease. However, luminal perfusion with UA at
physiological, elevated physiological and supraphysiological concentrations did not
affect vasoconstriction to PE, endothelium-dependent vasodilation to ACh, or
endothelium-independent vasodilatation to SNP. These results demonstrated that acute
endothelial exposure to UA is not cytotoxic or injurious to the EC in this model and
does not induce severe functional impairment. This also mitigates a direct causal role
for UA in the development of cardiovascular disease via the development of endothelial
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dysfunction. Therefore, it is suggested that the correlation between elevated UA and the
pathogenesis of cardiovascular disease may be due to either the indirect association of
UA with vascular disease or its risk factors, or a compensatory response to protect
against the development of this disease. For example, UA is a major hydrophilic
antioxidant and serum concentrations could be elevated to combat the increased O2 ~ and
oxidative stress that occurs in various conditions that predispose to the development to
cardiovascular disease.
9.4 THE INTERACTION OF UA AND LDL ON ENDOTHELIAL
FUNCTION
The role of UA in cardiovascular disease may be further determined by examining the
interaction of UA with established cardiovascular risk factors. Elevated UA
concentrations are commonly associated with hypercholesterolaemia (Wannamethee et
al, 1997), a recognised risk factor for the development of cardiovascular disease
(Goldstein & Brown, 1977; Steinberg, 1983; Martin et al, 1986). However, before the
interaction of UA and LDL could be examined, the effects of LDL upon vascular
function had to be clarified.
Chapter 5 focused on the inhibitory action of LDL on vascular function following
perfusion into the arterial lumen, and demonstrated that NO-mediated ACh-induced
vasodilatation was reduced in rat mesenteric arteries exposed to increasing
concentrations of human LDL. This finding is in agreement with previous studies that
have shown that both ox- and LDL can impair endothelium-dependent responses in
isolated vessel preparations in vitro (Andrews et al, 1987; Jacobs et al, 1990; Plane et
al, 1993; Fontana et al, 1999). This deleterious action is believed to occur via LDL-
induced generation of O2" by eNOS (Ohara et al, 1993; Keaney et al, 1995; Vergnani et
al, 2000). The increased oxidative stress and generation of O2" by eNOS could be
caused by an impairment of 1-arginine metabolism in the EC, as the uncoupling of 1-
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arginine oxidation and O2 reduction by the oxygenase and reductase domains of eNOS
respectively allows eNOS to be a source of O2 " generation (Klatt et al, 1993; Griffith &
Steuhr, 1995; Pritchard et al, 1995; Shinozaki et al, 1999). This proposed mechanism is
supported by the restoration of vascular function when the lipoprotein solution was
supplemented with ImM 1-arginine in the current study. The central role of O2 " is
supported by the observation that impaired endothelium-dependent vasodilatation in
hypercholesterolaemic conditions is improved by the administration of SOD or SOD-
mimetics (White et al, 1994; Fontana et al, 1999). This was not demonstrated in the
current study, as supplementation of the LDL solution with SOD did not restore
vasodilatation. However, this may be due by the failure of the exogenous SOD to
access the EC and compete effectively with the rapid reaction between O2 ~ and NO.
Chapter 6 examined the effect of UA upon the deleterious action of LDL by
supplementing the lipoprotein solution with various concentrations of UA prior to
luminal perfusion. Vasodilatation to ACh was significantly restored when UA was
added to the perfusing LDL solution at concentrations of 200, 400 or 600pM (62%,
70%, and 74% respectively), but was abolished by the addition of lOOpM L-NAME.
These results demonstrated that UA was able to restore NO-mediated vascular function
in a concentration-dependent manner. There was no significant oxidation of luminal
LDL during these experiments or the experiments with LDL only. This does not rule
out mild degrees of oxidation but argues against the effect of UA being due to the
antioxidant ability ofUA causing significant retardation of the oxidative modification of
LDL. It is more probable that UA improves NO-mediated vascular function by
protecting NO from the inhibitory action of LDL or restoring NO availability following
inactivation within the vascular wall. UA is a potent antioxidant that may be capable of
reacting with and inactivating O2 " (Ames et al, 1981; Santus et al 2001), although this
has been debated (Becker et al, 1989; Becker et al, 1991; Becker et al, 1993). It is
tempting to speculate that the beneficial action of UA may be mediated via this simple
antioxidant mechanism. However, this seems unlikely as O2" reacts more rapidly with
NO (Huie & Padmaja, 1993). Instead, it seems more likely that the benefits of UA on
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vasodilatation are related to the established ability of UA to scavenge ONOO" (Skinner
et al, 1998; Squadrito et al, 2000). Therefore, the protection of NO-mediated
vasodilatation by UA seems more likely to occur due to an action that restores bio¬
availability following inactivation by O2'", rather than via a protective mechanism that
prevents the inactivation ofNO by LDL.
To determine if this protective effect was unique for UA, supplementation with two
other major hydrophilic antioxidants was examined. UA was compared to AA and GSH
at physiological concentrations (40 and 400pM), chosen as they approximate the
concentrations of UA, AA and thiols in human plasma. Only 400pM UA was able to
improve LDL induced vascular dysfunction. The results demonstrated that UA
conferred greater protection on vascular function in the presence of LDL when
compared to AA and GSH. These results also support the hypothesis that the action of
UA was distinct from its antioxidant radical-scavenging ability, as both AA and GSH
are potent free radical scavengers. The apparent superiority of UA over these
antioxidants could occur because only UA is able to gain access to the intracellular
environment in sufficient concentrations to restore NO-mediated vasodilatation (Becker,
1989; Becker, 1993). However, none of the antioxidants studied could be expected to
compete effectively with the rapid reaction between O2 and NO, to prevent the
formation of ONOO". However, UA is an efficient scavenger of ONOO" in biological
systems (Skinner et al, 1998; Squadrito et al, 2000). The restoration of vascular
function by UA could be independent from its antioxidant potential, and due to the
unique ability to scavenge ONOO" and form a UA derivative with the potential to
induce vasodilatation (Skinner et al, 1998).
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9.5 THE MECHANISM BY WHICH UA RESTORES NO-
MEDIATED VASCULAR FUNCTION FOLLOWING
IMPAIRMENT BY LDL
Chapter 8 investigated the mechanism by which UA could restore the impairment of
NO-mediated vascular function by LDL. The chapter focused on the ability of UA to
form an NO-donor. This was examined by transferring the superfusate from organ bath
chambers containing endothelium-intact vessels to endothelium-denuded vessels,
following the stimulation of intact vessels with ACh in the presence of LDL and UA.
This experiment was performed using wire myography and thoracic aorta ring segments
from the same rat species as used in the previous studies. The experimental model was
changed to facilitate the ease of transfer. The transfer of physiological, UA or LDL
solutions containing ACh did not cause vasodilatation of the denuded ring segments.
However, exposure of stimulated intact aortic ring segments in the presence of both
LDL and UA led to the formation of an endothelium-independent vasodilator in
solution, with a half-life of approximately 29-30 minutes. The vasodilatation produced
by this species was UA concentration-dependent. The formation of this species also
required ACh-mediated stimulation of the intact vessels to be formed. The molecular
nature of this UA-derived vasodilator was not characterised, but is believed to be a
nitration product of the reaction between UA and ONOO". The role of ONOO" in the
formation of this species is supported by the requirement for LDL, which increases the
local oxidative stress and subsequently generates ONOO". The decay time of the
vasodilator product is comparable to that of the UA-derived vasodilating species formed
in the studies by Skinner et al (Skinner et al, 1998). The ox-Hb-sensitive nature of the
vasodilatation suggests that the UA-derived vasodilator is a NO-donor which produces
vasodilatation via the spontaneous release of NO in the extracellular environment. This
is likely to induce vasodilatation via a cGMP-dependent mechanism but requires further
investigation.
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Nevertheless, these studies have demonstrated that UA can restore endothelial function
in the presence of LDL most likely by forming a UA-derived vasoactive species that
acts as an NO-donor to restore vascular function. This restoration is unique when
compared to other major hydrophilic antioxidants. The NO-donor is produced as a
result of the ability of UA to scavenge ONOO", generated following EC exposure to
LDL and the resultant increase in O2" generation. It is believed that this study provides
the first evidence that a UA-based vasodilator can be formed in an intact biological
system.
9.6 PHYSIOLOGICAL RELEVANCE
It is intriguing to speculate that the interaction between UA and LDL may be relevant to
the function of human blood vessels. In human physiology, arteries are exposed to
higher lipoprotein concentrations than most other species and this has the potential to
have adverse effects on arterial structure and function. The mechanism demonstrated in
this study suggests that UA could mitigate some of these effects, specifically by
improving the availability of NO in the vascular wall. The high UA concentrations
found in human plasma may be a factor that enables the vascular system to remain
healthy and responsive when persistently exposed to LDL. The elevated UA
concentrations present could occur due to LDL increasing oxidative stress in the
vascular wall, which in turn activates XO (Sobey et al, 1992; Tesfamariam et al, 1992;
Sobey et al, 1993; Castelli et al, 1995), resulting in the enhanced generation and release
of UA by the EC (Parks & Granger, 1986). This may also explain the correlation
between elevated UA and other conditions associated with increased oxidative stress.
UA is the most abundant radical-scavenging antioxidant in human extracellular fluid
(Stacker & Lrei, 1991; Maxwell et al, 1997), and all aqueous tissue compartments
contain UA as a replenishable antioxidant. Intravenous UA supplementation
significantly increases plasma antioxidant activity in healthy individuals (Waring et al,
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2001). The high concentrations of UA in human physiology, the evolutionary loss of
urate oxidase and the manner in which the body re-absorbs and conserves UA suggest it
may confer some physiological advantage in humans and could be associated with to
the prolonged life-span when compared to other species (Ames et al, 1981). The
epidemiological evidence that associates UA with cardiovascular disease does not
necessarily contradict the present study. This may be explained by the close association
of hyperuricaemia with established risk factors and the release of UA to combat
increased oxidative stress. From the results of the current study, it may be
hypothesised that the elevated UA concentrations associated with conditions such as
hypercholesterolaemia occur as a compensatory mechanism to protect against the
detrimental effects of LDL and prevent the development of cardiovascular disease.
However, relating the findings of the current study to the in vivo situation may not be so
simple.
Under physiological conditions, the generation of UA from xanthine is catalysed by
XDH. This reaction is not accompanied by free radical production and the antioxidant
ability of UA is prominent. However, under pathophysiological conditions, such as
oxidative stress and hypercholesterolaemia, XO activity is increased and catalyses the
generation of UA (Ohara et al, 1993). This could occur as a compensatory mechanism
to generate greater concentrations of UA to combat the increased oxidative stress and
reduced NO-availability. However, the stoichiometry of the XO system results in the
excess generation of O2 " over UA (Becker et al, 1991; Ohara et al, 1993). The excess
generation of O2 " could potentially negate the protection conferred by increased UA
production in vivo. This must be taken into consideration when interpreting the results
produced. Increased UA concentrations were achieved in the current studies by
supplementation with exogenous UA. Therefore, the experimental conditions used were
not complicated by the generation of O2" that accompanies the increased UA production
associated with hypercholesterolaemia. Consequently, the current study did not
examine the potential effect of increased UA generation, and may only be used to
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interpret the direct action of elevated UA following the generation and release from the
EC to plasma.
The protection conferred by UA upon NO-mediated vascular function in the current
studies has been attributed to the formation of a UA-derivative that spontaneously
releases NO. The in vivo formation of this vasoactive species remains to be established,
however, the generation of a UA-based vasodilator or NO-donor is biologically
plausible. The formation of such a compound has previously been reported in human
plasma in vitro (Skinner et al, 1998). The current study has provided supportive
evidence for the formation of a UA-derived NO-donor in an intact biological system.
This could have wide reaching implications for the association between elevated UA
concentrations and pathophysiological conditions predisposing to cardiovascular disease
in human physiology. The observation that the formed vasodilator releases NO in a
spontaneous and continuous fashion could suggest that the product plays a significant
role in the restoration of vascular function. The ability to form this vasoactive species
in vivo may provide a beneficial reason for the evolutionary elevation in plasma UA
concentrations, as this may provide enhanced protection against high levels of
circulating LDL. The UA-derived vasodilator could play a vital role in human
pathophysiology by releasing NO to maintain vascular function, blood flow and tissue
perfusion (Kengatharan et al, 1996; Mellander et al, 1997). Furthermore, a nitrated UA
product could also potentially exhibit the anti-inflammatory properties of NO by
preventing platelet aggregation and adherence (Radomski et al, 1993; Radomski &
Moncada, 1993; Cooke & Tsao, 1994) as well as inhibiting leukocyte adhesion to the
endothelial surface (Granger & Kubes, 1994).
The experimental model used may affect the ability to relate the current results to
human physiology, as the current studies were performed using rodent tissue. The use
of isolated human blood vessels is difficult to plan and very restrictive. Therefore, the
isolated vessel studies were performed using animal tissue. However, the lipoprotein
samples were extracted from human plasma and the concentration used for the majority
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of the studies (250pg/ml) was typical of that found in human and WKY rat plasma
(Kitts et al, 1998). The impaired vascular function demonstrated in these studies is also
in accord with previous human in vivo studies that have demonstrated impaired
responses under hypercholesterolaemic conditions. Therefore, the inhibition and
restoration of vasodilatation demonstrated in the in vitro model may be relevant with
regards to human physiology.
9.7 EVOLUTIONARY IMPLICATIONS
The potential role of UA as a restorative mediator to protect against the deleterious
action of increased LDL levels may have evolutionary implications. UA is present in
the human plasma largely as the monoanion urate (Simic & Javanovic, 1989) and the
concentration of UA in human blood (200-400pM) is almost saturating. This is 5-10
times greater than the concentrations ofAA in plasma (20-60pM) and 100 times greater
than GSH (>2pM). A major factor in lengthening human life span during the course of
human evolution is the improved antioxidant defences against oxidative damage by free
radicals. Several mutational events have resulted in the loss of urate oxidase activity,
which oxidises UA to allantoin (Wu et al, 1992), and the development of an active
kidney re-absorption system for UA. This has resulted in plasma UA concentrations in
humans that are 10 times greater than those found in most other mammals (Roch-
Rammel & Peters, 1978). Interspecies comparison gives a positive correlation between
plasma UA concentrations and species life-span. This positive association may be
attributed to the antioxidant ability ofUA (Ames et al, 1981; Becker 1993). The current
study demonstrated that a UA concentration comparable that those found in species
expressing urate oxidase did not prevent LDL-induced endothelial dysfunction, however
concentrations physiologically relevant to humans did. This supports the evolutionary
hypothesis that the loss of urate oxidase expression occurred as elevated serum UA
concentrations have an important role in human physiology, and may be an adaptive
mechanism to combat the increasing role of lipoproteins in pathophysiology. This
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could also explain the established association of hyperuricaemia and disease states such
as hypercholesterolaemia (Wannamethee et al, 1997),
The evolutionary loss of enzymatic UA oxidation has also been accompanied by a loss
of ascorbate synthetase activity during human evolution. This prevents the synthesis of
AA, thus requiring in vivo concentrations to be replenished by dietary consumption. It
has been proposed that the loss of urate oxidase occurred to compensate for the loss of
ascorbate synthetase (Ames et al, 1981). As a result, humans and higher primates may
have higher concentrations of serum UA to offset the decreased antioxidant potential
caused by the reduction of circulating AA concentrations. This evolutionary process
could have occurred as the ability ofAA to act as an antioxidant may be inhibited by its
tendency under certain conditions to auto-oxidise, resulting in the generation of oxygen
radicals (Sevanian et al, 1991) and mutagens (Koh et al, 1980). However, the current
results demonstrated the superiority ofUA in preventing the deleterious action of LDL
on vascular function when compared to AA and GSH. Therefore, it is hypothesised that
the evolutionary elevation of UA concentrations is an adaptive mechanism to provide
greater protection against the continual exposure of the human vascular system to
increased concentrations of LDL. It is also hypothesised that this has occurred because
UA is the major antioxidant for restoring vascular function following the impairment of
NO availability by increased oxidative stress in the vascular wall. This is supported by
the current studies, as the other major endogenous hydrophilic antioxidants were
ineffective against the direct action of LDL upon vascular function.
9.8 CLINICAL AND THERAPEUTIC POTENTIAL
Although the current studies were performed to investigate the in vivo relationship
between elevated UA levels and cardiovascular disease, the ability of UA to scavenge
ONOO" and form a potential NO-donating species may be of significant therapeutic
interest. Due to the occurrence of endothelial dysfunction in cardiovascular disease, the
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delivery of exogenous NO to areas of reduced NO availability is a frequently used
therapy and drugs that release NO have been clinically utilised for over a hundred years.
NO-donors may induce vasodilatation and prevent oxidative stress-mediated EC injury
in cardiovascular disease (Chang et al, 1996; Terada et al, 1996). They may also be
used to treat and prevent tissue damage associated with other conditions such
pulmonary hypertension, acute respiratory distress and various other disease states.
Organic nitrates, such as GTN, are the most widely used NO-donor drugs and rapidly
dilate veins, coronary arteries and collateral vessels (Parker, 1987; Bauer et al, 1995).
However, tolerance, defined as the loss of therapeutic effect with continued
administration, is a major limitation of these compounds (Megson & Webb, 2002), and
may involve the induction of haemodynamic compensatory mechanisms (Dupuis et al,
1990; Parker et al, 1991; Munzel et al, 1995) and oxidative stress (Munzel et al, 1995;
Munzel et al, 1999). Increased oxidative stress may induce tolerance (Munzel et al,
1999), and studies have shown that tolerance to organic nitrates may be partially
reversed by several antioxidants, including AA (Bassenge et al, 1998; Watanabe et al,
1998). It is possible that the use of a UA-derived NO donor could prevent the induction
of tolerance by increased oxidative stress, as the UA-derived species could potentially
exert a radical scavenging ability following the release of NO, to prevent any
inactivation by ROS. Tolerance may also develop due to depletion of tissue thiols,
previously thought to be essential to the metabolic process involved in the release ofNO
from organic nitrates (Needleman et al, 1973; Ignarro & Gruetter, 1980; Munzel et al,
1995). Thiols may be depleted under conditions of oxidative stress, such as
hypercholesterolaemia, thus diminishing the therapeutic effect of these NO-donors
(Hanspal et al, 2001). The development of new drugs that negate these limitations and
have a wider range of applications is of great interest and potential benefit. The release
ofNO from the UA-derived compound formed is spontaneous and is not believed to be
thiol-dependent. This is in agreement with the findings of Skinner et al that
demonstrated the release ofNO was not accelerated by the addition of thiols (Skinner et
al, 1998). Therefore, the use of the nitrated UA-derivative as an NO-donor would not
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be hampered by the depletion of intracellular thiols. This is a potential therapeutic
advantage of the mechanism of action of the UA-dcrivcd NO donor formed in the
present study.
Furthermore, while this species could act as a NO-donor, it could also exert other
physiological properties. The NO-mediated dilating species formed in this study is
thought to be a nitrosated UA-adduct (Skinner et al, 1998). Nitrosated-adducts may act
as hybrid NO-donors; these are NO-donating species formed from compounds that are
structurally modified to incorporate NO-groups. This class of NO-donors can release
NO whilst retaining the pharmacological activity of the original compound. The
development of a combined NO-donor/antioxidant compound would be of great
therapeutic interest, as this may release NO to restore vascular function and also
enhance the antioxidant potential. The compound formed in the present study could
fulfill such criteria, given the established antioxidant and ONOO" scavenging potential
of UA and the ability of the formed product to induce NO-mediated vasodilatation. It is
interesting to speculate that such a species could be used to treat clinical conditions in
which increased oxidative stress and diminished antioxidant potential contribute to the
development of vascular dysfunction. The combined vasoactive and antioxidant
properties of such a UA-derived NO-donor may also make it ideally suited for the
treatment and prevention of vascular dysfunction and cardiovascular disease. This
product could also be used to treat other clinical conditions associated with oxidative
tissue damage, such as organ transplantation and multiple organ dysfunction. The
release of NO from the UA-derived product could also minimise tissue damage
following conditions such as ischaemia or reperfusion, which may be caused by
increased oxidative stress.
However, before this may be regarded as a realistic therapeutic option several
limitations must be considered. Therapeutic treatment using an UA-derived NO-donor
may result in the accumulation of excessive UA concentrations in the plasma. UA is
sparingly soluble in aqueous media and reaches saturation at approximately 415pM.
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Persistent exposure to excessive serum concentrations predisposes to crystal depositions
within soft tissues and the development of conditions such as gout (Emerson, 1996).
Furthermore, UA may also stimulate the adherence of granulocytes and macrophages to
the endothelium, which may have detrimental effects upon the vascular system (Duff et
al, 1983; Hutton et al, 1985; Leyva et al, 1998; Mazzali et al, 2002; Kanellis et al,
2003). These could not be examined in the current study, as no blood cells were present
within the organ bath, but must be investigated before the UA-derived vasodilator can
be considered as a realistic therapeutic alternative.
9.9 FURTHER STUDY
The present studies demonstrated that the association of elevated UA and
hypercholesterolaemia could occur due to a unique mechanism by which UA restores
impaired NO-mediated vasodilatation. However, further investigation is required to
fully clarify the mechanism by which this occurs and gain a better understanding of
relationship between UA and the development of cardiovascular disease
The priority of any future study must be to identify the formed vasoactive species. It
has previously been suggested by Skinner et al. that the scavenging of ONOO" by UA in
vitro results in the formation of 2-nitrito-4-amino-5-hydroxyimidazoline, a nitrated UA-
derivative that produces NO-mediated vasodilatation of rat aortic ring segments
(Skinner et al, 1998). The findings of Skinner et al are widely cited with regards to the
role of UA in human physiology and pathophysiology. However, to our knowledge this
has never been expanded upon and the formation a UA-derived NO-donor in an intact
biological system has never been demonstrated. Therefore, this study is believed to be
the first to report the formation of such a compound in an intact biological system.
Consequently, it is of the utmost importance that the vasodilatory species formed in the
current experimental model is identified. This could be identified by repeating the
experiments, collecting the intraluminal LDL solution and performing electron spin
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resonance, HPLC and electrospray mass spectroscopic analysis to study the reaction of
UA with ONOO" and identify the vasodilator produced. This could be supported by
experiments examining the formation of a UA-derived compound in EC cultures
incubated with various concentrations of LDL and UA. The solution present could then
be added to isolated vessel preparations and vascular function examined. This solution
would also be collected and analysed to identify any vasodilator formed.
The previous chapter demonstrated that UA did not cause vasodilatation in denuded ring
segments bathed in LDL. These experiments should be repeated to examine the effects
of solution transfer from denuded aortic rings to other denuded rings, as this was not
performed in the current studies. This should demonstrate that the proposed formation
of a UA-derived vasodilator has an absolute requirement on the presence of an intact
endothelium as a source ofNO. Further study is also required to determine the potential
site of action of UA, prior to the formation of the UA-derived vasodilator. This could
be achieved by examining the ability ofUA to generate a vasodilatory species in models
of intra- and extracellular oxidative stress. The experiments performed in Chapter 8
could be repeated and LDL replaced with pyrogallol, as a source of extracellular 02 \ or
DECTA to inhibit endogenous Cu-Zn SOD and increase intracellular 02'~.
Investigation is also required to fully understand the mechanism of NO-dependent
vasodilatation. The dilatation produced is likely to occur via the direct activation of
VSMC cGMP by NO (Ignarro & Gruetter, 1980; Ignarro et al, 1986; Waldman &
Murad, 1987). However, vasodilatation to NO is not exclusively mediated by cGMP
(Trottier et al, 1998; Weisbrod et al, 1998) and several NO-donating species may act via
cGMP-independent mechanism (Brunner et al, 1996; Plane et al, 1998; Homer &
Wanstall, 2000). This may be influenced by the site of NO release. The UA-derived
vasodilator produces ox-Hb-sensitive vasodilatation, implying that NO is released in the
extracellular environment, and could produce dilatation by cGMP-independent
mechanism. Therefore, the vessel studies should be repeated in the presence of 1H-
[l,2,3]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ), a selective inhibitor of sGC,
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(Garthwaite et al, 1995; Hobbs et al, 1997), to examine if the vasodilatation produced is
mediated through the NO/cGMP pathway. It would also be of significant interest to
measure the concentration ofNO released from this dilator species and compare to the
physiological release of NO from EC in this experimental model. The role of NO was
demonstrated in the present studies by assessing changes in vascular function.
However, the direct generation of NO from the UA-derived vasodilator may be
examined using an NO-electrode. The quantification of NO could be achieved by
collecting organ bath samples, following endothelial activation, and measuring the NO
released from the UA-derived vasodilator using an isolated NO-electrode in the
presence and absence of vascular tissue, with and without endothelium. The NO release
would be compared to calibration curves produced by the generation of known NO
concentrations using authentic NO solution, formed in the laboratory. Such
experiments would clarify the mechanism of action of the UA-derived vasodilator and
may help to further elucidate the role of elevated UA concentrations in human
physiology.
Following identification of the UA-derived vasodilator and the mechanism of action,
future studies should examine the specificity of the restorative action, to ascertain if the
restoration of vascular function also occurs in other cardiovascular risk factors with
which increased UA is associated. Elevated UA concentrations are frequently
associated with other pathophysiological conditions such as hypertension and type II
diabetes (Lehto et al, 1998; Ward, 1998; Fang & Alderman, 2000; Alderman, 2002).
Endothelial dysfunction is prevalent in these states and, as with hypercholesterolaemia,
may be caused by increased oxidative stress and the inactivation of NO by ROS within
the vascular wall. Consequently, UA could be expected to exert a similar restorative
action. The demonstration of this would give further support to the potentially
beneficial role of UA in human physiology and pathophysiology, and should be
examined to further determine the relationship between, UA, cardiovascular disease and
the associated risk factors.
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9.10 CONCLUSION
The results of these studies mitigate any direct causal role for UA in endothelial
dysfunction and cardiovascular disease, as it is demonstrated that UA is not directly
injurious to the endothelium. On the contrary, the results highlight the importance of
UA in protecting vascular function from the detrimental action of LDL. It is shown that
LDL may have a prominent role in cardiovascular disease by increasing oxidative stress
within the vascular wall, which in turn impairs NO-mediated endothelium-dependent
vasodilatation. The present studies have demonstrated that UA is able to restore NO-
mediated vascular function following endothelial exposure to LDL, and does so more
effectively than other hydrophilic antioxidants. The ability of UA to prevent the
inhibitory effect of LDL is thought to be due to a restorative action that occurs via the
unique ability of UA to scavenge ONOO" and form UA-derived NO-dependent
vasoactive species. It is believed that the current study provides the first evidence for
the formation of such a UA-derived vasodilator in an intact biological system. These
results have demonstrated a distinct physiological role for UA in the prevention of
LDL-induced vascular dysfunction, and suggest a means by which the higher
concentrations of UA in human plasma may confer an important biological advantage in
human physiology. This could provide a beneficial reason for the loss of urate oxidase
activity and the subsequent increases in UA concentrations that have occurred during




10. Appendix I - Preparation of Solutions
Krebs-Ringer Buffer
Amounts stated are to make 1L Krebs solution (final concentration in mM).
Stock Normal Krebs Hieh K+ Krebs
NaCl g 6.9g (118) 0.28g (4.7)
KC1 g 0.35g (4.7) 8.8g (118)
MgS04 g 1.45g (1.2) 1.45g (1.2)
NaHC03 g 2-lg (25) 2-lg (25)
KH2PO4 g 0.16g (1.2) 0.16g (1.2)
Glucose g 2.0g (11.1) 2.0g (11.1)
Make up to 950ml with de-ionised water and bubble with 95% 02/5% CO2 for 10 minutes.
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